

# The Genetic Landscape of Renal Complications in Type 1 Diabetes

Consortium, S. U. M. M. I. T., McKnight, A. J., & Maxwell, A. (2017). The Genetic Landscape of Renal Complications in Type 1 Diabetes. *Journal of the American Society of Nephrology*, 28(2), 557-574. DOI: 10.1681/ASN.2016020231

**Published in:**

Journal of the American Society of Nephrology

**Document Version:**

Peer reviewed version

**Queen's University Belfast - Research Portal:**

[Link to publication record in Queen's University Belfast Research Portal](#)

**Publisher rights**

Copyright © 2016 by the American Society of Nephrology. This article has been accepted for publication in the *Journal of the American Society of Nephrology*.

**General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

**Systematic Dissection of the The Genetic Landscape of Renal Complications in Type 1 Diabetes****Running title: Genome-wide dissection of diabetic kidney disease**

Niina Sandholm<sup>1,2,3</sup>, Natalie Van Zuydam<sup>4,5,6</sup>, Emma Ahlqvist<sup>7</sup>, Thorhildur Juliusdottir<sup>4</sup>, Harshal A. Deshmukh<sup>8</sup>, N. William Rayner<sup>4,5,9</sup>, Barbara Di Camillo<sup>10</sup>, Carol Forsblom<sup>1,2,3</sup>, Joao Fadista<sup>7</sup>, Daniel Ziemek<sup>11</sup>, Rany M. Salem<sup>12,13,14</sup>, Linda T. Hiraki<sup>15</sup>, Marcus Pezzolesi<sup>16</sup>, David Trégouët<sup>17,18</sup>, Emma Dahlström<sup>1,2,3</sup>, Erkka Valo<sup>1,2,3</sup>, Nikolay Oskolkov<sup>7</sup>, Claes Ladenvall<sup>7</sup>, M. Loredana Marcovecchio<sup>19</sup>, Jason Cooper<sup>20</sup>, Francesco Sambo<sup>10</sup>, Alberto Malovini<sup>21,22</sup>, Marco Manfrini<sup>10</sup>, Amy Jayne McKnight<sup>23</sup>, Maria Lajer<sup>24</sup>, Valma Harjutsalo<sup>1,2,3,25</sup>, Daniel Gordin<sup>1,2,3</sup>, Maija Parkkonen<sup>1,2,3</sup>, Jaakko Tuomilehto<sup>25,26,27,28</sup>, Valeriya Lyssenko<sup>7,24</sup>, Paul M. McKeigue<sup>29</sup>, Stephen S. Rich<sup>30</sup>, Mary Julia Brosnan<sup>31</sup>, Eric Fauman<sup>32</sup>, Riccardo Bellazzi<sup>21</sup>, Peter Rossing<sup>24,33,34</sup>, Samy Hadjadj<sup>35,36,37</sup>, Andrzej Krolewski<sup>16</sup>, Andrew D. Paterson<sup>15</sup>, Jose C. Florez<sup>38,39,40</sup>, Joel N. Hirschhorn<sup>12,13,14</sup>, Alexander P. Maxwell<sup>23,41</sup>, David Dunger<sup>19</sup>, The DCCT/EDIC Study Group<sup>^</sup>, GENIE Consortium<sup>^</sup>, The FinnDiane Study Group<sup>^</sup>, Claudio Cobelli<sup>10</sup>, Helen M. Colhoun<sup>8</sup>, Leif Groop<sup>7</sup>, Mark I McCarthy<sup>4,5,42</sup>, Per-Henrik Groop<sup>1,2,3,43</sup>, on behalf of The SUMMIT Consortium<sup>^</sup>

1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, 00290, Helsinki, Finland
2. Abdominal Center, Nephrology, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland
3. Research Programs Unit, Diabetes and Obesity, University of Helsinki, 00290, Helsinki, Finland
4. Wellcome Trust Centre for Human Genetics, University of Oxford, OX3 7BN, Oxford, UK
5. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, OX3 7LE, Oxford, UK
6. Medical Research Institute, University of Dundee, UK
7. Department of Clinical Sciences, Diabetes and Endocrinology, Skåne University Hospital, Lund University, 20502, Malmö, Sweden
8. Division of Population Health Sciences, University of Dundee, DD1 9SY, Dundee, UK
9. Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK
10. Department of Information Engineering, University of Padova, 35131, Padova, Italy
11. Computational Sciences, Pfizer Worldwide Research and Development, 10785, Berlin, Germany
12. Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
13. Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
14. Divisions of Endocrinology and Genetics, Boston Children's Hospital, Boston, MA 02115, USA
15. Genetics and Genome Biology Program, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada
16. Joslin Diabetes Center, Boston, MA 02215, USA
17. UMR\_S 1166, Team Genomics & Pathophysiology of Cardiovascular Diseases, Sorbonne Universités, UPMC Univ. Paris 06, INSERM, 75013, Paris, France
18. ICAN Institute for Cardiometabolism and Nutrition, 75013, Paris, France
19. Department of Paediatrics, Institute of Metabolic Science, University of Cambridge, CB2 0QQ, Cambridge, UK
20. Department of Chemical Engineering and Biotechnology, University of Cambridge, CB2 3RA, Cambridge, UK
21. Department of Electrical, Computer and Biomedical Engineering, University of Pavia, 27100, Pavia, Italy
22. IRCCS Fondazione Salvatore Maugeri, 27100, Pavia, Italy
23. Nephrology Research, Centre for Public Health, Queen's University of Belfast, BT7 1NN, Belfast, UK
24. Steno Diabetes Center, 2820, Gentofte, Denmark
25. The Chronic Disease Prevention Unit, National Institute for Health and Welfare, 00271, Helsinki, Finland

26. Centre for Vascular Prevention, Danube-University Krems, 3500, Krems, Austria
27. Diabetes Research Group, King Abdulaziz University, 80200, Jeddah, Saudi Arabia
28. Dasman Diabetes Institute, Dasman, Kuwait
29. Centre for Population Health Sciences, University of Edinburgh, EH8 9AG, Edinburgh, UK
30. Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA
31. CV and Metabolic Diseases (CVMET) Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
32. Computational Sciences, Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
33. Health, Aarhus University, 8000, Aarhus, Denmark
34. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200, Copenhagen, Denmark
35. UFR Médecine Pharmacie, Centre d'Investigation clinique, Université de Poitiers, 86021, Poitiers, France
36. Service d'Endocrinologie-Diabetologie and Centre d'Investigation clinique, CHU de Poitiers, 86021, Poitiers, France
37. CIC1402 and U1082, Inserm, 86021, Poitiers, France
38. Programs in Metabolism and Medical & Population Genetics, Broad Institute, Cambridge, MA 02142, USA
39. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
40. Diabetes Unit and Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
41. Regional Nephrology Unit, Belfast City Hospital, BT9 7AB, Belfast, UK
42. Oxford NIHR Biomedical Research Centre, University of Oxford, OX3 7LE, Oxford UK
43. Baker IDI Heart & Diabetes Institute, Melbourne, VIC 3004, Australia

The authors of this manuscript are those listed above. Membership of the listed consortia is provided in supplementary material, but those members who are NOT listed on page 1 do not meet the criteria for authorship.

Information on the complete list of participants in the DCCT/EDIC research group is provided in the Acknowledgements. Membership of the GENIE Consortium is provided in Supplemental Table 27. Membership of the FinnDiane Study Group is provided in Supplemental Table 28. Membership of the SUMMIT Consortium (SURrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools) is provided in Supplemental Table 29.

**Word count, main text: 2,998/3,000 words** (excl. title page, methods, figure legends, tables, and references)

**Word count, abstract: 238/250 words**

**Tables: 2**

**Figures: 4**

**Supplementary information: Complete methods, 29 Supplemental Tables, 13 Supplemental Figures**

**Keywords:** diabetic kidney disease, genetics and development, genome-wide association study, whole exome sequencing

**Corresponding author:**

Per-Henrik GROOP, MD DMSc FRCPE

Professor, Chief Physician

Abdominal Center Nephrology

University of Helsinki and Helsinki University Hospital

Biomedicum Helsinki (C318b)

Hartmaninkatu 8

1  
2 FIN-00290 Helsinki  
3 FINLAND  
4 Tel: +358-500-430 436 or +358-2941-25459 (office)  
5 Email: per-henrik.groop@helsinki.fi  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

## Abstract

Diabetes is the leading cause of end stage renal disease. Despite evidence for a substantial heritability of diabetic kidney disease, efforts to identify genetic susceptibility variants have had limited success. We extended previous efforts in three dimensions, examining a more comprehensive set of genetic variants in larger numbers of subjects with type 1 diabetes characterized for a wider range of cross-sectional diabetic kidney disease phenotypes. In 2,843 subjects, we estimated that the heritability of diabetic kidney disease was 35% ( $p=6\times 10^{-3}$ ). Genome-wide association analysis and replication in 12,540 individuals identified no single variants reaching stringent levels of significance and, despite excellent power, provided little independent confirmation of previously published associated variants. Whole exome sequencing in 997 subjects failed to identify any large-effect coding alleles of lower frequency influencing the risk of diabetic kidney disease. However, sets of alleles increasing body mass index ( $p=2.2\times 10^{-5}$ ) and the risk of type 2 diabetes ( $p=6.1\times 10^{-4}$ ) were associated with the risk of diabetic kidney disease. We also found genome-wide genetic correlation between diabetic kidney disease and failure at smoking cessation ( $p=1.1\times 10^{-4}$ ). Pathway analysis implicated ascorbate and aldarate metabolism ( $p=9\times 10^{-6}$ ), and pentose and glucuronate interconversions ( $p=3\times 10^{-6}$ ) in pathogenesis of diabetic kidney disease.

These data provide further evidence for the role of genetic factors influencing diabetic kidney disease in those with type 1 diabetes and highlight some key pathways that may be responsible. Altogether these results reveal important biology behind the major cause of kidney disease.

## Introduction

Diabetes is the leading cause of end stage renal disease (ESRD).<sup>1</sup> Among the patients with type 1 diabetes (T1D), as many as one third develop serious renal complications,<sup>2</sup> characterized by increasing urinary albumin excretion rates (AER) and decreasing kidney function, measured by estimated glomerular filtration rate (eGFR), with 10%-20% of the subjects progressing to ESRD.<sup>3,4</sup> In the vast majority of patients with T1D, renal complications reflect the condition of diabetic nephropathy,<sup>5</sup> though we use the term diabetic kidney disease (DKD) here to reflect the fact that not all have histological evidence of DN. While DKD is associated with high risk of cardiovascular disease<sup>6</sup> and premature mortality,<sup>7</sup> those who manage to avoid DKD have much better prognosis with survival rates comparable to subjects without diabetes.<sup>7</sup> The treatment of DKD, primarily relying on the control of blood glucose levels and on the use of anti-hypertensive medication, can only retard disease progression rather than restore kidney function or efficiently prevent ESRD. This highlights the need for a better mechanistic understanding of DKD which would provide improved therapeutic targets and biomarkers of progression, both of which are expected to lead to improved personalization of care.

Family studies have shown familial clustering of DKD with a 2.1 – 2.3 fold increased risk of DKD in T1D siblings of probands with DKD.<sup>8-10</sup> There is also evidence for shared genetic background between DKD and other diseases: the parents of the subjects with T1D and DKD have more type 2 diabetes (T2D) and cardiovascular disease<sup>11-13</sup>. Despite evidence for genetic predisposition, few compelling signals have been identified for DKD. Positive reports of association with a range of candidate genes have generally failed to find support in larger analyses of independent samples,<sup>14</sup> and only a few loci have been identified with genome-wide association studies (GWAS)<sup>15-17</sup>. In contrast, there have been a number of a robust, replicated associations described for chronic kidney disease (CKD) in the general population<sup>18-20</sup>. However, evidence that these variants influence predisposition to CKD in diabetes is mixed<sup>15,20</sup>.

## Genome-wide dissection of diabetic kidney disease

1  
2 The limited success of GWAS on DKD thus far may be due to multiple factors: relatively small sample sizes (in  
3  
4 the thousands at the discovery stage); imprecise and variable diagnostics or phenotypic heterogeneity; and a  
5  
6 focus on common variants (minor allele frequency [MAF]  $\geq 5\%$ ), that neglects the possible contribution of lower  
7  
8 frequency variants to DKD predisposition. In other complex traits, such as schizophrenia, initial challenges in  
9  
10 identifying robust association signals have been overcome as sample sizes have increased<sup>21,22</sup>.

11  
12  
13  
14 To overcome the limitations of previous studies in DKD, in this study we: increased sample size through GWAS  
15  
16 meta-analysis; analysed a range of phenotypic comparisons that encompass different stages and severity of  
17  
18 DKD in subjects with T1D; and extended the genome-wide association screen from common variants to lower  
19  
20 frequency coding variants through whole exome sequencing (WES).  
21  
22  
23  
24  
25  
26  
27  
28

## 29 Results

### 30 DKD traits are heritable

31  
32  
33 Since no comprehensive evaluation of heritability exists for the various stages of DKD, we estimated the  
34  
35 narrow-sense, “chip” heritability (i.e. the proportion of phenotypic variance explained by genome-wide SNPs;  
36  
37  $h^2$ ) for the seven applied DKD phenotypic comparisons (Figure 1) in the context of T1D using data from the  
38  
39 largest included GWAS study, the Finnish Diabetic Nephropathy (FinnDiane) Study<sup>23</sup>. Heritability estimates  
40  
41 varied greatly across the comparisons (Figure 2): For the primary, ‘combined DKD’ phenotypic comparison  
42  
43 (micro- or macroalbuminuria or ESRD versus normal AER),  $h^2$  was 35% ( $p=6 \times 10^{-3}$ ; Supplemental Table 1). The  
44  
45 highest value,  $h^2 = 59\%$ , was obtained for ‘CKD+DKD’ (those with both CKD and DKD assigned as cases, and  
46  
47 those with no CKD and no DKD as controls;  $p=1 \times 10^{-3}$ ). Other late stage phenotype definitions also yielded high  
48  
49 estimates of heritability, e.g. 47% for ‘ESRD versus no DKD’ ( $p=3 \times 10^{-3}$ ). When we included gender, diabetes  
50  
51 duration, and age at diabetes diagnosis as covariates, the proportion of the remaining phenotypic variance  
52  
53 explained by the genotyped SNPs increased for each phenotypic comparison, e.g. from 35 % to 50% for  
54  
55  
56  
57  
58  
59  
60



## Genome-wide dissection of diabetic kidney disease

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

'combined DKD' ( $p=2.5\times 10^{-4}$ ). The estimates represent lower limits for the total heritability of DKD traits, as the method considers only those causal variants captured by the variants genotyped on the array.

**GWAS**

The GWAS discovery stage included 3,135-5,156 subjects with T1D, depending on phenotypic comparison (Supplemental Figure 1), from four studies: FinnDiane<sup>23</sup>, the EURODIAB Family Study<sup>24</sup>, the Scania Diabetes Registry (SDR)<sup>25</sup>, and the UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/Cambridge)<sup>26,27</sup> (Table 1, Supplemental Tables 2 and 3).

With 2,563 T1D DKD cases and 2,593 T1D non-DKD controls for the 'combined DKD' phenotype in the discovery cohorts, we estimated >80% statistical power to detect variants with  $MAF\geq 10\%$  and allelic odds ratios (OR)  $\geq 1.55$  at genome-wide significance ( $p<5\times 10^{-8}$ ; Supplemental Table 4). Results from meta-analyses were well calibrated (genomic control [ $\lambda_{GC}$ ] 1.01-1.05; Supplemental Figure 2) but showed little deviation from the null with no SNP reaching  $p<5\times 10^{-8}$  (no adjustment for multiple phenotypes). Across seven DKD case-control comparisons, a total of 101 regional lead SNPs reached a suggestive  $p$ -value of  $<5\times 10^{-6}$  in at least one analysis (Supplemental Table 5). These 101 associations were tested for all DKD phenotypes available in the various stage 2 samples (Supplemental Tables 2 and 3), though meta-analysis results were only compiled across data for equivalent phenotypes. The two-stage design provided  $\geq 80\%$  power for the primary 'combined DKD' comparison to reach  $p<5\times 10^{-8}$  for variants with an  $OR\geq 1.47$  and  $MAF\geq 10\%$  (Supplemental Table 6).

In the joint meta-analysis of stage 1 and 2 samples, no SNP reached  $p<5\times 10^{-8}$ , while three achieved  $p<1\times 10^{-6}$ , all for the ESRD based case definitions: rs1989248 near *CNTNAP2*, rs61277444 in *PTPN13*, and rs7562121 in *AFF3* (Supplemental Figure 3, Supplemental Table 5). We also identified rs72809865 near *NRG3* for further replication based on nominal replication ( $p=0.047$ ) for 'combined DKD' in stage 2. These four SNPs were examined in 1,087 additional subjects using *de novo* genotyping (Stage 3), though direct genotyping was



Genome-wide dissection of diabetic kidney disease

1  
2 unsuccessful for rs1989248 (near *CNTNAP2*). After the joint analysis of stage 1-3 results, the association at  
3  
4 rs7562121 in *AFF3* remained suggestive ( $p < 1 \times 10^{-6}$ ; Table 2).  
5  
6

7 **Rs7562121 in *AFF3*** is in moderate linkage disequilibrium (LD) with rs7583877 ( $r^2 = 0.67$ ,  $D' = 0.94$ ), the variant  
8  
9 previously associated with ESRD in T1D<sup>15</sup>. Conditional analysis showed that both SNPs represent the same  
10  
11 signal (Supplemental Table 7). However, the present study cannot be considered replication of previous reports  
12  
13 because of substantial overlap of study samples. Analysis in non-overlapping samples (222 ESRD cases, 1,640  
14  
15 non-ESRD controls) provided no independent corroboration of the *AFF3* association ( $OR = 1.02$ ,  $p = 0.82$ ).  
16  
17

18  
19 The substantial heritability captured by SNPs on the genotyping array, and the failure to detect genome-wide  
20  
21 significant signals, suggest that the causal variants are beyond detection in the present study, due to **more**  
22  
23 modest effect size (e.g.  $OR < 1.47$  for  $MAF \geq 10\%$ ) and/or imperfect capture by common variant-focused GWAS  
24  
25 analyses.  
26  
27  
28  
29  
30  
31  
32

### 33 **Re-evaluation of previous DKD associations**

34  
35 The enlarged sample size provided an opportunity to investigate the **previous**, often contradictory reports of  
36  
37 SNP associations.<sup>28</sup> We selected signals from three sources: a literature-based meta-analysis of candidate gene  
38  
39 associations;<sup>28</sup> GWASs on DKD in subjects with either T1D<sup>15,17,29-31</sup> or T2D<sup>32,33</sup>; and GWASs on CKD irrespective of  
40  
41 underlying pathology<sup>20</sup>. Many of these previous studies included subjects overlapping with those in the present  
42  
43 analysis.  
44  
45  
46  
47

48 We estimate >80% statistical power to detect associations with allelic  $OR \geq 1.25$  and  $MAF \geq 10\%$  at nominal  
49  
50 significance ( $\alpha = 0.05$ ; Supplemental Table 8) for the 'late DKD' phenotype, which was most commonly used in  
51  
52 previous publications. We observed only a modest deviation from the null  $p$ -value distribution for the set of  
53  
54 previously-associated variants, suggesting that many of these have been false positive findings (Supplemental  
55  
56 Figure 4). Nevertheless, in addition to the *AFF3* SNP associations described above, the associations between  
57  
58  
59  
60

Genome-wide dissection of diabetic kidney disease

rs2838302 (in *SIK1*) and 'ESRD vs. non-ESRD', and between rs17709344 (*RGMA-MCTP2*) and 'CKD+DKD' were directionally consistent and significant ( $p < 1.1 \times 10^{-3}$  to correct for 46 loci). The association between rs2838302 (*SIK1*) and 'ESRD vs. no DKD' remained nominally significant ( $p = 0.04$ ) even after exclusion of the substantial overlap of the subjects (Supplemental Table 9).

We observed directionally consistent associations (less stringent  $p < 0.05$ ) for variants near *WNT4-ZBTB40*, *SEMA6D-SLC24A5*, *ELMO1*, *ERBB4*, 4p15.1 and 13q regions (Supplemental Figure 5). However, at four of these loci, the modest evidence of association was lost when overlapping samples were removed. Independent replication of previously reported signals (directionally consistent  $p < 0.05$ ) was therefore restricted to the signals at *ELMO1*, 13q and *SIK1* (Supplemental Table 9).

### DKD shows shared genetic background with obesity, T2D, and smoking cessation

BMI, systolic blood pressure, serum lipids, and smoking have been associated with DKD in epidemiological studies<sup>24,34-36</sup> while T2D, obesity, hypertension, and lipid disorders have been reported to cluster in families with DKD<sup>11,12,37</sup>, suggesting a shared genetic background or a close correlation amongst these phenotypes. We constructed weighted genetic risk scores (GRS) for 19 diabetes,<sup>38-45</sup> obesity,<sup>46-48</sup> hypertension,<sup>49</sup> or lipid-related<sup>50</sup> intermediate phenotypes based on 10 to 96 established SNPs ( $p < 5 \times 10^{-8}$ ) for each phenotype from previously published GWAS. The GRS for increasing BMI<sup>46</sup> was associated ( $p < 2.6 \times 10^{-3}$  to correct for 19 traits) with multiple DKD traits ( $p = 2.2 \times 10^{-5}$  for 'late DKD'; Figure 3; Supplemental Table 10), implicating a causal role of BMI for DKD. While observational studies have shown contradictory results,<sup>51,52</sup> these findings are consistent with those from a recent Mendelian Randomization study including FinnDiane subjects.<sup>53</sup> The GRS predisposing to T2D was associated with increased risk of multiple DKD traits (e.g.  $p = 1.9 \times 10^{-3}$  for 'combined DKD' excluding pleiotropic lipid and glycemic SNPs;  $p = 6.1 \times 10^{-4}$  for 'combined DKD' including pleiotropic lipid SNPs) in line with previous reports of parental T2D being associated with DKD in subjects with T1D.<sup>12</sup> These data support a causal, mechanistic link between metabolic syndrome and DKD in T1D.<sup>23</sup>

## Genome-wide dissection of diabetic kidney disease

We also applied the LD score regression method to estimate the genetic correlation between traits. In contrast to the GRS approach which uses only the most associated variants, this method examines the allelic effects of all SNPs in the meta-analysis.<sup>54,55</sup> As expected, the seven DKD phenotypes were highly correlated with each other, **at least in part due to overlapping phenotypic definitions**, with the exception of 'early DKD' (Supplemental Figure 6). Smoking cessation was inversely correlated with 'CKD' ( $p=1.1\times 10^{-4}$ ) and other DKD traits (Figure 4). This is in line with a previous epidemiological study showing higher risk of DKD for smokers, whereby ex-smokers had similar risk of developing DKD as non-smokers.<sup>36</sup>

**Gene set enrichment analyses suggest glucuronidation and other pathways affecting DKD**

We performed gene set enrichment analyses (GSEA) of the GWAS results to identify biological pathways and processes enriched among the most significant GWAS signals. The ascorbate and aldarate metabolism, and pentose and glucuronate interconversions pathways showed **significant enrichment ( $p<1.6\times 10^{-5}$  to correct for multiple tested pathways)**. Literature linking ascorbate metabolism to DKD is sparse, but cell studies have **suggested a reduced uptake rate of ascorbic acid (vitamin C) in DKD,<sup>56</sup> and vitamin C plus E supplementation was reported to improve glomerular function in T2D.<sup>57</sup>** In the latter pathway, the flagged genes overlapped especially the glucuronate sub-pathway (Supplemental Figure 7). Negatively charged glucuronic acid units on heparan sulfate side chains participate in the maintenance of the negative charge selectivity of the glomerular basement membrane in the kidneys, and their cleavage by heparanase (endo- $\beta$ -D-glucuronidase) has been suggested as an underlying cause for DKD.<sup>58</sup> While knock-out of the *HSPE* (heparanase) gene protects mice from DKD,<sup>59</sup> no specific genetic variants in or near *HSPE* have been associated with DKD. Other gene sets with less marked enrichment (**false discovery rate (FDR) $<0.05$** ; Supplemental Table 11) included the cholesterol biosynthesis pathway ( $p=8.0\times 10^{-4}$ ) flagging among others the *HMGCR* gene (lowest  $p=0.023$  for rs11726245 for 'CKD'), which encodes the main target of statins, commonly used for prevention of diabetic macrovascular

Genome-wide dissection of diabetic kidney disease

1 complications. Cholesterol levels are reported to be related to eGFR decline in T1D, while statin use improved  
2 eGFR in subjects with T2D in some<sup>60</sup> but not all studies.<sup>61</sup>  
3  
4  
5  
6  
7  
8  
9

### 10 **Single-marker association tests of whole exome sequencing show suggestive associations for ESRD**

11 To identify low frequency ( $1\% \leq \text{MAF} < 5\%$ ) and rare ( $\text{MAF} < 1\%$ ) coding variants contributing to DKD, we  
12 performed WES of 997 subjects with T1D from the FinnDiane, SDR and Steno Diabetes Center. To maximize  
13 power, subjects were ascertained from the tails of the liability distribution: we selected cases with onset of  
14 macroalbuminuria or ESRD relatively soon after diagnosis of T1D, and controls with normal AER despite  
15 prolonged duration of T1D (Supplemental Table 12). This setting allowed us to study the 'late DKD' and 'ESRD  
16 vs. no DKD' case-control contrasts (Figure 1).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 No associations were observed at exome-wide significance ( $p < 5 \times 10^{-7}$ ; Supplemental Figure 8). Variants in five  
28 loci reached a  $p$ -value of  $< 1 \times 10^{-5}$  for association with 'ESRD vs. no DKD' (Supplemental Tables 13 and 14) with  
29 the strongest associations obtained for an intronic SNP rs188427269 within *NVL* ( $\text{MAF} 0.2\%$ ,  $p = 3.3 \times 10^{-7}$ ) and  
30 for rs13003941 in the 3'UTR of *ERBB4* ( $\text{MAF} 35\%$ ,  $p = 3.5 \times 10^{-6}$ ). Other variants in *ERBB4* (not in LD with  
31 rs13003941) were previously suggestively associated with DKD,<sup>15</sup> and *ErbB4* was shown important for the  
32 development of kidneys in mouse models.<sup>62</sup>  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Gene aggregate tests of WES**

47 To improve power to detect low frequency and rare variant associations, we performed gene-level aggregate  
48 tests using three complementary approaches: a variable threshold (VT) burden test,<sup>63</sup> a dispersion test  
49 (SKAT),<sup>64</sup> and a hybrid test (SKAT-O)<sup>65</sup>. No gene achieved exome-wide significance ( $p < 2.5 \times 10^{-6}$ , adjusted for  
50 20,000 genes; Supplemental Figures 9 and 10). For the 'late DKD' phenotype, the lowest  $p$ -value was for *GGA1*  
51 ( $p = 3.1 \times 10^{-5}$ ; Supplemental Figure 11), showing rare ( $\text{MAF} \leq 0.13\%$ )<sup>66</sup> missense alleles in seven cases but no  
52  
53  
54  
55  
56  
57  
58  
59  
60

Genome-wide dissection of diabetic kidney disease

controls across five **variant sites** (Supplemental Tables 15-17). For the 'ESRD vs. no DKD' phenotype, the strongest associations were found at *CCDC77* ( $p=2.1\times 10^{-5}$ ), *THADA* ( $p=8.3\times 10^{-5}$ ) and *CHPT1* ( $p=1.9\times 10^{-5}$ ; Supplemental Figure 12, Supplemental Tables 18-20).

While it has been hypothesized that common disease diagnoses are partially comprised of rare monogenic forms of the disease, we did not see enrichment in genes causing rare human glomerular diseases in our WES results (Supplemental Table 21). **In addition**, there was no enrichment between the WES signals and those arising from **our** GWAS studies. Thus, the variants and genes **generating suggestive evidence for association** in WES seem independent of rare variants identified for monogenic forms of kidney disease, and of the common variant contribution to DKD in subjects with T1D.

### **Bivariate analysis of GWAS and WES data**

As some genetic factors may affect disease outcome only in the presence of interacting genetic factors, we complemented the GWAS and WES analyses using a multivariate variant selection method (ABACUS)<sup>67</sup> applied to both GWAS and WES data. Although no variant reached simulation  $p$ -value ( $p_5 < 5\times 10^{-8}$ ), suggestive evidence of association was obtained for variants in *OSGIN1* in two different data sets ( $p_5 < 5\times 10^{-6}$  for 'ESRD vs. no DKD' in EURODIAB GWAS and in Steno WES; Supplemental Tables 22 and 23). Functional clustering of the results pointed at processes previously linked with DKD such as cholesterol and sucrose/glucose metabolism and inflammatory response pathway (Supplemental Tables 24 and 25).

### **Discussion**

This study represents a systematic evaluation of common genetic risk factors and rare coding variants for a broad range of kidney complication phenotypes in T1D. To complement the association analyses, we

Genome-wide dissection of diabetic kidney disease

performed various enrichment and correlation analyses considering the genome-wide content to obtain insight of the genetic architecture, biological background, and correlation with other traits.

This study confirmed that renal complications in T1D are highly heritable, as a substantial proportion of the phenotypic variation can be captured by common variants on the GWAS chip, with the strongest heritability estimates observed for the most extreme phenotypic comparisons. This captured heritability could consist of common variants with modest effects, and/or variants of lower frequency, some of them imperfectly tagged by common SNPs. The limited evidence for linkage to DKD<sup>68</sup> and general experience regarding the architecture of other common complex traits, suggest that it is unlikely that DKD risk is dominated by rare variants of large effect, though ultimately sequence based studies will be required for definitive evaluation.

We found suggestive common variant signals for DKD in or near *AFF3*, *CNTNAP2*, *NRG3*, and *PTPN13* genes, but additional data sets will be needed to confirm (or refute) these signals and to increase power to detect others. For example, the effective sample size required to implicate a risk allele of MAF 20% and allelic OR 1.2 at genome wide significance is ~15,000. We demonstrated that many previously claimed DKD associations signals are likely to be false positives, although modest, independent evidence was found for associations near *ELMO1*, 13q and *SIK1* ( $p < 0.05$ ). While the three-stage analysis of this study brings together the largest studies with the largest number of participants with T1D for GWAS on DKD, the total sample size remains modest. Future efforts to identify novel genetic risk factors for DKD will require investment in additional sample ascertainment and genotyping.

Different genetic factors may affect the various stages of DKD progression. To address the phenotypic heterogeneity within DKD, we applied selection of sub-phenotypes for the evaluation of renal complications. As various phenotypic comparisons yielded significant findings for different tests, these comparisons may address diverse aspects of the disease progression. Future studies would likely benefit from improved phenotyping and, in particular from the detailed longitudinal follow-up of research participants.

Genome-wide dissection of diabetic kidney disease

Even though this study concentrated on patients with T1D, some of the results may be extended to DKD in T2D as well. However, as the pathology behind renal complications in T2D is more heterogenous,<sup>5</sup> with ageing, atherosclerosis and hypertension contributing appreciably to the renal function, the genetic background of DKD in T2D may have more features of the kidney disease in the general population.

Although no novel susceptibility loci were identified in this study, some signals are starting to appear when we aggregated genetic data as in pathway analysis, genetic risk score and LD score regression analysis. The pathway analyses, for example, highlighted involvement of glucuronate interconversions pathway and supported the role of cholesterol metabolism in DKD. Analysis of genetic risk scores suggested that high BMI, as well as the genetic risk factors behind T2D, causally increase the risk of DKD in T1D. Finally, the LD score regression identified genetic correlation between smoking cessation and reduced risk of DKD in subjects with T1D, supporting the previous research of smoking as a risk factor for DKD<sup>36</sup>. Altogether, these results may provide valuable clues to the biological processes relevant to the pathogenesis of DKD.

## Concise Methods

### Subjects with T1D in GWAS and WES

The GWAS discovery stage included subjects with T1D from the FinnDiane Study,<sup>23</sup> the EURODIAB Family Study<sup>24</sup>, SDR<sup>25</sup>, and NFS-ORPS<sup>26,27</sup>. WES included subjects from FinnDiane, SDR, and Steno Diabetes Center (characterized in Supplemental Table 12). All studies were approved by the local ethics committees and conducted according to the principles of the Declaration of Helsinki. Written consent was obtained from the participants in FinnDiane, EURODIAB, SDR and Steno Studies. In the NFS-ORPS study, written consent was obtained from parents, and verbal assent was obtained from children.



## Genome-wide dissection of diabetic kidney disease

**Phenotype definitions:** All subjects had T1D as diagnosed by their attending physician, with age at diabetes onset  $\leq 40$  years and insulin treatment initiated within one year of diagnosis. The kidney status was classified based on AER and eGFR (please see Complete Methods and Supplemental Table 26). Patients receiving dialysis treatment, with a kidney transplant, or with an eGFR  $\leq 15$  ml/min/1.73m<sup>2</sup> were defined to have ESRD. Based on these definitions, we analysed seven different case – control phenotypes (Figure 1).

**Patient selection for WES:** Patients were selected from the extreme ends of the liability distribution of DKD from each participating study. Cases had rapid onset of macroalbuminuria (within 20/25 years of diabetes onset in FinnDiane and Steno, respectively; no threshold in SDR) or ESRD (onset within 25 years of diabetes onset in FinnDiane and Steno). Controls were subjects with normal AER despite prolonged duration of T1D ( $\geq 32$ , 30, or 27 years in FinnDiane, Steno, and SDR, respectively). In addition, the FinnDiane controls were enriched for higher HbA<sub>1c</sub> values (excluding subjects with HbA<sub>1c</sub> < 6.5 %).

## Genotypes

**Genome-wide genotyping and imputation of the discovery cohorts:** The genome-wide genotyping of the subjects in the SDR, NFS-ORPS, and EURODIAB was performed with the Illumina OmniExpress assays (Illumina, San Diego, CA, USA). In quality control, samples with a call rate <98%, gender discrepancy, extremely high or low heterozygosity, or excess of estimated relatedness, were removed. Common SNPs (MAF  $\geq 5\%$ ) with genotyping rate <95% or not in Hardy-Weinberg equilibrium (HWE;  $p \leq 5.7 \times 10^{-7}$ ) were removed. For low-frequency SNPs (MAF 1% – 5%), the thresholds were 99% and  $p < 10^{-4}$ , respectively. In the FinnDiane Study, genotyping was performed with the Illumina 610Quad assay and the quality control was similar to the other studies, as described previously in detail.<sup>15</sup> Principal component analysis was performed in all cohorts with Eigensoft.<sup>69</sup> Imputation was performed with IMPUTE2<sup>70</sup> using the 1000 Genomes project (phase 1 v.3, released March 2012) as the imputation reference panel.<sup>71</sup> Variants were filtered post-imputation to those with MAF  $\geq 1\%$ , minor allele count  $\geq 10$  in both cases and controls, and SNPtest INFO estimate of imputation quality  $\geq 0.4$ .

## Genome-wide dissection of diabetic kidney disease

**Whole exome sequencing and variant calling:** Samples were sequenced at two centres. Sequencing was performed on an Illumina HiSeq2000. We required an average 20x target capture above 80% coverage, otherwise additional DNA was requested to 'top up' the sample. This resulted in mean sequencing depth of 54.97 (FinnDiane) and 42.23 (SDR and Steno) bases per position. After additional sequencing 497 samples were included from FinnDiane and 500 from SDR and Steno. Samples were mapped with Burrows-Wheeler aligner v7.4. Genome analysis toolkit v2.1 (GATK) was used to refine and recalibrate the sequences and to call variants. Polymorphic variants (MAF>0) with a mapping quality < 250, HWE  $p$ -value  $>1 \times 10^{-10}$  and call rate  $\geq 75\%$  were retained in the analysis. Samples with  $\geq 10\%$  missingness or extreme heterozygosity were excluded. Population outliers, duplicates and related samples were removed. Variants were annotated using CHAos (<http://www.well.ox.ac.uk/~kgaulton/chaos.shtml>), snpEff<sup>72</sup> and VEP<sup>73</sup> for functional class and transcript.

With 530,565 variants (491,553 SNPs and 39,012 indels) across 479 controls and 481 cases after the quality control, each individual carried a mean of 7,566 synonymous, 6,452 missense and 103 protein truncating variants. The lower number of total variant sites compared to other, more outbred populations<sup>74</sup> is in line with fewer variable sites seen in founder populations such as the Finns.<sup>75</sup>

## Statistical methods

**Heritability estimates:** The narrow-sense heritability of the kidney phenotypes was estimated as the proportion of the phenotypic variance explained by the additive effects of the genotyped SNPs based on the FinnDiane GWAS data using the GCTA v. 0.93.9, excluding samples with estimated relatedness  $\geq 0.025$ .<sup>76</sup> The observed variance explained was transformed to the underlying population scale based on rough prevalence estimates as given in Supplemental Table 1. The heritability was estimated without covariates, and adjusting for sex, duration of T1D and age at T1D onset.

## Genome-wide dissection of diabetic kidney disease

**GWAS analysis:** The genome-wide association analyses in stage 1 studies were performed with two methods in parallel. To obtain stable effect size estimates, we performed additive test for association using SNPtest with the score method adjusted for sex, diabetes duration, age at diabetes onset, and the two first principal components. *P*-values were obtained with a variance component based mixed model method, EMMAX, which accounts for the sample structure, allowing to include relatives in the analysis.<sup>77</sup> Models were adjusted for sex, diabetes duration and age at diabetes onset and the kinship matrix was calculated with EMMAX. EMMAX algorithm was implemented with the EPACTS software ([www.sph.umich.edu/csg/kang/epacts/](http://www.sph.umich.edu/csg/kang/epacts/)). Meta-analyses of the effect sizes were performed with the fixed-effect inverse variance method (GWAMA<sup>78</sup> and METAL<sup>79</sup>), while *p*-values were combined based on the study-wise *p*-values, sample sizes and effect directions (METAL<sup>79</sup>). Meta-analysis results were further filtered to those with valid results from at least two studies. *P*-values below  $5 \times 10^{-8}$  were considered genome-wide significant, not correcting for multiple testing due to seven phenotypic comparisons, as the case and control groups were overlapping and the traits were correlated with each other. Power calculations were performed with the genetic power calculator ([pengu.mgh.harvard.edu/~purcell/gpc/](http://pengu.mgh.harvard.edu/~purcell/gpc/)) for simple case-control setting,<sup>80</sup> and with Power Calculator for Two Stage Association Studies (CaTS; <http://csg.sph.umich.edu//abecasis/cats/>).<sup>81</sup>

**Replication:** Independent variants with  $p < 5 \times 10^{-6}$  were selected for *in silico* replication in six additional studies: the All Ireland – Warren 3 – Genetics of Kidneys in Diabetes UK collection (UK-ROI)<sup>15</sup> and the Genetics of Kidneys in Diabetes US Study (GoKinD US)<sup>15</sup> from the GENIE Consortium, the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study<sup>82,83</sup>, 1,073 subjects from the Joslin Diabetes Center T1D nephropathy collection, and the French, Belgian and Danish subjects (the Steno Diabetes Center) from the French-Danish Effort<sup>84</sup> (Supplemental Tables 2 and 3). After *in silico* replication, variants that replicated with a  $p < 0.05$  or had a combined *p*-value  $< 1 \times 10^{-7}$  after meta-analysis were selected for *de novo* genotyping with TaqMan in 1,095 additional FinnDiane patients, not part of the GWAS (Supplemental Table 2). rs1989248 was not successfully genotyped. Association testing was performed

Genome-wide dissection of diabetic kidney disease

with logistic regression (implemented in PLINK or SNPtest, depending on the study), adjusted for sex, duration of diabetes, age at diabetes onset, and study specific covariates.

**Genetic risk score analysis:** SNPs associated ( $p < 5 \times 10^{-8}$ ) in previous studies with Waist-Hip-ratio (adjusted for BMI)<sup>47</sup>, BMI (untransformed<sup>48</sup> and z-transformed<sup>46</sup>), systolic blood pressure (SBP),<sup>49</sup> low-density lipoprotein cholesterol (LDL-C), triglycerides, high-density lipoprotein cholesterol (HDL-C)<sup>50</sup>, T1D<sup>39</sup>, T2D<sup>38</sup> (including all SNPs, and without any other effects other than on T2D or lipids<sup>50</sup> and T2D or glycemic traits<sup>41,85</sup>), 2-hr glucose (adjusted for BMI),<sup>40</sup> fasting glucose (adjusted for BMI),<sup>41</sup> glycosylated haemoglobin (HbA1c),<sup>42</sup> fasting insulin (natural log transformed and adjusted for BMI),<sup>41</sup> fasting pro-insulin (adjusted for BMI and fasting glucose),<sup>43</sup> HOMA-B, HOMA-IR,<sup>44</sup> and insulin resistance<sup>45</sup> were included in a genetic risk score (GRS) for each trait respectively. The GRS was weighted by the allelic effect of each variant on the DKD risk factor and associated with the DKD phenotypes using the stage 1 GWAS meta-analysis data.<sup>49</sup> The lipid GRS were restricted to variants that predicted that specific trait and removed those that had effects on other lipid traits. We did not include a GRS for smoking behaviours as there were too few genome-wide significant associations to form a sufficient instrument.

**LD score regression to estimate genetic correlation:** To estimate the genetic correlation between the GWAS stage 1 meta-analysis results for DKD phenotypes, and the related traits, we assembled the genome-wide summary statistics from all the studies used to calculate GRS except for systolic blood pressure and T1D as the full summary statistics were not available. We additionally computed genetic correlation with smoking behaviour phenotypes (cigarettes per day, smoking addiction, smoking cessation and age at smoking onset).<sup>86</sup>

**Gene set enrichment analyses:** gene set enrichment analysis was performed in the GWAS stage 1 meta-analysis results with the MAGENTA(vs.2)<sup>87</sup> applied on 10,992 partially overlapping gene sets from GO, PANTHER, INGENUITY, KEGG, REACTOME, and BIOCARTA data bases; 3,126 gene sets with  $\geq 10$  genes were analysed. The 95 percentile cut-off for the gene scores was employed to define the significant results.

Genome-wide dissection of diabetic kidney disease

**Correction for multiple testing:** The significance threshold for the results of the evaluation of previous loci, GRS, LD score regression, and pathway enrichment analyses were Bonferroni corrected for multiple testing with  $\alpha=0.05$  significance level, accounting for the number of tested loci, traits, or pathways. The results were not corrected for the seven phenotypic comparisons due to a considerable overlap of the case and control groups.

**WES single variant analysis:** Single variants were tested for association with DKD (cases N=481, controls N=479) and ESRD (cases N=168, controls N=479) using the logistic score test<sup>88</sup> implemented in Epacts, with sex and two principal components as covariates. Related individuals, monomorphic SNPs and those with standard error greater than 10 were excluded from the analysis. While the study setting provided low statistical power to detect rare variants (MAF<1%) with exome-wide significance ( $p<9\times 10^{-8}$  to correct for 530,776 tested variants) in line with previous reports on the statistical power to detect rare variants,<sup>89</sup> we had sufficient power (80%) to detect a low frequency variant (MAF=5%) with a large OR of 5.65 (Supplemental Figure 13).

**WES gene-based analysis:** We applied three series of gene based tests: a burden test (VT)<sup>63</sup> that assumes the direction of effect of grouped variants is the same, a dispersion test (SKAT)<sup>64</sup> that performs well when the direction of variant effect differs, and a hybrid (SKAT-O)<sup>65</sup> that uses multiple methods in a single test. Analyses were adjusted for sex and principal components. For all three tests we grouped variants into four categories: protein truncating variants (PTV; e.g. nonsense, frameshift, essential splice site), deleterious protein altering variants sub-divided into "strict" and "broad" grouping if predicted deleterious by all five/ at least one annotation algorithm, and any protein altering variants (e.g. missense, in-frame indel, non-essential splice-site). These four groups are referred to as 1) PTV-only, 2) PTV+strict, 3 ) PTV+broad, and 4) PTV+missense, from the strictest to the most permissive class. A MAF threshold of 1% was applied to the more permissive masks PTV+missense and PTV+broad to exclude common variants from the WES analysis.

**WES gene set enrichment analysis:** A total of 43 gene sets were created, based on top findings from the GWAS analyses, kidney-related functional terms in public databases, text mining approaches and kidney gene

Genome-wide dissection of diabetic kidney disease

1  
2 expression (Supplemental Table 21). These gene sets were analysed for enrichment in 'Late DKD' WES  
3  
4 association results (SKAT-O, all four masks) using the GSEA method with SKAT-O's p-value as the ranking  
5  
6 statistic<sup>90</sup>. To guard against potential miscalibration of GSEA's reported p-values we conducted 100  
7  
8 permutations of case/control status and subsequently re-ran burden tests and GSEA analysis for each  
9  
10 permutation. Significance of enrichment was validated with permutation. For validation of enrichment of  
11  
12 GWAS result, the samples in WES were removed from the GWAS data and the analyses were repeated.  
13  
14

15  
16  
17 **Bivariate analysis of GWAS and WES data:** We applied ABACUS<sup>67</sup> to the individual GWAS discovery cohorts  
18  
19 on each of the seven different case-control phenotypes. In addition, ABACUS was applied to the WES cohorts  
20  
21 (FinnDiane, Steno and SDR) on the two phenotypic comparisons. SNP-sets were defined based on REACTOME,  
22  
23 KEGG and GO Biological Processes. To analyse non-annotated and intergenic SNPs, we also defined SNP-sets of  
24  
25 continuous 3,000 SNPs. Functional clustering of the ABACUS results was performed with DAVID software<sup>91,92</sup>.  
26  
27  
28  
29  
30  
31

## 32 Acknowledgements

33  
34  
35  
36 We thank A. Sandelin, A-R. Salonen, T. Soppela and J. Tuomikangas for skillful laboratory assistance. We also  
37  
38 thank all the subjects who participated in the FinnDiane study and gratefully acknowledge all the physicians  
39  
40 and nurses at each centre involved in the recruitment of participants (Supplemental Table 28).  
41  
42

43  
44 We thank the participants in the EURODIAB FAMILY STUDY and gratefully acknowledge the physicians and  
45  
46 nurses at each centre involved in subject recruitment.  
47  
48

49  
50 A complete list of participants in the DCCT/EDIC research group can be found in New England Journal of  
51  
52 Medicine, 2011;365:2366-2376<sup>82</sup>.  
53  
54  
55  
56  
57  
58  
59  
60

**Funding**

The research was supported by the European Union's Seventh Framework Program (FP7/2007-2013) for the Innovative Medicine Initiative under grant agreement IMI/115006 (the SUMMIT consortium)

The FinnDiane Study was supported by grants from the Folkhälsan Research Foundation, the Wilhelm and Else Stockmann Foundation, the Liv och Hälsa Foundation, Helsinki University Central Hospital Research Funds (EVO), the Signe and Ane Gyllenberg Foundation, Finska Läkaresällskapet, the Novo Nordisk Foundation (NNF14SA0003, and the Academy of Finland (134379 and 275614).

The EURODIAB Family Study was funded by the EU Biomedicine and Health Programme.

The NFS-ORPS Study was supported by NIHR/Wellcome Trust Cambridge Clinical Research Facility.

The GENIE consortium was funded by National Institutes of Health/ National Institute of Diabetes and Digestive and Kidney Diseases (NIH NIDDK, R01-DK081923) to JNH, JCF and P-HG, the Northern Ireland Research and Development Office (APM) and Science Foundation Ireland.

The DCCT/EDIC has been supported by cooperative agreement grants (1982-1993, 2012-2017), and contracts (1982-2012) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease (current grant numbers U01 DK094176 and U01 DK094157), and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the General Clinical Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-present), Bethesda, Maryland, USA.

Industry contributors have had no role in the DCCT/EDIC study but have provided free or discounted supplies or equipment to support participants' adherence to the study: Abbott Diabetes Care (Alameda, CA), Animas (Westchester, PA), Bayer Diabetes Care (North America Headquarters, Tarrytown, NY), Becton Dickinson (Franklin Lakes, NJ), Eli Lilly (Indianapolis, IN), Extend Nutrition (St. Louis, MO), Insulet Corporation (Bedford, MA), Lifescan (Milpitas, CA), Medtronic Diabetes (Minneapolis, MN), Nipro Home Diagnostics (Ft. Lauderdale,



Genome-wide dissection of diabetic kidney disease

1  
2 FL), Nova Diabetes Care (Billerica, MA), Omron (Shelton, CT), Perrigo Diabetes Care (Allegan, MI), Roche  
3  
4 Diabetes Care (Indianapolis, IN) , and Sanofi-Aventis (Bridgewater NJ).  
5  
6

7 SSR was supported by JDRF (grant 17-2012-542).  
8  
9

### 10 11 12 13 14 **Presentation of results prior publication**

15  
16 Parts of this study have been presented in abstract form at the 49<sup>th</sup> European Association for the Study of  
17  
18 Diabetes (EASD) Annual Meeting 2013 in Barcelona, Spain; at the 74<sup>th</sup> American Diabetes Association (ADA)  
19  
20 Scientific Session 2014 in San Francisco, CA, USA; at the 75<sup>th</sup> ADA Scientific Session 2015 in Boston, MA, USA;  
21  
22 and at the 51<sup>st</sup> EASD Annual Meeting 2015 in Stockholm, Sweden.  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Statement of competing financial interests**

32  
33 P-HG has received lecture honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genzyme, MSD,  
34  
35 Novartis, Novo Nordisk, and Sanofi, and research grants from Eli Lilly and Roche. P-HG is also an advisory board  
36  
37 member for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Novartis and Sanofi.  
38  
39

40  
41 HMC has acted as consultant / advisory panel for Pfizer, Sanofi Aventis, Regeneron and Eli Lilly, Data safety  
42  
43 panel for Novartis;; has received research support from Roche, Pfizer, Eli Lilly, Boehringer Ingelheim,  
44  
45 AstraZeneca, Sanofi; has participated in a lecture/speaker's bureau and received honorarium from Pfizer; and is  
46  
47 a shareholder in Roche.  
48  
49

50  
51  
52 JT has acted as consultant / advisory panel for Bayer Health Care, Sanofi Aventis, Eli Lilly, Roche, Impeto  
53  
54 Medical and Novo Nordisk, and has received research support from Roche, Pfizer, Eli Lilly, Boehringer  
55  
56 Ingelheim, AstraZeneca, Sanofi; and is a shareholder in Orion Pharma.  
57  
58  
59  
60

Genome-wide dissection of diabetic kidney disease

PR has acted as consultant /advisory panel for Eli Lilly, Novo Nordisk, AbbVie, Boehringer Ingelheim, Astra Zeneca, Janssen, Astellas, BMS and MSD (all honoraria to institution). Has received research grants from Novo Nordisk, Astra Zeneca and Novartis. Has shares in Novo Nordisk AS.

JCF has acted as consultant for Sanofi.

DZ, MJB, and EF are employees and stockholders of Pfizer.

## References

1. U.S. Renal Data System: USRDS 2011 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the united states, national institutes of health, national institute of diabetes and digestive and kidney diseases, Bethesda, MD.2011
2. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ: The 30-year natural history of type 1 diabetes complications: The pittsburgh epidemiology of diabetes complications study experience. [Electronic version]. *Diabetes* 55: 1463-1469, 2006
3. Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C: Incidence of end-stage renal disease in patients with type 1 diabetes. [Electronic version]. *JAMA* 294: 1782-1787, 2005
4. Harjutsalo V, Maric C, Forsblom C, Thorn L, Waden J, Groop PH, FinnDiane Study Group: Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. [Electronic version]. *Diabetologia* 54: 1992-1999, 2011
5. Fioretto P, & Mauer M: Histopathology of diabetic nephropathy. [Electronic version]. *Semin Nephrol* 27: 195-207, 2007
6. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T: Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. [Electronic version]. *Diabetologia* 30: 144-148, 1987
7. Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, Mäkinen VP, Rosengård-Bärlund M, Saraheimo M, Hietala K, Heikkilä O, Forsblom C, FinnDiane Study Group: The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. [Electronic version]. *Diabetes* 58: 1651-1658, 2009
8. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. [Electronic version]. *N Engl J Med* 320: 1161-1165, 1989

## Genome-wide dissection of diabetic kidney disease

- 1  
2 9. Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH: Is diabetic  
3 nephropathy an inherited complication. [Electronic version]. *Kidney Int* 41: 719-722, 1992
- 4  
5 10. Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J: Population-based assessment of familial clustering of  
6 diabetic nephropathy in type 1 diabetes. [Electronic version]. *Diabetes* 53: 2449-2454, 2004
- 7  
8 11. Thorn LM, Forsblom C, Fagerudd J, Pettersson-Fernholm K, Kilpikari R, Groop PH, FinnDiane Study Group:  
9 Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy. [Electronic version].  
10 *Diabetes Care* 30: 1162-1167, 2007
- 11  
12 12. Fagerudd JA, Pettersson-Fernholm KJ, Gronhagen-Riska C, Groop PH: The impact of a family history of type  
13 II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with type I  
14 (insulin-dependent) diabetes mellitus. [Electronic version]. *Diabetologia* 42: 519-526, 1999
- 15  
16 13. Earle K, Walker J, Hill C, Viberti G: Familial clustering of cardiovascular disease in patients with insulin-  
17 dependent diabetes and nephropathy. [Electronic version]. *N Engl J Med* 326: 673-677, 1992
- 18  
19 14. Williams WW, Salem RM, McKnight AJ, Sandholm N, Forsblom C, Taylor A, Guiducci C, McAteer JB, McKay  
20 GJ, Isakova T, Brennan EP, Sadlier DM, Palmer C, Soderlund J, Fagerholm E, Harjutsalo V, Lithovius R,  
21 Gordin D, Hietala K, Kyto J, Parkkonen M, Rosengard-Barlund M, Thorn L, Syreeni A, Tolonen N, Saraheimo  
22 M, Waden J, Pitkaniemi J, Sarti C, Tuomilehto J, Tryggvason K, Osterholm AM, He B, Bain S, Martin F,  
23 Godson C, Hirschhorn JN, Maxwell AP, Groop PH, Florez JC, GENIE Consortium: Association testing of  
24 previously reported variants in a large case-control meta-analysis of diabetic nephropathy. [Electronic  
25 version]. *Diabetes* 61: 2187-2194, 2012
- 26  
27 15. Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ, Williams WW, Sadlier  
28 DM, Makinen VP, Swan EJ, Palmer C, Boright AP, Ahlqvist E, Deshmukh HA, Keller BJ, Huang H, Ahola AJ,  
29 Fagerholm E, Gordin D, Harjutsalo V, He B, Heikkila O, Hietala K, Kyto J, Lahermo P, Lehto M, Lithovius R,  
30 Osterholm AM, Parkkonen M, Pitkaniemi J, Rosengard-Barlund M, Saraheimo M, Sarti C, Soderlund J,  
31 Soro-Paavonen A, Syreeni A, Thorn LM, Tikkanen H, Tolonen N, Tryggvason K, Tuomilehto J, Waden J, Gill  
32 GV, Prior S, Guiducci C, Mirel DB, Taylor A, Hosseini SM, DCCT/EDIC Research Group, Parving HH, Rossing  
33 P, Tarnow L, Ladenvall C, Alhenc-Gelas F, Lefebvre P, Rigalleau V, Rousset R, Tregouet DA, Maestroni A,  
34 Maestroni S, Falhammar H, Gu T, Mollsten A, Cimponeriu D, Ioana M, Mota M, Mota E, Serafinceanu C,  
35 Stavarachi M, Hanson RL, Nelson RG, Kretzler M, Colhoun HM, Panduru NM, Gu HF, Brismar K, Zerbini G,  
36 Hadjadj S, Marre M, Groop L, Lajer M, Bull SB, Waggott D, Paterson AD, Savage DA, Bain SC, Martin F,  
37 Hirschhorn JN, Godson C, Florez JC, Groop PH, Maxwell AP: New susceptibility loci associated with kidney  
38 disease in type 1 diabetes. [Electronic version]. *PLoS Genet* 8: e1002921, 2012
- 39  
40 16. Sandholm N, McKnight AJ, Salem RM, Brennan EP, Forsblom C, Harjutsalo V, Makinen VP, McKay GJ, Sadlier  
41 DM, Williams WW, Martin F, Panduru NM, Tarnow L, Tuomilehto J, Tryggvason K, Zerbini G, Comeau ME,  
42 Langefeld CD, FIND Consortium, Godson C, Hirschhorn JN, Maxwell AP, Florez JC, Groop PH, FinnDiane  
43 Study Group and the GENIE Consortium: Chromosome 2q31.1 associates with ESRD in women with type 1  
44 diabetes. [Electronic version]. *J Am Soc Nephrol* 24: 1537-1543, 2013
- 45  
46 17. Sandholm N, Forsblom C, Makinen VP, McKnight AJ, Osterholm AM, He B, Harjutsalo V, Lithovius R, Gordin  
47 D, Parkkonen M, Saraheimo M, Thorn LM, Tolonen N, Waden J, Tuomilehto J, Lajer M, Ahlqvist E, Mollsten  
48 A, Marcovecchio ML, Cooper J, Dunger D, Paterson AD, Zerbini G, Groop L, SUMMIT Consortium, Tarnow  
49 L, Maxwell AP, Tryggvason K, Groop PH, FinnDiane Study Group: Genome-wide association study of  
50 urinary albumin excretion rate in patients with type 1 diabetes. [Electronic version]. *Diabetologia* 57:  
51 1143-1153, 2014
- 52  
53  
54  
55  
56  
57  
58  
59  
60

## Genome-wide dissection of diabetic kidney disease

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
18. Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, Yang Q, Gudnason V, Launer LJ, Harris TB, Smith AV, Arking DE, Astor BC, Boerwinkle E, Ehret GB, Ruczinski I, Scharpf RB, Chen YD, de Boer IH, Haritunians T, Lumley T, Sarnak M, Siscovick D, Benjamin EJ, Levy D, Upadhyay A, Aulchenko YS, Hofman A, Rivadeneira F, Uitterlinden AG, van Duijn CM, Chasman DI, Pare G, Ridker PM, Kao WH, Witteman JC, Coresh J, Shlipak MG, Fox CS: Multiple loci associated with indices of renal function and chronic kidney disease. [Electronic version]. *Nat Genet* 41: 712-717, 2009
19. Pattaro C, Kottgen A, Teumer A, Garnaas M, Boger CA, Fuchsberger C, Olden M, Chen MH, Tin A, Taliun D, Li M, Gao X, Gorski M, Yang Q, Hundertmark C, Foster MC, O'Seaghdha CM, Glazer N, Isaacs A, Liu CT, Smith AV, O'Connell JR, Struchalin M, Tanaka T, Li G, Johnson AD, Gierman HJ, Feitosa M, Hwang SJ, Atkinson EJ, Lohman K, Cornelis MC, Johansson A, Tonjes A, Dehghan A, Chouraki V, Holliday EG, Sorice R, Kutalik Z, Lehtimäki T, Esko T, Deshmukh H, Ulivi S, Chu AY, Murgia F, Trompet S, Imboden M, Kollerits B, Pistis G, CARDIoGRAM Consortium, ICBP Consortium, CARE Consortium, Wellcome Trust Case Control Consortium 2 (WTCCC2), Harris TB, Launer LJ, Aspelund T, Eiriksdottir G, Mitchell BD, Boerwinkle E, Schmidt H, Cavalieri M, Rao M, Hu FB, Demirkan A, Oostra BA, de Andrade M, Turner ST, Ding J, Andrews JS, Freedman BI, Koenig W, Illig T, Doring A, Wichmann HE, Kolcic I, Zemunik T, Boban M, Minelli C, Wheeler HE, Igl W, Zaboli G, Wild SH, Wright AF, Campbell H, Ellinghaus D, Nothlings U, Jacobs G, Biffar R, Endlich K, Ernst F, Homuth G, Kroemer HK, Nauck M, Stracke S, Volker U, Volzke H, Kovacs P, Stumvoll M, Magi R, Hofman A, Uitterlinden AG, Rivadeneira F, Aulchenko YS, Polasek O, Hastie N, Vitart V, Helmer C, Wang JJ, Ruggiero D, Bergmann S, Kahonen M, Viikari J, Nikopensus T, Province M, Ketkar S, Colhoun H, Doney A, Robino A, Giulianini F, Kramer BK, Portas L, Ford I, Buckley BM, Adam M, Thun GA, Paulweber B, Haun M, Sala C, Metzger M, Mitchell P, Ciullo M, Kim SK, Vollenweider P, Raitakari O, Metspalu A, Palmer C, Gasparini P, Pirastu M, Jukema JW, Probst-Hensch NM, Kronenberg F, Toniolo D, Gudnason V, Shuldiner AR, Coresh J, Schmidt R, Ferrucci L, Siscovick DS, van Duijn CM, Borecki I, Kardia SL, Liu Y, Curhan GC, Rudan I, Gyllensten U, Wilson JF, Franke A, Pramstaller PP, Rettig R, Prokopenko I, Witteman JC, Hayward C, Ridker P, Parsa A, Bochud M, Heid IM, Goessling W, Chasman DI, Kao WH, Fox CS: Genome-wide association and functional follow-up reveals new loci for kidney function. [Electronic version]. *PLoS Genet* 8: e1002584, 2012
20. Köttgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, O'Connell JR, Li M, Schmidt H, Tanaka T, Isaacs A, Ketkar S, Hwang SJ, Johnson AD, Dehghan A, Teumer A, Pare G, Atkinson EJ, Zeller T, Lohman K, Cornelis MC, Probst-Hensch NM, Kronenberg F, Tonjes A, Hayward C, Aspelund T, Eiriksdottir G, Launer LJ, Harris TB, Rampersaud E, Mitchell BD, Arking DE, Boerwinkle E, Struchalin M, Cavalieri M, Singleton A, Giallauria F, Metter J, de Boer IH, Haritunians T, Lumley T, Siscovick D, Psaty BM, Zillikens MC, Oostra BA, Feitosa M, Province M, de Andrade M, Turner ST, Schillert A, Ziegler A, Wild PS, Schnabel RB, Wilde S, Munzel TF, Leak TS, Illig T, Klopp N, Meisinger C, Wichmann HE, Koenig W, Zgaga L, Zemunik T, Kolcic I, Minelli C, Hu FB, Johansson A, Igl W, Zaboli G, Wild SH, Wright AF, Campbell H, Ellinghaus D, Schreiber S, Aulchenko YS, Felix JF, Rivadeneira F, Uitterlinden AG, Hofman A, Imboden M, Nitsch D, Brandstätter A, Kollerits B, Kedenko L, Magi R, Stumvoll M, Kovacs P, Boban M, Campbell S, Endlich K, Volzke H, Kroemer HK, Nauck M, Volker U, Polasek O, Vitart V, Badola S, Parker AN, Ridker PM, Kardia SL, Blankenberg S, Liu Y, Curhan GC, Franke A, Roach T, Paulweber B, Prokopenko I, Wang W, Gudnason V, Shuldiner AR, Coresh J, Schmidt R, Ferrucci L, Shlipak MG, van Duijn CM, Borecki I, Kramer BK, Rudan I, Gyllensten U, Wilson JF, Witteman JC, Pramstaller PP, Rettig R, Hastie N, Chasman DI, Kao WH, Heid IM, Fox CS: New loci associated with kidney function and chronic kidney disease. [Electronic version]. *Nat Genet* 42: 376-384, 2010
21. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. [Electronic version]. *Nature* 460: 748-752, 2009

## Genome-wide dissection of diabetic kidney disease

22. Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. [Electronic version]. *Nature* 511: 421-427, 2014
23. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Waden J, Ronnback M, Rosengard-Barlund M, Bjorkestén CG, Taskinen MR, Groop PH, FinnDiane Study Group: Metabolic syndrome in type 1 diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study). [Electronic version]. *Diabetes Care* 28: 2019-2024, 2005
24. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold. [Electronic version]. *Kidney Int* 60: 219-227, 2001
25. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD: Classifying diabetes according to the new WHO clinical stages. [Electronic version]. *Eur J Epidemiol* 17: 983-989, 2001
26. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, Marcovecchio L, Neil A, Dalton RN, Dunger DB: Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: Prospective observational study. [Electronic version]. *BMJ* 336: 697-701, 2008
27. Marcovecchio ML, Dalton RN, Schwarze CP, Prevost AT, Neil HA, Acerini CL, Barrett T, Cooper JD, Edge J, Shield J, Widmer B, Todd JA, Dunger DB: Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. [Electronic version]. *Diabetologia* 52: 1173-1181, 2009
28. Mooyaart A, Valk EJJ, van Es L, Bruijn J, de Heer E, Freedman B, Dekkers O, Baelde H: Genetic associations in diabetic nephropathy: A meta-analysis. [Electronic version]. *Diabetologia* 54: 544-553, 2011
29. Sambo F, Malovini A, Sandholm N, Stavarachi M, Forsblom C, Makinen VP, Harjutsalo V, Lithovius R, Gordin D, Parkkonen M, Saraheimo M, Thorn LM, Tolonen N, Waden J, He B, Osterholm AM, Tuomilehto J, Lajer M, Salem RM, McKnight AJ, The GENIE Consortium, Tarnow L, Panduru NM, Barbarini N, Di Camillo B, Toffolo GM, Tryggvason K, Bellazzi R, Cobelli C, The FinnDiane Study Group, Groop PH: Novel genetic susceptibility loci for diabetic end-stage renal disease identified through robust naive bayes classification. *Diabetologia* 57: 1611-1622, 2014
30. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DPK, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB, 'DCCT/EDIC Research Group', Doria A, Rogus JJ, Rich SS, Warram JH, Krolewski AS: Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. [Electronic version]. *Diabetes* 58: 1403-1410, 2009
31. Craig DW, Millis MP, DiStefano JK: Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to type 1 diabetes. [Electronic version]. *Diabet Med* 26: 1090-1098, 2009
32. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D, Babazono T, Tanaka Y, Matsuda M, Kawai K, Iizumi T, Imanishi M, Shinosaki T, Yanagimoto T, Ikeda M, Omachi S, Kashiwagi A, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakajima M, Nakamura Y, Maeda S: Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. [Electronic version]. *Diabetes* 54: 1171-1178, 2005



## Genome-wide dissection of diabetic kidney disease

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
33. McDonough CW, Palmer ND, Hicks PJ, Roh BH, An SS, Cooke JN, Hester JM, Wing MR, Bostrom MA, Rudock ME, Lewis JP, Talbert ME, Blevins RA, Lu L, Ng MC, Sale MM, Divers J, Langefeld CD, Freedman BI, Bowden DW: A genome-wide association study for diabetic nephropathy genes in african americans. [Electronic version]. *Kidney Int* 79: 563-572, 2011
34. Tolonen N, Forsblom C, Thorn L, Waden J, Rosengard-Barlund M, Saraheimo M, Feodoroff M, Makinen VP, Gordin D, Taskinen MR, Groop PH, FinnDiane Study Group: Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. [Electronic version]. *Diabetologia* 52: 2522-2530, 2009
35. Wiseman M, Viberti G, Mackintosh D, Jarrett RJ, Keen H: Glycaemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus. [Electronic version]. *Diabetologia* 26: 401-405, 1984
36. Feodoroff M, Harjutsalo V, Forsblom C, Thorn L, Waden J, Tolonen N, Lithovius R, Groop PH: Smoking and progression of diabetic nephropathy in patients with type 1 diabetes. [Electronic version]. *Acta Diabetol* 2015
37. Hadjadj S, Pean F, Gallois Y, Passa P, Aubert R, Weekers L, Rigalleau V, Bauduceau B, Bekherras A, Roussel R, Dussol B, Rodier M, Marechaud R, Lefebvre PJ, Marre M, Genesis France-Belgium Study: Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: The genesis france-belgium study. [Electronic version]. *Diabetes Care* 27: 2661-2668, 2004
38. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium, Mexican American Type 2 Diabetes (MAT2D) Consortium, Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES) Consortium, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, Horikoshi M, Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, Adair LS, Almgren P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI, Benediktsson R, Bergman RN, Boehm BO, Boerwinkle E, Bonnycastle LL, Burtt N, Cai Q, Campbell H, Carey J, Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, Chen CH, Chen H, Chen YT, Chia KS, Chidambaram M, Chines PS, Cho NH, Cho YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E, Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao Y, Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A, Han BG, Hara K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jockel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukkaanniemi KM, Kelly AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyovalti E, Kowlessur S, Kraft P, Kravic J, Kristensen MM, Krithika S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA, Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Magi R, Mannisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mihailov E, Moebus S, Mohan V, Mohlke KL, Morris AD, Muhleisen TW, Muller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, Nilsson PM, Njolstad I, Nothen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, Peters A, Pinidiyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD, Rehnberg E, Ripatti S,

## Genome-wide dissection of diabetic kidney disease

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segre AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu XO, Shuldiner AR, Sigurdsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY, Stancakova A, Stefansson K, Steinbach G, Steinhorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvanen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, Morris AP: Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. [Electronic version]. *Nat Genet* 46: 234-244, 2014
39. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS: Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. [Electronic version]. *Nat Genet* 41: 703-707, 2009
40. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, Kao WH, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N, Boesgaard TW, Lecoeur C, Shrader P, O'Connell J, Ingelsson E, Couper DJ, Rice K, Song K, Andreasen CH, Dina C, Kottgen A, Le Bacquer O, Pattou F, Taneera J, Steinhorsdottir V, Rybin D, Ardlie K, Sampson M, Qi L, van Hoek M, Weedon MN, Aulchenko YS, Voight BF, Grallert H, Balkau B, Bergman RN, Bielinski SJ, Bonnetfond A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Buchanan TA, Bumpstead SJ, Cavalcanti-Proenca C, Charpentier G, Chen YD, Chines PS, Collins FS, Cornelis M, J Crawford G, Delplanque J, Doney A, Egan JM, Erdos MR, Firmann M, Forouhi NG, Fox CS, Goodarzi MO, Graessler J, Hingorani A, Isomaa B, Jorgensen T, Kivimaki M, Kovacs P, Krohn K, Kumari M, Lauritzen T, Levy-Marchal C, Mayor V, McAteer JB, Meyre D, Mitchell BD, Mohlke KL, Morken MA, Narisu N, Palmer CN, Pakyz R, Pascoe L, Payne F, Pearson D, Rathmann W, Sandbaek A, Sayer AA, Scott LJ, Sharp SJ, Sijbrands E, Singleton A, Siscovick DS, Smith NL, Sparso T, Swift AJ, Syddall H, Thorleifsson G, Tonjes A, Tuomi T, Tuomilehto J, Valle TT, Waeber G, Walley A, Waterworth DM, Zeggini E, Zhao JH, GIANT consortium, MAGIC investigators, Illig T, Wichmann HE, Wilson JF, van Duijn C, Hu FB, Morris AD, Frayling TM, Hattersley AT, Thorsteinsdottir U, Stefansson K, Nilsson P, Syvanen AC, Shuldiner AR, Walker M, Bornstein SR, Schwarz P, Williams GH, Nathan DM, Kuusisto J, Laakso M, Cooper C, Marmot M, Ferrucci L, Mooser V, Stumvoll M, Loos RJ, Altshuler D, Psaty BM, Rotter JI, Boerwinkle E, Hansen T, Pedersen O, Florez JC, McCarthy MI, Boehnke M, Barroso I, Sladek R, Froguel P, Meigs JB, Groop L, Wareham NJ, Watanabe RM: Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. [Electronic version]. *Nat Genet* 42: 142-148, 2010
41. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin D, Liu CT, Bielak LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, Ingelsson E, Jackson AU, Johnson T, Kanoni S, Ladenvall C, Lagou V, Lahti J, Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser ME, Navarro P, Perry JR, Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, Tanaka T, van Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, Boban M, Boehnke M, Boerwinkle E, Bonnycastle LL, Boomsma DI, Borecki IB, Bottcher Y, Bouchard C, Brunner E, Budimir D, Campbell H, Carlson O, Chines PS, Clarke R, Collins FS, Corbaton-Anchuelo A, Couper D, de Faire U, Dedoussis GV, Deloukas P, Dimitriou M, Egan JM, Eiriksdottir G, Erdos MR, Eriksson JG, Eury E, Ferrucci L, Ford I, Forouhi NG, Fox CS, Franzosi MG, Franks PW, Frayling TM, Froguel P, Galan P, de Geus E, Gigante B, Glazer NL, Goel A, Groop L, Gudnason V, Hallmans G,



## Genome-wide dissection of diabetic kidney disease

Hamsten A, Hansson O, Harris TB, Hayward C, Heath S, Hercberg S, Hicks AA, Hingorani A, Hofman A, Hui J, Hung J, Jarvelin MR, Jhun MA, Johnson PC, Jukema JW, Jula A, Kao WH, Kaprio J, Kardina SL, Keinanen-Kiukaanniemi S, Kivimaki M, Kolcic I, Kovacs P, Kumari M, Kuusisto J, Kyvik KO, Laakso M, Lakka T, Lannfelt L, Lathrop GM, Launer LJ, Leander K, Li G, Lind L, Lindstrom J, Lobbens S, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Marmot M, Meneton P, Mohlke KL, Mooser V, Morken MA, Miljkovic I, Narisu N, O'Connell J, Ong KK, Oostra BA, Palmer LJ, Palotie A, Pankow JS, Peden JF, Pedersen NL, Pehlic M, Peltonen L, Penninx B, Pericic M, Perola M, Perusse L, Peyser PA, Polasek O, Pramstaller PP, Province MA, Raikonen K, Rauramaa R, Rehnberg E, Rice K, Rotter JI, Rudan I, Ruokonen A, Saaristo T, Sabater-Lleal M, Salomaa V, Savage DB, Saxena R, Schwarz P, Seedorf U, Sennblad B, Serrano-Rios M, Shuldiner AR, Sijbrands EJ, Siscovick DS, Smit JH, Small KS, Smith NL, Smith AV, Stancakova A, Stirrups K, Stumvoll M, Sun YV, Swift AJ, Tonjes A, Tuomilehto J, Trompet S, Uitterlinden AG, Uusitupa M, Vikstrom M, Vitart V, Vohl MC, Voight BF, Vollenweider P, Waeber G, Waterworth DM, Watkins H, Wheeler E, Widen E, Wild SH, Willems SM, Willemsen G, Wilson JF, Wittteman JC, Wright AF, Yaghoobkar H, Zelenika D, Zemunik T, Zgaga L, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Multiple Tissue Human Expression Resource (MUTHER) Consortium, Wareham NJ, McCarthy MI, Barroso I, Watanabe RM, Florez JC, Dupuis J, Meigs JB, Langenberg C: A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. [Electronic version]. *Nat Genet* 44: 659-669, 2012

42. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL, Stewart AF, Voight BF, Willenborg C, Wright B, Altshuler D, Arking D, Balkau B, Barnes D, Boerwinkle E, Boehm B, Bonnefond A, Bonnycastle LL, Boomsma DI, Bornstein SR, Bottcher Y, Bumpstead S, Burnett-Miller MS, Campbell H, Cao A, Chambers J, Clark R, Collins FS, Coresh J, de Geus EJ, Dei M, Deloukas P, Doring A, Egan JM, Elosua R, Ferrucci L, Forouhi N, Fox CS, Franklin C, Franzosi MG, Gallina S, Goel A, Graessler J, Grallert H, Greinacher A, Hadley D, Hall A, Hamsten A, Hayward C, Heath S, Herder C, Homuth G, Hottenga JJ, Hunter-Merrill R, Illig T, Jackson AU, Jula A, Kleber M, Knouff CW, Kong A, Kooner J, Kottgen A, Kovacs P, Krohn K, Kuhnel B, Kuusisto J, Laakso M, Lathrop M, Lecoeur C, Li M, Li M, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Malarstig A, Mangino M, Martinez-Larrad MT, Marz W, McArdle WL, McPherson R, Meisinger C, Meitinger T, Melander O, Mohlke KL, Mooser VE, Morken MA, Narisu N, Nathan DM, Nauck M, O'Donnell C, Oexle K, Olla N, Pankow JS, Payne F, Peden JF, Pedersen NL, Peltonen L, Perola M, Polasek O, Porcu E, Rader DJ, Rathmann W, Ripatti S, Rocheleau G, Roden M, Rudan I, Salomaa V, Saxena R, Schlessinger D, Schunkert H, Schwarz P, Seedorf U, Selvin E, Serrano-Rios M, Shrader P, Silveira A, Siscovick D, Song K, Spector TD, Stefansson K, Steinthorsdottir V, Strachan DP, Strawbridge R, Stumvoll M, Surakka I, Swift AJ, Tanaka T, Teumer A, Thorleifsson G, Thorsteinsdottir U, Tonjes A, Usala G, Vitart V, Volzke H, Wallaschofski H, Waterworth DM, Watkins H, Wichmann HE, Wild SH, Willemsen G, Williams GH, Wilson JF, Winkelmann J, Wright AF, WTCCC, Zabena C, Zhao JH, Epstein SE, Erdmann J, Hakonarson HH, Kathiresan S, Khaw KT, Roberts R, Samani NJ, Fleming MD, Sladek R, Abecasis G, Boehnke M, Froguel P, Groop L, McCarthy MI, Kao WH, Florez JC, Uda M, Wareham NJ, Barroso I, Meigs JB: Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. [Electronic version]. *Diabetes* 59: 3229-3239, 2010

43. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas AS, Nica A, Wheeler E, Chen H, Voight BF, Taneera J, Kanoni S, Peden JF, Turrini F, Gustafsson S, Zabena C, Almgren P, Barker DJ, Barnes D, Dennison EM, Eriksson JG, Eriksson P, Eury E, Folkersen L, Fox CS, Frayling TM, Goel A, Gu HF, Horikoshi M, Isomaa B, Jackson AU, Jameson KA, Kajantie E, Kerr-Conte J, Kuulasmaa T, Kuusisto J, Loos RJ, Luan J, Makrilakis K, Manning AK, Martinez-Larrad MT, Narisu N, Nastase Mannila M, Ohrvik J, Osmond C, Pascoe L, Payne F, Sayer AA, Sennblad B, Silveira A, Stancakova A, Stirrups K, Swift AJ, Syvanen AC, Tuomi T, van 't Hooft FM, Walker M, Weedon MN, Xie W, Zethelius B, DIAGRAM Consortium, GIANT Consortium, MuTHER Consortium, CARDIoGRAM Consortium, C4D Consortium, Ongen

## Genome-wide dissection of diabetic kidney disease

H, Malarstig A, Hopewell JC, Saleheen D, Chambers J, Parish S, Danesh J, Kooner J, Ostenson CG, Lind L, Cooper CC, Serrano-Rios M, Ferrannini E, Forsen TJ, Clarke R, Franzosi MG, Seedorf U, Watkins H, Froguel P, Johnson P, Deloukas P, Collins FS, Laakso M, Dermitzakis ET, Boehnke M, McCarthy MI, Wareham NJ, Groop L, Pattou F, Gloyn AL, Dedoussis GV, Lyssenko V, Meigs JB, Barroso I, Watanabe RM, Ingelsson E, Langenberg C, Hamsten A, Florez JC: Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. [Electronic version]. *Diabetes* 60: 2624-2634, 2011

44. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Magi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JR, Egan JM, Lajunen T, Grarup N, Sparso T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proenca C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Ruccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YD, Chines P, Clarke R, Coin LJ, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day IN, de Geus EJ, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllenstein U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL, Hassanali N, Hayward C, Heath SC, Herberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PR, Jorgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martinez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orru M, Pakyz R, Palmer CN, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AF, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, Sigurdsson G, Sijbrands EJ, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvanen AC, Tanaka T, Thorand B, Tichet J, Tonjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemssen G, Witteman JC, Yarnell JW, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, DIAGRAM Consortium, GIANT Consortium, Global BPgen Consortium, Borecki IB, Loos RJ, Meneton P, Magnusson PK, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Rios M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WH, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF, Anders Hamsten on behalf of Procardis Consortium, MAGIC investigators, Bergman RN, Buchanan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JI, Siscovick DS, Penninx BW, Boomsma DI, Deloukas P, Spector TD, Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A, Schlessinger D, Uda M, Ruukonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI, Florez JC, Barroso I: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. [Electronic version]. *Nat Genet* 42: 105-116, 2010
45. Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, Ferrannini E, Forouhi NG, Franks PW, Gavrila D, Giedraitis V, Grioni S, Groop LC, Kaaks R, Key TJ, Kuhn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quiros JR, Rolandsson O, Roswall N, Sacerdote C, Sala N, Sanchez MJ, Schulze MB, Siddiq A, Slimani N, Sluijs I,

## Genome-wide dissection of diabetic kidney disease

1  
2 Spijkerman AM, Tjonneland A, Tumino R, van der ADL, Yaghootkar H, RISC Study Group, EPIC-InterAct  
3 Consortium, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB,  
4 Langenberg C, Wareham NJ: Common genetic variants highlight the role of insulin resistance and body fat  
5 distribution in type 2 diabetes, independent of obesity. [Electronic version]. *Diabetes* 63: 4378-4387, 2014  
6  
7

8 46. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, Styrkarsdottir U,  
9 Gretarsdottir S, Thorlacius S, Jonsdottir I, Jonsdottir T, Olafsdottir EJ, Olafsdottir GH, Jonsson T, Jonsson F,  
10 Borch-Johnsen K, Hansen T, Andersen G, Jorgensen T, Lauritzen T, Aben KK, Verbeek AL, Roeleveld N,  
11 Kampman E, Yanek LR, Becker LC, Tryggvadottir L, Rafnar T, Becker DM, Gulcher J, Kiemenev LA, Pedersen  
12 O, Kong A, Thorsteinsdottir U, Stefansson K: Genome-wide association yields new sequence variants at  
13 seven loci that associate with measures of obesity. [Electronic version]. *Nat Genet* 41: 18-24, 2009  
14  
15

16 47. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, Fischer  
17 K, Justice AE, Workalemahu T, Wu JM, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C,  
18 Gustafsson S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J,  
19 Fehrmann R, Karjalainen J, Kahali B, Liu CT, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M,  
20 Bragg-Gresham JL, Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME,  
21 Kristiansson K, Mangino M, Mateo Leach I, Medina-Gomez C, Palmer CD, Pasko D, Pechlivanis S, Peters  
22 MJ, Prokopenko I, Stancakova A, Ju Sung Y, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang  
23 W, Albrecht E, Arnlov J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M,  
24 Bohringer S, Bonnet F, Bottcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Daw EW, Deelen J,  
25 Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR, Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis  
26 V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB, Grassler J, Grewal J, Groves CJ, Haller T, Hallmans G,  
27 Hartman CA, Hassinen M, Hayward C, Heikkila K, Herzig KH, Helmer Q, Hillege HL, Holmen O, Hunt SC,  
28 Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP, Kinnunen L, Koenig W, Kooner IK,  
29 Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Lobbens S, Lorentzon M, Mach F,  
30 Magnusson PK, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, Moayyeri A,  
31 Monda KL, Mooijaart SP, Muhleisen TW, Mulas A, Muller G, Muller-Nurasyid M, Nagaraja R, Nalls MA,  
32 Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna  
33 S, Scharnagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Vernon Smith A, Stirrups K, Stringham  
34 HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A,  
35 Troffa C, van Oort FV, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A,  
36 Zhang Q, Hua Zhao J, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG,  
37 Hedman AK, Hivert MF, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B,  
38 McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G,  
39 Nyholt DR, Olsson C, Perry JR, Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE,  
40 Westra HJ, Zondervan KT, ADIPOGen Consortium, CARDIOGRAMplusC4D Consortium, CKDGen  
41 Consortium, GEFOS Consortium, GENIE Consortium, GLGC, ICBP, International Endogene Consortium,  
42 LifeLines Cohort Study, MAGIC Investigators, MuTHER Consortium, PAGE Consortium, ReproGen  
43 Consortium, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Brown MJ, Burnier M,  
44 Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de  
45 Geus EJ, Dorr M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrieres J, Forouhi NG, Forrester T, Franco  
46 OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliovaara M, Hicks AA,  
47 Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hypponen E, Illig T, Jarvelin MR,  
48 Johansen B, Jousilahti P, Jula AM, Kaprio J, Kee F, Keinanen-Kiukkaanniemi SM, Kooner JS, Kooperberg C,  
49 Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimaki  
50 T, Lyssenko V, Mannisto S, Marette A, Matisse TC, McKenzie CA, McKnight B, Musk AW, Mohlenkamp S,  
51 Morris AD, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP,  
52 Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ,  
53 Saramies J, Sarzynski MA, Schwarz PE, Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K,  
54  
55  
56  
57  
58  
59  
60

## Genome-wide dissection of diabetic kidney disease

Tonjes A, Tremblay A, Tremoli E, Vohl MC, Volker U, Vollenweider P, Wilson JF, Wittteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ, Hamsten A, Hui J, Hveem K, Jockel KH, Kivimaki M, Kuh D, Laakso M, Liu Y, Marz W, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ, Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Stefansson K, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL: New genetic loci link adipose and insulin biology to body fat distribution. [Electronic version]. *Nature* 518: 187-196, 2015

48. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Hua Zhao J, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlov J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida Chen YD, Clarke R, Daw EW, de Craen AJ, Delgado G, Dimitriou M, Doney AS, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Sin Lo K, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PK, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Vernon Smith A, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, LifeLines Cohort Study, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JR, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, Van't Hooft FM, Vinkhuyzen AA, Westra HJ, Zheng W, Zondervan KT, ADIPOGen Consortium, AGEN-BMI Working Group, CARDIOGRAMplusC4D Consortium, CKDGen Consortium, GLGC, ICBP, MAGIC Investigators, MuTHER Consortium, MIGen Consortium, PAGE Consortium, ReproGen Consortium, GENIE Consortium, International Endogene Consortium, Heath AC, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllenstein U, Hall AS, Harris TB, Hattersley AT, Hicks AA,



## Genome-wide dissection of diabetic kidney disease

Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJ, Keinanen-Kiukkaanniemi SM, Kiemeny LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PA, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PE, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Volker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimäki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJ, Speliotes EK: Genetic studies of body mass index yield new insights for obesity biology. [Electronic version]. *Nature* 518: 197-206, 2015

49. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sober S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milanese Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH, Sjogren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, Lehtimäki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uitterwaal CS, Adeyemo A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND, CARDIoGRAM consortium, CKDGen Consortium, KidneyGen Consortium, EchoGen consortium, CHARGE-HF consortium, Aspelund T, Garcia M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Kardina SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC, Kahonen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Bolton JA, Kottgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grassler J, Groop L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Soler Artigas M, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y, Ogihara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stancakova A, Raffel LJ, Yao J, Kathiresan S, O'Donnell CJ, Schwartz SM, Ikram MA, Longstreth WT, Jr, Mosley TH, Seshadri S, Shrine NR, Wain LV, Morcken MA, Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani KR, Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs A, Rivadeneira

## Genome-wide dissection of diabetic kidney disease

- 1  
2 F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ, Lyytikainen LP, Soininen P, Tukiainen T, Wurtz  
3 P, Ong RT, Dorr M, Kroemer HK, Volker U, Volzke H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas  
4 P, Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MV, Denniff M,  
5 Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, Schwarz PE, Hayward C, Guo X,  
6 Rotimi C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer  
7 LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Tai ES, Cooper RS,  
8 Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen D,  
9 Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker PM, Bandinelli S,  
10 Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller PP, Elosua R, Soranzo  
11 N, Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ,  
12 Gudnason V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS,  
13 Boerwinkle E, Vasani RS, Boehnke M, Larson MG, Jarvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott  
14 P, van Duijn CM, Newton-Cheh C, Levy D, Caulfield MJ, Johnson T: Genetic variants in novel pathways  
15 influence blood pressure and cardiovascular disease risk. [Electronic version]. *Nature* 478: 103-109, 2011  
16  
17  
18  
19 50. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS,  
20 Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morcken MA, Narisu  
21 N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ,  
22 Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G,  
23 Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM,  
24 Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR: Newly identified loci that influence lipid  
25 concentrations and risk of coronary artery disease. [Electronic version]. *Nat Genet* 40: 161-169, 2008  
26  
27  
28 51. Klein R, Klein BE, Moss SE: Is obesity related to microvascular and macrovascular complications in diabetes?  
29 the wisconsin epidemiologic study of diabetic retinopathy. [Electronic version]. *Arch Intern Med* 157: 650-  
30 656, 1997  
31  
32  
33 52. Hill CJ, Cardwell CR, Maxwell AP, Young RJ, Matthews B, O'Donoghue DJ, Fogarty DG: Obesity and kidney  
34 disease in type 1 and 2 diabetes: An analysis of the national diabetes audit. [Electronic version]. *QJM* 106:  
35 933-942, 2013  
36  
37  
38 53. Todd JN, Dahlstrom EH, Salem RM, Sandholm N, Forsblom C, FinnDiane Study Group, McKnight AJ, Maxwell  
39 AP, Brennan E, Sadlier D, Godson C, Groop PH, Hirschhorn JN, Florez JC: Genetic evidence for a causal role  
40 of obesity in diabetic kidney disease. [Electronic version]. *Diabetes* 64: 4238-4246, 2015  
41  
42  
43 54. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric  
44 Genomics Consortium, Patterson N, Daly MJ, Price AL, Neale BM: LD score regression distinguishes  
45 confounding from polygenicity in genome-wide association studies. [Electronic version]. *Nat Genet* 47:  
46 291-295, 2015  
47  
48  
49 55. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, ReproGen Consortium, Psychiatric  
50 Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control  
51 Consortium 3, Duncan L, Perry JR, Patterson N, Robinson EB, Daly MJ, Price AL, Neale BM: An atlas of  
52 genetic correlations across human diseases and traits. [Electronic version]. *Nat Genet* 2015  
53  
54  
55 56. Ng LL, Ngkeekwong FC, Quinn PA, Davies JE: Uptake mechanisms for ascorbate and dehydroascorbate in  
56 lymphoblasts from diabetic nephropathy and hypertensive patients. [Electronic version]. *Diabetologia* 41:  
57 435-442, 1998  
58  
59  
60

## Genome-wide dissection of diabetic kidney disease

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
57. Farvid MS, Jalali M, Siassi F, Hosseini M: Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. [Electronic version]. *Diabetes Care* 28: 2458-2464, 2005
58. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage. the steno hypothesis. [Electronic version]. *Diabetologia* 32: 219-226, 1989
59. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP, van der Vlag J, Vlodaysky I, Elkin M: Heparanase is essential for the development of diabetic nephropathy in mice. [Electronic version]. *Diabetes* 61: 208-216, 2012
60. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK, Treating to New Targets Steering Committee and Investigators: Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. [Electronic version]. *Mayo Clin Proc* 83: 870-879, 2008
61. Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: A meta-analysis. [Electronic version]. *J Am Soc Nephrol* 17: 2006-2016, 2006
62. Veikkolainen V, Naillat F, Railo A, Chi L, Manninen A, Hohenstein P, Hastie N, Vainio S, Elenius K: ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. [Electronic version]. *J Am Soc Nephrol* 23: 112-122, 2012
63. Price AL, Kryukov GV, de Bakker PI, Purcell SM, Staples J, Wei LJ, Sunyaev SR: Pooled association tests for rare variants in exon-resequencing studies. [Electronic version]. *Am J Hum Genet* 86: 832-838, 2010
64. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X: Rare-variant association testing for sequencing data with the sequence kernel association test. [Electronic version]. *Am J Hum Genet* 89: 82-93, 2011
65. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, NHLBI GO Exome Sequencing Project-ESP Lung Project Team, Christiani DC, Wurfel MM, Lin X: Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. [Electronic version]. *Am J Hum Genet* 91: 224-237, 2012
66. Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T, O'Donnell-Luria A, Ware J, Hill A, Cummings B, Tukiainen T, Birnbaum D, Kosmicki J, Duncan L, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Cooper D, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki M, Levy Moonshine A, Natarajan P, Orozco L, Peloso G, Poplin R, Rivas M, Ruano-Rubio V, Ruderfer D, Shakir K, Stenson P, Stevens C, Thomas B, Tiao G, Tusie-Luna M, Weisburd B, Won H, Yu D, Altshuler D, Ardissino D, Boehnke M, Danesh J, Roberto E, Florez J, Gabriel S, Getz G, Hultman C, Kathiresan S, Laakso M, McCarroll S, McCarthy M, McGovern D, McPherson R, Neale B, Palotie A, Purcell S, Saleheen D, Scharf J, Sklar P, Patrick S, Tuomilehto J, Watkins H, Wilson J, Daly M, MacArthur D: Analysis of protein-coding genetic variation in 60,706 humans. [Electronic version]. *bioRxiv* 2015
67. Di Camillo B, Sambo F, Toffolo G, Cobelli C: ABACUS: An entropy-based cumulative bivariate statistic robust to rare variants and different direction of genotype effect. [Electronic version]. *Bioinformatics* 30: 384-391, 2014
68. Wessman M, Forsblom C, Kaunisto MA, Soderlund J, Ilonen J, Sallinen R, Hiekkalinna T, Parkkonen M, Maxwell AP, Tarnow L, Parving HH, Hadjadj S, Marre M, Peltonen L, Groop PH, FinnDiane Study Group:

## Genome-wide dissection of diabetic kidney disease

- 1  
2 Novel susceptibility locus at 22q11 for diabetic nephropathy in type 1 diabetes. [Electronic version]. *PLoS*  
3 *One* 6: e24053, 2011  
4
- 5  
6 69. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis  
7 corrects for stratification in genome-wide association studies. [Electronic version]. *Nat Genet* 38: 904-909,  
8 2006  
9
- 10  
11 70. Howie BN, Donnelly P, Marchini J: A flexible and accurate genotype imputation method for the next  
12 generation of genome-wide association studies. [Electronic version]. *PLoS Genet* 5: e1000529, 2009  
13
- 14  
15 71. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker  
16 RE, Kang HM, Marth GT, McVean GA: An integrated map of genetic variation from 1,092 human genomes.  
17 [Electronic version]. *Nature* 491: 56-65, 2012  
18
- 19  
20 72. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM: A program for  
21 annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of  
22 *drosophila melanogaster* strain w1118; iso-2; iso-3. [Electronic version]. *Fly (Austin)* 6: 80-92, 2012  
23
- 24  
25 73. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F: Deriving the consequences of genomic  
26 variants with the ensembl API and SNP effect predictor. [Electronic version]. *Bioinformatics* 26: 2069-  
27 2070, 2010  
28
- 29  
30 74. Ruark E, Münz M, Renwick A, Clarke M, Ramsay E, Hanks S, Mahamdallie S, Elliott A, Seal S, Strydom A,  
31 Gerton L, Rahman N: The ICR1000 UK exome series: A resource of gene variation in an outbred population  
32 [version 1; referees: 2 approved]. *F1000Research* 4:2015  
33
- 34  
35 75. Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstrom K, Esko T, Magi R, Inouye M, Lappalainen T,  
36 Chan Y, Salem RM, Lek M, Flannick J, Sim X, Manning A, Ladenvall C, Bumpstead S, Hamalainen E, Aalto K,  
37 Maksimow M, Salmi M, Blankenberg S, Ardissino D, Shah S, Horne B, McPherson R, Hovingh GK, Reilly MP,  
38 Watkins H, Goel A, Farrall M, Girelli D, Reiner AP, Stitzel NO, Kathiresan S, Gabriel S, Barrett JC, Lehtimäki  
39 T, Laakso M, Groop L, Kaprio J, Perola M, McCarthy MI, Boehnke M, Altshuler DM, Lindgren CM,  
40 Hirschhorn JN, Metspalu A, Freimer NB, Zeller T, Jalkanen S, Koskinen S, Raitakari O, Durbin R, MacArthur  
41 DG, Salomaa V, Ripatti S, Daly MJ, Palotie A, Sequencing Initiative Suomi (SISu) Project: Distribution and  
42 medical impact of loss-of-function variants in the finnish founder population. [Electronic version]. *PLoS*  
43 *Genet* 10: e1004494, 2014  
44
- 45  
46 76. Yang J, Lee SH, Goddard ME, Visscher PM: GCTA: A tool for genome-wide complex trait analysis. [Electronic  
47 version]. *Am J Hum Genet* 88: 76-82, 2011  
48
- 49  
50 77. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, Freimer NB, Sabatti C, Eskin E: Variance component model  
51 to account for sample structure in genome-wide association studies. [Electronic version]. *Nat Genet* 42:  
52 348-354, 2010  
53
- 54  
55 78. Magi R, & Morris AP: GWAMA: Software for genome-wide association meta-analysis. [Electronic version].  
56 *BMC Bioinformatics* 11: 288-2105-11-288, 2010  
57
- 58  
59 79. Willer CJ, Li Y, Abecasis GR: METAL: Fast and efficient meta-analysis of genomewide association scans.  
60 [Electronic version]. *Bioinformatics* 26: 2190-2191, 2010



## Genome-wide dissection of diabetic kidney disease

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
80. Purcell S, Cherny SS, Sham PC: Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. [Electronic version]. *Bioinformatics* 19: 149-150, 2003
81. Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. [Electronic version]. *Nat Genet* 38: 209-213, 2006
82. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. [Electronic version]. *N Engl J Med* 365: 2366-2376, 2011
83. DCCT/EDIC research group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study. [Electronic version]. *Lancet Diabetes Endocrinol* 2: 793-800, 2014
84. Germain M, Pezzolesi MG, Sandholm N, McKnight AJ, Susztak K, Lajer M, Forsblom C, Marre M, Parving HH, Rossing P, Toppila I, Skupien J, Roussel R, Ko YA, Ledo N, Folkersen L, Civelek M, Maxwell AP, Tregouet DA, Groop PH, Tarnow L, Hadjadj S: SORBS1 gene, a new candidate for diabetic nephropathy: Results from a multi-stage genome-wide association study in patients with type 1 diabetes. [Electronic version]. *Diabetologia* 58: 543-548, 2015
85. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Magi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PC, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks AA, An P, Muller-Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJ, Edkins S, Varga TV, Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJ, Kong A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, Uitterlinden AG, Palmer CN, Doney AS, Willemsen G, Smit JH, Campbell S, Polasek O, Bonnycastle LL, Hercberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, Lindstrom J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert H, DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province MA, Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, de Geus EJ, Penninx BW, Hofman A, Oostra BA, Psaty BM, Vollenweider P, Wilson JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PK, Kyvik KO, Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser PA, Beilby JP, Korner A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PE, Lakka TA, Rauramaa R, Adair LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki M, Hingorani A, Keinanen-Kiukkaanniemi SM, Saaristo TE, Boomsma DI, Stefansson K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, Langenberg C, Ingelsson E, Prokopenko I, Barroso I: Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. [Electronic version]. *Nat Genet* 44: 991-1005, 2012
86. Tobacco and Genetics Consortium: Genome-wide meta-analyses identify multiple loci associated with smoking behavior. [Electronic version]. *Nat Genet* 42: 441-447, 2010

## Genome-wide dissection of diabetic kidney disease

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
87. Segre AV, DIAGRAM Consortium, MAGIC investigators, Groop L, Mootha VK, Daly MJ, Altshuler D: Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemc traits. [Electronic version]. *PLoS Genet* 6: e1001058, 2010
88. Lin DY, & Tang ZZ: A general framework for detecting disease associations with rare variants in sequencing studies. [Electronic version]. *Am J Hum Genet* 89: 354-367, 2011
89. Moutsianas L, Agarwala V, Fuchsberger C, Flannick J, Rivas MA, Gaulton KJ, Albers PK, GoT2D Consortium, McVean G, Boehnke M, Altshuler D, McCarthy MI: The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. [Electronic version]. *PLoS Genet* 11: e1005165, 2015
90. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. [Electronic version]. *Proc Natl Acad Sci U S A* 102: 15545-15550, 2005
91. Huang da W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. [Electronic version]. *Nucleic Acids Res* 37: 1-13, 2009
92. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. [Electronic version]. *Nat Protoc* 4: 44-57, 2009

## Figure legends

**Figure 1: Schematic picture of the DKD phenotypic comparisons based on measured AER and eGFR, encompassing different stages and severity of DKD.** ‘Combined DKD’ and ‘Late DKD’ (conventionally used in many previous genetic studies of DKD) are expected to capture genetic factors affecting DKD in general; ‘Early DKD’ comparison targets the genetic factors affecting the initiation of DKD, or with milder effect on the phenotype, whereas the two ESRD-based case definitions are expected to capture factors related to the late progression of DKD such as fibrotic processes, or genetic factors with particularly strong effect on the phenotype. While the ‘CKD’ phenotype may reveal genetic factors for reduced renal function irrespective of the presence of albuminuria, the ‘CKD+DKD’ phenotype is an extreme phenotype that requires that controls have no signs of renal complications (neither AER or eGFR based). AER thresholds are given in  $\mu\text{g}/\text{min}$ , eGFR thresholds in  $\text{ml}/\text{min}$  per  $1.73 \text{ m}^2$ . Normo: Normal AER; miA: microalbuminuria; maA: macroalbuminuria. Number of samples per sub-phenotype: Normo: 2,593; miA: 800; maA: 944; ESRD: 813; no CKD: 2,909; CKD: 1,255; no CKD, no DKD: 2,018; CKD+DKD: 1,117.

**Figure 2: The proportion of phenotypic variance explained by genotypes ( $V(G)/V(p_L)$ ), i.e. the narrow-sense heritability, of the seven studied DKD phenotypic comparisons indicate high heritability especially for the more extreme phenotype definitions.** Error bars represent the standard error.

**Figure 3: The genetic risk scores (GRS) for body mass index (BMI) and type 2 diabetes (T2D) were associated with diabetic kidney disease (DKD) phenotypes in subjects with type 1 diabetes.** A GRS for body mass index (BMI; z-transformed) was associated ( $p < 2.6 \times 10^{-3}$  to account for multiple testing, 19 GRS traits) with combined and late DKD, and CKD phenotypes; GRS for T2D was associated with late DKD.

Genome-wide dissection of diabetic kidney disease

1  
2 24 **Figure 4: Genome-wide comparison of DKD traits and other phenotypes, evaluated with LD score regression,**  
3  
4 25 **shows negative correlation between DKD traits, and smoking cessation.** Significant correlations ( $p < 0.0029$  to  
5  
6 26 **account for multiple testing, 17 related phenotypes**) are indicated with \*. Bars represent 95% confidence  
7  
8  
9 27 intervals.

For Peer Review

## TABLES

Table 1: Clinical characteristics of the subjects, divided into cases and controls based on the 'combined DKD' phenotype definition

Cohort (N)	FinnDiane (N=3,415)		EURODIAB (N=789)		SDR (N=558)		Cambridge (N=396)	
	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
N	1,802	1,613	298	491	266	292	197	199
N Males (%)	1,067 (59)	669 (41)	170 (57.2)	222 (45.3)	150 (56)	160 (55)	109 (54)	93 (47)
Age of onset of diabetes [year] <sup>a</sup>	13.4 (8.4)	15.6 (8.8)	16.7 (8.3)	17.9 (8.1)	15.9 (9.4)	17.1 (9.5)	9.1 (4.0)	7.6 (6.0)
Age [year] <sup>a</sup>	45.1 (11.1)	43.6 (11.7)	40.3 (10.3)	42.9 (10.2)	48.2 (14.5)	48.7 (13.2)	17.0 (5.7)	23.4 (10.2)
Duration of diabetes [year] <sup>a</sup>	31.7 (9.9)	27.9 (9.6)	23.7 (9.07)	25.0 (7.7)	32.3 (14.0)	31.5 (12.3)	7.9 (5.4)	15.8 (6.8)
BMI [kg/m <sup>2</sup> ] <sup>a</sup>	25.7 (4.1)	25.3 (3.5)	24.6 (3.7)	25.1 (3.42)	24.6 (3.3)	24.4 (3.2)	-	-
HbA <sub>1c</sub> [%] <sup>a</sup>	8.7 (1.6)	8.1 (1.2)	8.3 (1.9)	7.7 (1.6)	7.9 (1.1)	7.1 (0.9)	10.5 (2.3)	8.7 (1.6)
HbA <sub>1c</sub> [mmol/mol] <sup>a</sup>	72 (17)	65 (13)	68 (21)	61 (18)	63 (12)	54 (10)	91 (25)	72 (18)



<sup>a</sup>mean (sd)

**Table 2: Association analysis results for the top SNPs from the GWAS discovery + *in silico* replication analysis, selected for additional *de novo* replication.**

SNP	rs61277444*	rs7562121	rs1989248	rs72809865			
CHR	4	2	7	10			
Gene**	in <i>PTPN13</i>	in <i>AFF3</i>	23kb to <i>CNTNAP2</i>	350kb to <i>NRG3</i>			
Pheno	<sup>a,b</sup> ESRD vs. non-ESRD	<sup>b</sup> ESRD vs. no DKD	<sup>a,b</sup> ESRD vs. non-ESRD	<sup>b</sup> CKD+DKD	<sup>a</sup> ESRD vs. no DKD	<sup>a</sup> Combined DKD	
Stage I	N	813/3,995	813/2,394	813/3,995	1,117/2,018	813/2,394	2,563/2,593
	EAF	0.09	0.09	0.23	0.28	0.28	0.16
	OR	1.55	1.58	1.46	1.28	1.40	1.30
	95% CI	1.26–1.91	1.26–1.97	1.28–1.66	1.12–1.47	1.21–1.62	1.16–1.46
	<i>P</i>	4.3×10 <sup>-6</sup>	8.7×10 <sup>-6</sup>	8.9×10 <sup>-8</sup>	1.8×10 <sup>-4</sup>	4.0×10 <sup>-6</sup>	5.0×10 <sup>-6</sup>
Stage II	N	964/4,806	964/3,187	964/4,806	1,104/1,981	964/3,187	2,659/3,842
	<i>P</i>	2×10 <sup>-3</sup>	3×10 <sup>-3</sup>	0.037	1×10 <sup>-3</sup>	0.021	0.047
Stage III	N	94/993	94/627	67/822			367/516
	<i>P</i>	0.19	0.14	0.59			0.54
All	N	1,871/9,794	1,871/6,208	1,844/9,623	2,221/3,999	1,777/5,581	5,589/6,951
	N total	11,665	8,079	11,467	6,220	7,358	12,540
	OR	1.41	1.42	1.27	1.26	1.29	1.17
	95% CI	1.21–1.65	1.20–1.67	1.17–1.39	1.15–1.38	1.17–1.43	1.09–1.26
	<i>P</i>	1.9×10 <sup>-6</sup>	6.0×10 <sup>-6</sup>	3.5×10 <sup>-7</sup>	6.0×10 <sup>-7</sup>	1.8×10 <sup>-6</sup>	7.4×10 <sup>-6</sup>

**N: number of cases/ controls.** EAF: Effect allele frequency. Selection criteria for *de novo* replication: <sup>a</sup> *p*-value < 10<sup>-6</sup> for discovery + stage two meta-analysis. <sup>b</sup> *p*-value < 0.05 in the *in silico* replication for the phenotype selected for replication; \*Due to moderate imputation quality at the discovery stage, rs61277444 was directly genotyped in 2,913/3,415 FinnDiane subjects. The association in FinnDiane was moderately attenuated from OR=1.49 (95% CI 1.19 - 1.86, *p*=4.5×10<sup>-4</sup>; ESRD vs. non-ESRD) and OR=1.50 (95% CI 1.18 - 1.91, *p*=1×10<sup>-3</sup>; ESRD vs. no DKD) with the imputed data to OR=1.36 (95% CI 1.11 - 1.66, *p*=3.0×10<sup>-3</sup>; ESRD vs. non-ESRD) and OR=1.40 (95% CI 1.11 - 1.75, *p*=3.9×10<sup>-3</sup>; ESRD vs. no DKD) using directly genotyped data. \*\* The closest gene/genes.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Pheno	Normo	miA	maA	ESRD*
Combined DKD	CTRL	CASE	CASE	CASE
Early DKD	CTRL	CASE		
Late DKD	CTRL		CASE	CASE
ESRD vs. no DKD	CTRL			CASE
ESRD vs. non-ESRD	CTRL	CTRL	CTRL	CASE

Pheno	≥60	(45,60]	<45**
CKD	CTRL	CASE	CASE
CKD+DKD	CTRL if normo		CASE if miA/ maA/ ESRD

\*ESRD: Dialysis/ transplant/ eGFR<15


\*\*eGFR<45 or ESRD

254x96mm (150 x 150 DPI)

Peer Review




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



76x65mm (600 x 600 DPI)


view

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



93x43mm (300 x 300 DPI)

Peer Review



194x129mm (300 x 300 DPI)

Review

**The Genetic Landscape of Renal Complications in Type 1 Diabetes****SUPPLEMENTAL INFORMATION**

Niina Sandholm, Natalie Van Zuydam, Emma Ahlqvist, Thorhildur Juliusdottir, Harshal A. Deshmukh, N. William Rayner, Barbara Di Camillo, Carol Forsblom, Joao Fadista, Daniel Ziemek, Rany M. Salem, Linda T. Hiraki, Marcus Pezzolesi, David Trégouët, Emma Dahlström, Erkka Valo, Nikolay Oskolkov, Claes Ladvall, M. Loredana Marcovecchio, Jason Cooper, Francesco Sambo, Alberto Malovini, Marco Manfrini, Amy Jayne McKnight, Maria Lajer, Valma Harjutsalo, Daniel Gordin, Maija Parkkonen, Jaakko Tuomilehto, Valeriya Lyssenko, Paul M. McKeigue, Stephen S. Rich, Mary Julia Brosnan, Eric Fauman, Riccardo Bellazzi, Peter Rossing, Samy Hadjadj, Andrzej Krolewski, Andrew D. Paterson, Jose C. Florez, Joel N. Hirschhorn, Alexander P. Maxwell, David Dunger, The DCCT/EDIC Study Group, GENIE Consortium, The FinnDiane Study Group, Claudio Cobelli, Helen M. Colhoun, Leif Groop, Mark I. McCarthy, Per-Henrik Groop, on behalf of The SUMMIT Consortium

1	<b>COMPLETE METHODS</b> .....	<b>4</b>
2		
3	Subjects with Type 1 diabetes (T1D) .....	4
4	Genotypes.....	7
5		
6	Statistical methods .....	9
7		
8	<b>SUPPLEMENTAL TABLES</b> .....	<b>14</b>
9		
10	Supplemental Table 1: Proportion of phenotypic variance explained by the GWAS genotypes in FinnDiane, estimated with GCTA.....	14
11		
12	Supplemental Table 2: Information on genotyping, and clinical characteristics of the discovery and replication patients divided based on the seven case – control definitions .....	15
13		
14	Supplemental Table 3: Number of subjects included in the analysis in the discovery and <i>in silico</i> replication cohorts .....	16
15		
16	Supplemental Table 4: Statistical power to detect association with ‘combined DKD’ with genome-wide significance ( $p < 5 \times 10^{-8}$ ) at the discovery stage.....	17
17		
18	Supplemental Table 5: Association analysis results for the 101 GWAS SNPs selected for <i>in silico</i> replication. ....	18
19		
20	Supplemental Table 6: Statistical power to detect association with ‘Combined DKD’ with genome-wide significance ( $p < 5 \times 10^{-8}$ ) with the two-stage study design.....	19
21		
22	Supplemental Table 7: Association at the <i>AFF3</i> locus with ‘ESRD vs. non-ESRD’ phenotypic comparison, conditional on the previously reported lead SNP rs7583877.....	20
23		
24	Supplemental Table 8: Statistical power to detect association with the ‘Late DKD’ phenotype for varying odds ratio and risk allele frequency.....	21
25		
26	Supplemental Table 9: Evaluation of previously reported candidate genes or GWAS loci on kidney complications in type 1 and type 2 diabetes, or GWAS on CKD in the general population. ....	22
27		
28	Supplemental Table 10: Association between diabetic kidney complications and genetic risk scores of related phenotypes.....	24
29		
30	Supplemental Table 11: MAGENTA Gene set enrichment results with FDR<0.05.....	28
31		
32	Supplemental Table 12: Characteristics of the patients selected for the whole exome sequencing .....	30
33		
34	Supplemental Table 13. Top 20 results of single variant analysis for WES ‘ESRD vs. no DKD’ using the score test ....	31
35		
36	Supplemental Table 14. Top 20 associations for WES ‘Late DKD’ using the single variant score test.....	32
37		
38	Supplemental Table 15: Top 10 associations to WES ‘Late DKD’ with VT with 4 masks .....	33
39		
40	Supplemental Table 16: Top 10 associations to WES ‘Late DKD’ using SKAT-O with 4 different masks.....	34
41		
42	Supplemental Table 17: Top 10 associations to WES ‘Late DKD’ using SKAT with 4 masks.....	35
43		
44	Supplemental table 18: Top 10 associations to WES ‘ESRD vs. no DKD’ with VT and 4 masks.....	36
45		
46	Supplemental Table 19: Top 10 associations to WES ‘ESRD vs. no DKD’ with SKAT-O with 4 masks .....	37
47		
48	Supplemental Table 20: Top 10 associations to WES ‘ESRD vs. no DKD’ with SKAT with 4 masks .....	38
49		
50	Supplemental Table 21: Gene-sets which showed enrichment in WES association data on the ‘Late DKD’ phenotype, with permutation (N=100) results.....	39
51		
52	Supplemental Table 22: ABACUS association analysis results for the top SNPs from the GWAS discovery.....	41
53		
54		
55		
56		
57		
58		
59		
60		

1	Supplemental Table 23: ABACUS association analysis results for the top SNPs from the WES discovery.....	43
2	Supplemental Table 24: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS	
3	software on GWAS data .....	44
4	Supplemental Table 25: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS	
5	software on WES data .....	46
6	Supplemental Table 26: Phenotype definitions. Table A: albuminuria- and eGFR based definitions. Table B: Case –	
7	control phenotypes. ....	48
8	Supplemental Table 27: Membership of the GENIE Consortium .....	50
9	Supplemental Table 28: List of the FinnDiane centers and participating physicians and nurses. ....	51
10	Supplemental Table 29: Membership of the SUMMIT Consortium.....	54
11	<b>SUPPLEMENTAL FIGURES .....</b>	<b>62</b>
12	Supplemental Figure 1: Schematic picture of the study plan. In the GWAS setting, the stage 1 included T1D patients	
13	from the FinnDiane, EURODIAB, SDR, and Cambridge studies. Stage 1 GWAS meta-analysis results were used for	
14	evaluation of the previously reported loci, analysis of genetic risk scores, LD score regression, and for the pathway	
15	analyses. Stage 2 included patients from the UK-ROI, GoKinD US, French-Danish effort, DCCT/EDIC, and Joslin	
16	studies. Stage 3 replication consisted of additional T1D FinnDiane patients not part of the FinnDiane GWAS. Whole	
17	exome sequencing (WES) included patients from the FinnDiane, SDR, and Steno studies. Finally, the bivariate	
18	association analyses were performed in all GWAS stage 1 studies and in WES studies.....	62
19	Supplemental Figure 2: Manhattan and QQ-plots for the seven studied phenotype definitions. ....	63
20	Supplemental Figure 3: LocusZoom and Forest plots of the top loci.....	66
21	Supplemental Figure 4: P-value distribution of association at the previously reported loci for DKD or CKD in the	
22	general population. ....	67
23	Supplemental Figure 5: Association at previously reported loci plotted by the previously reported A) p-values and	
24	by B) Z-scores.....	68
25	Supplemental Figure 6: Genome-wide comparison of the association results for the seven DKD traits, evaluated	
26	with LD score regression, shows high correlation between the DKD traits. ....	69
27	Supplemental Figure 7: KEGG pentose and glucuronate interconversions pathway with the red boxes indicating the	
28	genes flagged with MAGENTA enrichment analysis on the DKD phenotype.....	70
29	Supplemental Figure 8: WES QQ-plots of the p-value distribution of associations with ‘Late DKD’ and ‘ESRD vs. no	
30	DKD’ using the score test.....	71
31	Supplemental Figure 9: WES QQ-plots for ‘Late DKD’ for different masks using SKAT-O.....	72
32	Supplemental Figure 10: WES QQ-plots for ‘ESRD vs. no DKD’ for different masks using SKAT-O.....	73
33	Supplemental Figure 11: Top 20 associations for ‘Late DKD’ for the three gene based tests; VT, SKAT-O and SKAT	
34	with the PTV+broader and PTV+missense masks. ....	74
35	Supplemental Figure 12: Top 20 associations for ‘ESRD vs. no DKD’ for the three gene based tests; VT, SKAT-O and	
36	SKAT with the PTV+broader and PTV+missense masks. ....	75
37	Supplemental Figure 13: Statistical power to detect association at the WES with exome-wide statistical significance	
38	( $p < 9 \times 10^{-8}$ ) for ‘Late DKD’ setting (panels A and C) and for the ‘ESRD vs. no DKD’ comparison (panels B and D). ....	76
39	<b>REFERENCES .....</b>	<b>77</b>

## COMPLETE METHODS

### Subjects with Type 1 diabetes (T1D)

**Subjects in the GWAS discovery studies:** The GWAS discovery stage included subjects with T1D from four studies: The Finnish Diabetic Nephropathy (FinnDiane) Study<sup>1,2</sup>, the EURODIAB Family Study<sup>3</sup>, the Scania Diabetes Registry (SDR)<sup>4</sup>, and the UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/ Cambridge)<sup>5,6</sup>. All studies were approved by the local ethics committees and conducted according to the principles of the Declaration of Helsinki. Written consent was obtained from the participants in FinnDiane, Eurodiab, SDR and Steno Studies. In the NFS-ORPS study, written consent was obtained from parents, and verbal assent was obtained from children.

**The Finnish Diabetic Nephropathy (FinnDiane) Study<sup>1,2</sup>:** FinnDiane is a Finnish nationwide prospective multicenter study, with the aim to identify genetic, clinical, biochemical and environmental risk factors for diabetic complications. The study includes patients from all five Finnish University Central Hospitals, all 16 central hospitals, and 56 regional hospitals and health care centers. The study protocol and patient recruitment criteria have been previously described<sup>1</sup>. In short, patients with type 1 diabetes (T1D) were recruited at their own health care center by their attending physician, who completes the main questionnaire. Blood and urine samples are sent to the central laboratory of the FinnDiane Study. The patients have been followed up in prospective follow-up visits roughly 5-7 years after the baseline visit. In addition, FinnDiane Study includes patients with type 1 diabetes recruited by the Finnish National Institute of Health and Welfare across Finland. Retrospective data has been retrieved from medical records. Furthermore, information on major clinical events, such as the onset of ESRD, can be retrieved from the Finnish Hospital Discharge Registry (HILMO).

**The EURODIAB Family Study<sup>3</sup>:** The Eurodiab Insulin Dependent Diabetes (IDDM) Complications Study was a cross-sectional investigation of a stratified random sample of IDDM patients attending 31 clinics in 16 European countries that were carried out in 1989/91. These subjects were then followed up around 6-8 years later in the EURODIAB Prospective Complications Study. T1D was defined as diabetes onset <35 years with insulin within one year of diagnosis. This collection was supplemented by additional T1D cases with nephropathy at those EURODIAB



1 participating centres even if the patient hadn't participated in the original EURODIAB IDDM Complications study. We  
2  
3 also recruited several additional centres (UK, Austria & Poland) to focus specifically on late stage and dialysis patients.  
4  
5 The current GWAS study comprised cases with micro- or macroalbuminuria, ESRD, or elevated serum creatinine (>200  
6  
7  $\mu\text{mol/lit}$ ) consistent with ESRD. Cases were captured from several sources (EURODIAB at baseline, EURODIAB at  
8  
9 follow up, additional cases from these centres not in the original cohort study and renal failure cases from several  
10  
11 new non-EURODIAB centres). Non-DKD controls were only recruited from the original Eurodiab IDDM Complications  
12  
13 Study cohort. They had at least 15 years of T1D duration and remained normoalbuminuric for the follow-up period. In  
14  
15 addition to local MICRAL strip testing, the controls had normoalbuminuria confirmed by the central EURODIAB on  
16  
17 two overnight collections at follow up and on one collection at baseline.  
18  
19  
20  
21

22 **Scania Diabetes Registry (SDR)**<sup>4</sup>: Patients in SDR were randomly collected from the Department of Endocrinology,  
23  
24 Malmö Sweden and surrounding clinics in Skåne (Scania) Sweden. Patients of known non-Scandinavian origin were  
25  
26 excluded from the analysis. Diabetes classification was done based on presence of GAD antibodies and low c-peptide  
27  
28 levels, or in case of incomplete information, based on the diagnosis given by the treating physician. All patients with  
29  
30 T1D were diagnosed before 35 years of age.  
31  
32  
33  
34

35 **The UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/ Cambridge)**<sup>5,6</sup>:

36  
37 ORPS is a population-based inception cohort of childhood-onset T1D, established between 1986 and 1997, with the  
38  
39 aim of assessing the natural history of microalbuminuria<sup>5</sup>. Children diagnosed with T1D under the age of 16 years, in  
40  
41 the defined geographic region of the Oxford Health Authority, were recruited within 3 months of diagnosis of Type 1  
42  
43 diabetes to receive annual assessments. Ninety-one percent of eligible children were recruited at a mean age of 8.8  
44  
45 years and were followed annually thereafter. The overall dropout rate for the ORPS cohort has been 9.6%.  
46  
47  
48  
49

50 The NFS is a prospective study started in the year 2000 with the aim of assessing factors influencing changes in  
51  
52 albumin excretion during adolescence in young people with T1D<sup>6</sup>. Between 2000 and 2005, adolescents (aged 10–18  
53  
54 years), diagnosed with T1D before the age of 16 years, were recruited throughout England. Cases of secondary  
55  
56 diabetes treated with insulin or maturity-onset diabetes of the young were identified by clinical histories and  
57  
58  
59  
60

1 examination of case records, and were excluded. Similarly, children with chronic renal disease or other chronic  
2  
3 diseases likely to affect renal function were excluded.  
4

5  
6 Both cohorts were monitored with annual centralized assessments of ACR, based on three consecutive early morning  
7  
8 urine samples.  
9

10  
11 The studies received ethical approval from district ethics committees. Written consent was obtained from parents,  
12  
13 and verbal assent was obtained from children.  
14

15  
16  
17  
18  
19  
20 **Phenotype definitions:** All subjects had T1D as diagnosed by their attending physician. In addition, subjects were  
21  
22 limited to those with the age at diabetes onset  $\leq 40$  years and insulin treatment initiated within one year of diagnosis.  
23  
24 The kidney status was classified based on the urinary albumin excretion rate (AER) and on the estimated glomerular  
25  
26 filtration rate (eGFR). The subjects were classified as normal AER, microalbuminuria or macroalbuminuria based on  
27  
28 two out of three consecutive urine samples surpassing the required threshold (Supplemental Table 26). Patients  
29  
30 receiving dialysis treatment, with a kidney transplant, or with an eGFR  $\leq 15$  ml/min/1.73m<sup>2</sup> were defined to have  
31  
32 ESRD. eGFR was calculated either with the MDRD4<sup>7</sup> or the CKD-EPI<sup>8</sup> formula depending on the study. In addition,  
33  
34 subjects were classified to CKD classes: No CKD was defined as eGFR  $\geq 60$  ml/min/1.73m<sup>2</sup> (i.e. CKD classes 1 and 2),  
35  
36 and CKD as eGFR  $< 60$  ml/min/1.73m<sup>2</sup> (i.e. CKD classes 3-5). Based on these definitions, we analysed seven different  
37  
38 case – control phenotypes: i) cases with DKD (microalbuminuria or worse) versus controls with normal AER; ii) cases  
39  
40 with macroalbuminuria or ESRD versus normal AER; iii) cases with ESRD versus controls with normal AER; iv) cases  
41  
42 with ESRD versus everyone else; v) cases with microalbuminuria versus controls with normal AER; vi) cases with CKD  
43  
44 versus controls without CKD; vii) cases with severe CKD (eGFR  $\leq 45$  ml/min/1.73m<sup>2</sup>) and microalbuminuria or worse  
45  
46 versus controls with normal AER and no CKD. The number of subjects in the four discovery studies is specified for the  
47  
48 different phenotype definitions in Supplemental Table 3.  
49  
50  
51  
52  
53  
54

55  
56 **Patient selection for WES:** WES included subjects from FinnDiane, SDR, and Steno Diabetes Center (Supplemental  
57  
58 Table 12). Whilst we adopted broadly similar schemes for ascertaining the extremes in each of three contributing  
59  
60

1 studies, there were some differences. Patients were selected from the extreme ends of the liability distribution of  
2  
3 DKD from each participating study (FinnDiane, SDR, and Steno). Cases were defined as subjects with rapid onset of  
4  
5 macroalbuminuria (within 20/25 years of diabetes onset in FinnDiane and Steno, respectively; no threshold in SDR) or  
6  
7 ESRD (onset within 25 years of diabetes onset in FinnDiane and Steno). Controls were subjects with normal AER  
8  
9 despite prolonged duration of T1D ( $\geq 32$ , 30, or 27 years in FinnDiane, Steno, and SDR, respectively). In addition, the  
10  
11 FinnDiane controls were enriched for higher HbA<sub>1c</sub> values (excluding subjects with HbA<sub>1c</sub> < 6.5 %), and a half of the  
12  
13 controls were selected to have proliferative diabetic retinopathy or retinal laser treatment.  
14  
15  
16  
17  
18  
19  
20

## 21 Genotypes

22  
23 **Genome-wide genotyping and imputation of the discovery cohorts:** The genome-wide genotyping of the  
24  
25 subjects in the SDR, NFS-ORPS, and EURODIAB (a sub-study of the EURODIAB PCS) was performed within the SUMMIT  
26  
27 project with the Illumina OmniExpress assays (Illumina, San Diego, CA, USA). Samples with a call rate <98% or gender  
28  
29 discrepancy were removed in the first step of quality control. Subsequently, common single nucleotide  
30  
31 polymorphisms (SNPs; i.e. minor allele frequency (MAF)  $\geq 0.05$ ) with low genotyping rate (<95%) or not in Hardy-  
32  
33 Weinberg equilibrium (HWE;  $p$ -value  $\leq 5.7 \times 10^{-7}$ ) were removed. For non-common SNPs (MAF 0.01 – 0.05), the  
34  
35 thresholds were 99% and  $p$ -value  $< 10^{-4}$ , respectively. Samples with extremely high or low heterozygosity or excess of  
36  
37 estimated relatedness were removed due to suspected sample contamination or issues in the sample processing,  
38  
39 based on study specific distributions. In the FinnDiane Study, genotyping was performed with the Illumina 610Quad  
40  
41 assay and the quality control was similar to the other studies, as described previously in detail <sup>2</sup>. Principal component  
42  
43 analysis was performed in all cohorts with the Eigenstrat software (Eigensoft v. 3.0, <sup>9</sup>).  
44  
45  
46  
47  
48  
49

50 After the quality control, the SNP positions were converted to human genome build 37, and genome-wide imputation  
51  
52 was performed with IMPUTE2 ([https://mathgen.stats.ox.ac.uk/impute/impute\\_v2.html](https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) <sup>10</sup>) using 1,092 samples from  
53  
54 the 1000 Genomes project (<http://www.1000genomes.org>, phase 1 v.3, released March 2012) as the imputation  
55  
56 reference panel <sup>11</sup>. The pre-phasing and imputation were performed with the default parameters and the effective  
57  
58  
59  
60

1 sample size of 20,000 as suggested in the IMPUTE2 tutorial. Variants were filtered post-imputation to those with MAF  
2  
3  $\geq 0.01$ , minor allele count  $\geq 10$  in both cases and controls, and SNPtest INFO estimate of imputation quality  $\geq 0.4$ .  
4  
5

6 **Whole exome sequencing and variant calling:** Samples were sequenced at two centres. The samples were  
7  
8 prepared using the Illumina TruSeq™ DNA LT Sample Prep Kit, pooled into multiplexes of five and were captured  
9  
10 using the Illumina TruSeq™ Exome Enrichment Kit. The concentration of each library was determined by real-time  
11  
12 qPCR using Agilent qPCR Library Quantification Kit and a MX3005P instrument (Agilent). Sequencing was performed  
13  
14 on an Illumina HiSeq2000, using 100bp paired end reads and with an anticipated minimum yield of 30 Gb per lane.  
15  
16 Five exomes of 63Mb were run per lane (single lane for most), aiming for approximately 100x read depth. We  
17  
18 required an average 20x target capture above 80% coverage, otherwise additional DNA was requested to 'top up' the  
19  
20 sample. This resulted in mean sequencing depth of 54.97 (FinnDiane) and 42.23 (SDR and Steno) bases per position.  
21  
22 After additional sequencing 497 samples were included from FinnDiane and 500 from SDR and Steno.  
23  
24  
25  
26

27  
28 Samples were mapped with Burrows-Wheeler aligner v7.4 (BWA), refined by removing duplicates and realigning  
29  
30 around known insertions and deletions (INDELs), and recalibrated using genome analysis toolkit v2.1 (GATK). GATK's  
31  
32 UnifiedGenotyper was applied to call variants, followed by recalibration of SNVs using VQSR and hard filtering of  
33  
34 INDELs.  
35  
36

37  
38 Polymorphic variants (MAF>0) with a mapping quality < 250, HWE  $p$ -value  $> 1 \times 10^{-10}$  and call rate  $\geq 75\%$  were retained  
39  
40 in the analysis. Samples with  $\geq 10\%$  missingness or heterozygosity rate greater or less than 3 standard deviations from  
41  
42 the sample mean were excluded. Population outliers (based on visual inspection of the four first principal  
43  
44 components), duplicates and related samples were removed. Variants were annotated using CHAos  
45  
46 (<http://www.well.ox.ac.uk/~kgaulton/chaos.shtml>), snpEff (<http://snpeff.sourceforge.net/><sup>12</sup>) and VEP  
47  
48 (<http://www.ensembl.org/info/docs/tools/vep/><sup>13</sup>) for functional class and transcript.  
49  
50  
51

52  
53 With 530,565 variants (491,553 SNPs and 39,012 indels) across 479 controls and 481 cases after the quality control,  
54  
55 each individual carried a mean of 7,566 synonymous, 6,452 missense and 103 protein truncating variants. The lower  
56  
57 number of total variant sites compared to other, more outbred populations<sup>14</sup> is in line with fewer variable sites seen  
58  
59 in founder populations such as the Finns<sup>15</sup>.  
60

## Statistical methods

**Heritability estimates:** The narrow-sense heritability of the kidney phenotypes was estimated as the proportion of the phenotypic variance explained by the additive effects of the genotyped SNPs based on the FinnDiane GWAS data using the GCTA v. 0.93.9, excluding samples with estimated relatedness  $\geq 0.025$ <sup>16</sup>. The observed variance explained was transformed to the underlying population scale based on rough prevalence estimates as given in Supplemental Table 1. The heritability was estimated without covariates, and adjusting for sex, duration of T1D and age at T1D onset.

**GWAS analysis:** The genome-wide association analysis was performed with two methods in parallel. To obtain stable effect size estimates, we performed additive test for association using SNPtest with the score method and adjusted for sex, diabetes duration and age at diabetes onset<sup>17</sup>, and the two first principal components calculated with the Eigenstrat software (Eigensoft v. 3.0,<sup>9</sup>). Close relatives were not included in the analysis. *P*-values were obtained with a variance component based mixed model method, EMMAX, which accounts for the sample structure, allowing to include close relatives in the analysis<sup>18</sup>. Models were adjusted for sex, diabetes duration and age at diabetes onset and the kinship matrix was calculated with EMMAX. EMMAX algorithm was implemented with the EPACTS software ([www.sph.umich.edu/csg/kang/epacts/](http://www.sph.umich.edu/csg/kang/epacts/)).

Meta-analyses of the effect sizes were performed with the fixed-effect inverse variance method implemented in GWAMA<sup>19</sup>. *P*-values were combined with METAL software based on the study-wise *p*-values, sample sizes and effect directions<sup>20</sup>. Meta-analysis results were further filtered to those with valid results from at least two studies. ***P*-values below  $5 \times 10^{-8}$  were considered genome-wide significant, not correcting for multiple testing due to seven phenotypic comparisons, as the case and control groups were overlapping and the traits were correlated with each other.**

**Power calculations were performed with the genetic power calculator ([pngu.mgh.harvard.edu/~purcell/gpc/](http://pngu.mgh.harvard.edu/~purcell/gpc/)) for simple case-control setting,<sup>21</sup> and with Power Calculator for Two Stage Association Studies (CaTS; <http://csg.sph.umich.edu//abecasis/cats/>).<sup>22</sup>**

1 ***In silico* Replication:** Independent variants with a  $p$ -value  $< 5 \times 10^{-6}$  were selected for *in silico* replication. Variants  
2  
3 were defined independent if they were at least 100 kilo base pair (kbp) away from each other. The selection was  
4  
5 performed separately for each phenotype, and therefore, multiple variants were selected for some loci with different  
6  
7 lead variants for different phenotypes. Replication consisted of six additional studies: the All Ireland – Warren 3 –  
8  
9 Genetics of Kidneys in Diabetes UK collection (UK-ROI) <sup>2</sup> and the Genetics of Kidneys in Diabetes US Study (GoKinD  
10  
11 US) <sup>2</sup> from the GENIE Consortium, the Diabetes Control and Complications Trial and the Epidemiology of Diabetes  
12  
13 Interventions and Complications (DCCT/EDIC) study <sup>23,24</sup>, 1,073 subjects from the Joslin Diabetes Center T1D  
14  
15 nephropathy collection, and the French, Belgian and Danish subjects (the Steno Diabetes Center) from the French-  
16  
17 Danish Effort <sup>25</sup>. The number of subjects in each study is given in Supplemental Table 3. Association testing was  
18  
19 performed with PLINK or SNPtest depending on the study, using the same covariates as in the discovery stage.  
20  
21  
22  
23

24  
25 ***De novo* replication and genotyping:** After *in silico* replication, variants replicated with a  $p < 0.05$  or a combined  $p$ -  
26  
27 value  $< 1 \times 10^{-7}$  after meta-analysis were selected for *de novo* replication. A total of 1,095 additional FinnDiane  
28  
29 patients, not part of the GWAS, were genotyped for stage 3 analysis with TaqMan (Supplemental Table 2).  
30  
31 Additionally, subjects with T1D from the Diabetes in Region of Vaasa (DIREVA) study, a follow-up study from Finland  
32  
33 with  $> 5,000$  subjects with diabetes, were genotyped together with DIREVA subjects with T2D using either Taqman  
34  
35 (rs72809865) or Sequenom (the rest). rs1989248 was not successfully genotyped in either *de novo* replication study.  
36  
37 Additionally, genotyping of rs72809865 was unsuccessful in DIREVA, and only four cases with T1D and ESRD were  
38  
39 identified in DIREVA after removing subjects that were included in the FinnDiane discovery study. Thus, no SNPs  
40  
41 remained for analysis from DIREVA. Association analysis was performed in the FinnDiane replication cohort similarly  
42  
43 to *in silico* replication using logistic regression and adjusted for sex, duration of diabetes, and age at diabetes onset.  
44  
45 As one of the lead SNPs, rs61277444 was imputed with only moderate quality, that SNP was *de novo* genotyped also  
46  
47 in 2,913 FinnDiane subjects from the discovery study. Concordant to the imputation quality INFO score of 0.83 in  
48  
49 FinnDiane, the *de novo* genotyping agreed with the imputed genotypes (converted to most likely genotypes with  
50  
51 genotype likelihood threshold of 0.9) for 73% of the samples.  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Genetic risk score analysis:** SNPs associated with Waist-Hip-ratio (adjusted for BMI,  $N_{\text{SNPs}}=54$ )<sup>26</sup>, BMI (untransformed,  $N_{\text{SNPs}}=96$ <sup>27</sup> and z-transformed,  $N_{\text{SNPs}}=24$ <sup>28</sup>), systolic blood pressure (SBP,  $N_{\text{SNPs}}=22$ )<sup>29</sup>, low-density lipoprotein cholesterol (LDL-C,  $N_{\text{SNPs}}=24$ ), triglycerides (TRIG,  $N_{\text{SNPs}}=20$ ), high-density lipoprotein cholesterol (HDL-C,  $N_{\text{SNPs}}=26$ )<sup>30</sup>, T1D ( $N_{\text{SNPs}}=51$ )<sup>31</sup>, T2D<sup>32</sup> (including all SNPs ( $N_{\text{SNPs}}=70$ ), and without any other effects other than on T2D or lipids ( $N_{\text{SNPs}}=56$ )<sup>30</sup> and T2D or glycemic traits ( $N_{\text{SNPs}}=62$ )<sup>33,34</sup>), 2-hr glucose (adjusted for BMI,  $N_{\text{SNPs}}=15$ )<sup>35</sup>, fasting glucose (FG, adjusted for BMI,  $N_{\text{SNPs}}=21$ )<sup>34</sup>, glycated haemoglobin (HbA1c,  $N_{\text{SNPs}}=15$ )<sup>36</sup>, fasting insulin (natural log transformed and adjusted for BMI,  $N_{\text{SNPs}}=13$ )<sup>34</sup>, fasting pro-insulin (adjusted for BMI and FG,  $N_{\text{SNPs}}=10$ )<sup>37</sup>, HOMA-B ( $N_{\text{SNPs}}=15$ ), HOMA-IR ( $N_{\text{SNPs}}=15$ )<sup>38</sup> and insulin resistance<sup>39</sup> at genome-wide significance were included in a genetic risk score (GRS) for each trait respectively. The GRS was weighted by the allelic effect of each variant on the DKD risk factor and associated with the DKD phenotypes using meta-analysis data<sup>29</sup>. The lipid GRS were restricted to variants that predicted that specific trait and removed those that had effects on other lipid traits. We did not include a GRS for smoking behaviours as there were too few genome-wide significant associations to form a sufficient instrument.

**LD score regression to estimate genetic correlation:** Genetic correlation was estimated between the **GWAS stage 1 meta-analysis results of the** seven binary DKD phenotypes, and related traits. We assembled the summary statistics from all the studies used to calculate genetic risk scores except for systolic blood pressure and T1D as the full summary statistics were not available. We restricted the GRS and LD score regression analyses to reports from full genome-wide SNP data as LDscore regression takes the effect of all SNPs into account. We additionally computed genetic correlation with smoking behaviour phenotypes (cigarettes per day, smoking addiction, smoking cessation and age at smoking onset).<sup>40</sup>

**Gene set enrichment analyses:** MAGENTA gene set enrichment analysis was performed **in the GWAS stage 1 meta-analysis results** with the MAGENTA (vs.2) software,<sup>41</sup> applied on 10,992 partially overlapping gene sets from GO, PANTHER, INGENUITY, KEGG, REACTOME, and BIOCARTA data bases; 3,126 gene sets with  $\geq 10$  genes were analysed. Gene boundaries used for mapping SNPs onto genes were 110kb upstream to most extreme gene transcript start position, and 40kb downstream to most extreme gene transcript end position. The 95 percentile cut-off for the gene scores was employed to define the significant results.



1 **Correction for multiple testing:** The significance threshold for the results of the evaluation of previous loci, GRS, LD  
2  
3 score regression, and pathway enrichment analyses were Bonferroni corrected for multiple testing with  $\alpha=0.05$   
4  
5 significance level, accounting for the number of performed tests. The results were not corrected for the seven  
6  
7 phenotypic comparisons due to a considerable overlap of the case and control groups.  
8  
9

10 **WES single variant analysis:** Single variants were tested for association with DKD (N cases=481, N controls=479)  
11  
12 and ESRD (N cases=168, N controls=479) using the logistic score test <sup>42</sup> implemented in Epacts, with sex and two  
13  
14 principal components as covariates. Related individuals, monomorphic SNPs and those with standard error greater  
15  
16 than 10 were excluded from the analysis. While the study setting provided low statistical power to detect rare  
17  
18 variants with exome-wide significance ( $p < 9 \times 10^{-8}$  to correct for 530,776 tested variants) in line with previous reports  
19  
20 on the statistical power to detect rare variants <sup>43</sup>, we had sufficient power (80%) to detect a low frequency variant  
21  
22 (MAF=0.05) with a large OR of 5.65 (Supplemental Figure 13).  
23  
24  
25  
26  
27

28 **WES gene-based analysis:** We applied three series of gene based tests: a burden test (VT) <sup>44</sup> that assumes the  
29  
30 direction of effect of grouped variants is the same, a dispersion test (SKAT) <sup>45</sup> that performs well when the direction  
31  
32 of variant effect differs, and a hybrid (SKAT-O) <sup>46</sup> that uses multiple methods in a single test. Only unrelated  
33  
34 individuals were included in the analysis and sex and principal components were used as covariates to adjust for  
35  
36 population structure. For all three tests we grouped variants into four categories using the same procedure as  
37  
38 described in Mahajan *et al.* <sup>47</sup>, were variants were categorized as either protein truncating (PTV; e.g. nonsense,  
39  
40 frameshift, essential splice site), deleterious protein altering variants (e.g. missense, in-frame indel, and non-essential  
41  
42 splice-site variants predicted to be deleterious, further sub-divided into “strict” and “broad” grouping if predicted  
43  
44 deleterious by all five/ at least one annotation algorithm (Polyphen2-HumDiv, PolyPhen2-HumVar, LRT,  
45  
46 MutationTaster and SIFT), respectively, as described by Purcell *et al.* <sup>48</sup>, and any protein altering variants (e.g.  
47  
48 missense, in-frame indel, non-essential splice-site) if predicted to be so by at least one of three annotation algorithms  
49  
50 (snEff, CHAos and VEP). These four groups are referred to as 1) PTV-only, 2) PTV+strict, 3) PTV+broad, and 4)  
51  
52 PTV+missense, from the strictest to the most permissive class. A MAF threshold of 1% was applied to the more  
53  
54 permissive masks PTV+missense and PTV+broad to exclude common variants from the WES analysis.  
55  
56  
57  
58  
59  
60

1 **WES gene set enrichment analysis:** We were interested in seeing whether we could find any signals in common  
2  
3 with GWAS and WES association data, as well as detect enrichment for specific gene-sets. A total of 43 gene sets  
4  
5 were created, based on top findings from the GWAS analyses, kidney-related functional terms in public databases,  
6  
7 text mining approaches and kidney gene expression. These gene sets were analysed for enrichment in WES  
8  
9 association results (obtained with SKAT-O using the four different masks described above) **using the GSEA method**  
10  
11 **with SKAT-O's p-value as the ranking statistic**<sup>49</sup>. We applied permutations to the enriched gene sets to verify whether  
12  
13 this enrichment was greater than expected by chance, by randomly assigning case/control status to the samples prior  
14  
15 to re-analysing them with SKAT-O (using the same parameter settings as applied to the real data). This was repeated  
16  
17 100 times for each of the enriched gene sets, noting the number of times the top finding in the permuted data had a  
18  
19 better enrichment score than the candidate geneset in the real data. Since both of the enriched gene sets were  
20  
21 derived from GWAS data, which included some of the WES samples, we removed overlapping samples and re-created  
22  
23 the gene-sets and repeated the GSEA analysis.  
24  
25  
26  
27  
28

29 **Bivariate analysis of GWAS and WES data:** We applied ABACUS<sup>50</sup> to the individual GWAS discovery cohorts  
30  
31 (FinnDiane, EURODIAB, SDR, NFS-ORPS) on each of the seven different case-control phenotypes. In addition, ABACUS  
32  
33 was applied to the WES cohorts (FinnDiane, Steno and SDR) on the 'Late DKD' and 'ESRD vs. no DKD' phenotypic  
34  
35 comparisons as in the main WES analysis. For the SNP-sets definition we used REACTOME, KEGG and GO Biological  
36  
37 Process, as defined in MSigDB database (sets c2 and c5) after mapping SNPs to genes according to the Illumina  
38  
39 HumanOmniExpress.12v1\_J gene annotation file. In order to analyse non-annotated SNPs/genes, we also defined  
40  
41 SNP-sets of continuous 3,000 SNPs within each chromosome. Functional clustering of the ABACUS results was  
42  
43 performed with DAVID software<sup>51,52</sup>.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## SUPPLEMENTAL TABLES

**Supplemental Table 1: Proportion of phenotypic variance explained by the GWAS genotypes in FinnDiane, estimated with GCTA**

Phenotype	Prevalence	N	Adj	V(G)/V(p)	SE V(G)/V(p)	V(G)/V(p_L)	SE V(G)/V(p_L)	P
Combined DKD	0.3	2,843	no	0.24	0.10	0.35	0.15	6.4E-03
Combined DKD	0.3	2,843	yes	0.34	0.10	0.50	0.15	2.5E-04
Late DKD	0.2	2,495	no	0.32	0.11	0.43	0.15	1.3E-03
Late DKD	0.2	2,495	yes	0.51	0.12	0.67	0.15	2.0E-06
ESRD vs. no DKD	0.1	1,985	no	0.38	0.14	0.47	0.18	3.4E-03
ESRD vs. no DKD	0.1	1,985	yes	0.54	0.15	0.68	0.18	7.5E-05
ESRD vs. non-ESRD	0.1	2,843	no	0.31	0.10	0.51	0.17	1.2E-03
ESRD vs. non-ESRD	0.1	2,843	yes	0.34	0.10	0.57	0.17	4.7E-04
CKD	0.3	2,595	no	0.28	0.11	0.47	0.18	4.2E-03
CKD	0.3	2,595	yes	0.39	0.11	0.65	0.19	1.5E-04
CKD+DN	0.2	1,949	no	0.42	0.14	0.59	0.20	1.1E-03
CKD+DN	0.2	1,949	yes	0.59	0.15	0.84	0.20	9.8E-06
Early DKD	0.1	1,820	no	0.02	0.16	0.02	0.24	0.46
Early DKD	0.1	1,820	yes	0.03	0.16	0.04	0.24	0.43

Prevalence: Estimated prevalence of the cases in the T1D, employed for transforming the results for the underlying T1D population. Adj: no, model unadjusted; yes: model adjusted for sex, diabetes duration, and age at diabetes onset. V(G)/V(p) proportion of phenotypic variance explained by the genotypes, i.e. heritability, as observed in the study population. SE: standard error. V(G)/V(p\_L): proportion of phenotypic variance explained by the genotypes, i.e. heritability, transformed for the underlying population scale.

Prevalences were estimated as a combination of the following data:

**Microalbuminuria or worse:** Cumulative incidence of persistent micro-albuminuria was 33.6% (95% confidence interval 27.2% to 40.0%; median follow-up 18-years) in Hovind P. *et al.*, *BMJ* 2004<sup>53</sup>

**Macroalbuminuria or worse:** Cumulative incidence of persistent macroalbuminuria was 14.6% (8.9% to 20.3%; Median follow-up 18 years) in Hovind P. *et al.*, *BMJ* 2004<sup>53</sup>

**ESRD:** 40-year Cumulative risk of ESRD was 23.0% in Harjutsalo V. *et al.*, *Diabetologia* 2011<sup>54</sup>

**CKD (eGFR $\leq$ 60 ml/min/1.73m<sup>2</sup>):** The 16-year cumulative incidence of CKD was 31.7 percent in Shankar A *et al.*, *Exp Clin Endocrinol Diabetes* 2007<sup>55</sup>

**CKDDN:** All patients with ESRD, plus patients with macroalbuminuria and eGFR $<$ 45 ml/min/1.73m<sup>2</sup>.

1  
2 **Supplemental Table 2: Information on genotyping, and clinical characteristics of the discovery and**  
3 **replication patients divided based on the seven case – control definitions**

4 Supplemental Table 2 can be found on the Supplemental Excel sheet.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

Supplemental Table 3: Number of subjects included in the analysis in the discovery and *in silico* replication cohorts

Phenotype criteria	Cohort	Stage 1: Discovery GWAS					Stage 2: <i>In silico</i> replication						Total Stages 1+2
		FinnDiane	EURODIAB	SDR	NFS-ORPS	Total	UK-ROI	GoKinD US	French/Danish	DCCT/EDIC	Joslin	Total	
	<b>N total</b>	3,415	789	556	396	5,156	1,726	1,595	1,415	1,271	1,073	7,095	<b>12,251</b>
<b>Combined DKD</b>	<b>total</b>	3,415	789	556	396	5,156	1,726	1,595	1,430	1,271	1,073	7,095	<b>12,251</b>
miA/maA/ESRD	case	1,802	298	266	197	2,563	823	774	691	551	349	3,188	<b>5,751</b>
noA	control	1,613	491	290	199	2,593	903	821	739	720	724	3,907	<b>6,500</b>
<b>Early DKD</b>	<b>total</b>	2,076	586	382	349	3,393	–	–	931	1,130	–	2,061	<b>5,454</b>
miA	case	463	95	92	150	800	–	–	192	410	–	602	<b>1,402</b>
noA	control	1,613	491	290	199	2,593	–	–	739	720	–	1,459	<b>4,052</b>
<b>Late DKD</b>	<b>total</b>	2,952	694	458	246	4,350	1,726	1,595	1,188	861	1,073	6,443	<b>6,878</b>
maA/ESRD	case	1,339	203	168	47	1,757	823	774	449	141	349	2,536	<b>4,293</b>
noA	control	1,613	491	290	199	2,593	903	821	739	720	724	3,907	<b>6,500</b>
<b>ESRD vs. no DKD</b>	<b>total</b>	2,267	575	365	–	3,207	1,149	1,329	811	–	862	4,151	<b>7,358</b>
ESRD	case	654	84	75	–	813	246	508	72	–	138	964	<b>1,777</b>
noA	control	1,613	491	290	–	2,394	903	821	739	–	724	3,187	<b>5,581</b>
<b>ESRD vs. non-ESRD</b>	<b>total</b>	3,415	789	604	–	4,808	1,687	1,595	1,415	–	1,073	5,770	<b>5,385</b>
ESRD	case	654	84	75	–	813	246	508	72	–	138	964	<b>1,777</b>
noA/miA/maA	control	2,761	705	529	–	3,995	1,441	1,087	1,343	–	935	4,806	<b>8,801</b>
<b>CKD</b>	<b>total</b>	3,056	580	528	–	4,164	1,274	1,586	1,421	1,266	1,048	6,595	<b>10,759</b>
eGFR<60	case	979	113	163	–	1,255	668	710	391	79	198	2,046	<b>3,301</b>
eGFR>60	control	2,077	467	365	–	2,909	606	876	1,030	1,187	850	4,549	<b>7,458</b>
<b>CKD+DKD</b>	<b>total</b>	2,211	567	357	–	3,135	839	1,419	836	–	827	3,921	<b>7,056</b>
eGFR<45 AND miA/maA/ESRD	case	789	210	118	–	1,117	316	635	162	–	153	1,266	<b>2,383</b>
eGFR>60 AND noA	control	1,422	357	239	–	2,018	523	784	674	–	674	2,655	<b>4,673</b>

miA: microalbuminuria. maA: Macroalbuminuria. noA: normal albuminuria.

**Supplemental Table 4: Statistical power to detect association with 'combined DKD' with genome-wide significance ( $p < 5 \times 10^{-8}$ ) at the discovery stage.**

OR	RR (Aa)	RR (AA)	Risk Allele frequency				
			0.01	0.05	0.10	0.20	0.50
1.10	1.07	1.14	0.00	0.00	0.00	0.00	0.00
1.2	1.13	1.28	0.00	0.00	0.00	0.04	0.16
1.3	1.19	1.42	0.00	0.00	0.00	0.04	0.16
1.4	1.25	1.56	0.00	0.05	0.39	0.90	1.00
1.5	1.30	1.70	0.00	0.17	0.76	1.00	1.00
1.55	1.33	1.77	0.00	0.30	0.90	1.00	1.00
1.6	1.36	1.84	0.00	0.46	0.97	1.00	1.00
2.0	1.54	2.37	0.03	0.99	1.00	1.00	1.00

RR: Relative Risk, calculated as  $RR = OR / ((1 - \text{prev}) + (\text{prev} \times OR))$ , where prev is the incidence in non-carrier group, assumed to be 30% for the Combined DKD phenotype. RR (AA) was calculated as  $RR(Aa)^2$

**Supplemental Table 5: Association analysis results for the 101 GWAS SNPs selected for *in silico* replication.**

Supplemental Table 5 can be found on the Supplemental Excel sheet.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review



**Supplemental Table 6: Statistical power to detect association with 'Combined DKD' with genome-wide significance ( $p < 5 \times 10^{-8}$ ) with the two-stage study design.**

OR	RR (Aa)	RR (AA)	Risk allele frequency						
			0.01	0.05	0.10	0.20	0.30	0.40	0.50
1.10	1.07	1.14	0	0	0	0	0	0.01	0.01
1.2	1.13	1.28	0	0	0.01	0.09	0.19	0.25	0.25
1.3	1.19	1.42	0	0.02	0.17	0.57	0.78	0.84	0.83
1.4	1.25	1.56	0	0.13	0.57	0.95	0.99	0.99	0.99
1.47	1.29	1.66			0.80				
1.5	1.30	1.70	0	0.33	0.87	1	1	1	1
2	1.54	2.37	0.09	1	1	1	1	1	1

RR: Relative Risk, calculated as  $RR = OR / ((1 - \text{prev}) + (\text{prev} \times OR))$ , where prev is the incidence in non-carrier group, assumed to be 30% for the Combined DKD phenotype.

RR (AA) was calculated as  $RR(Aa)^2$

Power calculations were performed with Power Calculator for Two Stage Association Studies (CaTS; <http://csg.sph.umich.edu//abecasis/cats/>)

Parameters used in the calculations:

N= 5,751 cases, 6,500 controls; 42% of samples genotyped in stage 1

11/ 8,578,867 = 0.000128% of markers genotyped at stage 2

Significance level:  $p = 5 \times 10^{-8}$

Prevalence: 30%

Additive genetic model

**Supplemental Table 7: Association at the *AFF3* locus with 'ESRD vs. non-ESRD' phenotypic comparison, conditional on the previously reported lead SNP rs7583877**

Chr	SNP	bp	refA	freq	Raw results			Conditional on the other SNP		
					Beta	se	p	Beta	se	p
2	rs7583877	100460654	T	0.71	-0.26	-0.06	8.71E-05	0.01	0.04	0.78
2	rs7562121	100384354	G	0.77	-0.38	-0.07	8.92E-08	-0.16	0.04	1.97E-04

For Peer Review

**Supplemental Table 8: Statistical power to detect association with the 'Late DKD' phenotype for varying odds ratio and risk allele frequency.****Power to detect association with  $p < 0.05$** 

OR	RR (Aa)	RR (AA)	Risk allele Frequency			
			0.05	0.10	0.20	0.50
1.10	1.08	1.16	0.17	0.27	0.42	0.56
1.2	1.15	1.33	0.45	0.71	0.91	0.98
1.25	1.19	1.42	0.63	0.88	0.99	1.00
1.3	1.23	1.50	0.79	0.96	1.00	1.00
1.4	1.30	1.68	0.95	1.00	1.00	1.00
1.5	1.36	1.86	0.99	1.00	1.00	1.00
2	1.67	2.78	1.00	1.00	1.00	1.00
2.5	1.92	3.70	1.00	1.00	1.00	1.00

**Power to detect association with  $p < 1.1 \times 10^{-3}$  (correction for multiple testing)**

OR	RR (Aa)	RR (AA)	Risk allele Frequency			
			0.05	0.10	0.20	0.50
1.10	1.08	1.16	0.01	0.03	0.07	0.13
1.2	1.15	1.33	0.08	0.23	0.53	0.79
1.3	1.23	1.50	0.31	0.69	0.95	0.99
1.4	1.30	1.68	0.62	0.94	1.00	1.00
1.5	1.36	1.86	0.84	0.99	1.00	1.00
2	1.67	2.78	1.00	1.00	1.00	1.00
2.5	1.92	3.70	1.00	1.00	1.00	1.00

RR: Relative Risk, calculated as  $RR = OR / ((1 - \text{prev}) + (\text{prev} \times OR))$ , where prev is the incidence in non-carrier group, assumed to be 20% for the Late DKD phenotype. RR(AA) was calculated as  $RR(Aa)^2$ .

Supplemental Table 9: Evaluation of previously reported candidate genes or GWAS loci on kidney complications in type 1 and type 2 diabetes, or GWAS on CKD in the general population.

Table with columns: SNP, GENE, Source, Type, EA, NEA, DKD (EAF, P, OR), Early DKD (EAF, P, OR), Late DKD (EAF, P, OR), ESRD vs. no DKD (EAF, P, OR), ESRD vs. non-ESR (EAF, P, OR), CKD (EAF, P, OR), CKD+DKD (EAF, P, OR), Direction. Rows include genes like SIK1, AFF3, RGMA-MCTP2, WNT4-ZBTB40, PPARC, SEMA6D-SLC24A5, AGT, EPO, ELMO1, ERBB4, CCR5, AGTR1, PVT1, VEGFA, LOC100132891, GLRA3, ACACB, NOS3, PRKGA2, ZMIZ1, LIMK2, FRMD3, GREM1, SOX11, UNCL3B, CPVL/CHN2, CARS, ADIPOQ, PSD3-SH2D4A.

Supplementary information: Genome-wide dissection of diabetic kidney disease

1	rs6930576	SASH1	McDonough 2010	GWAS T2D-DN AA	A	G	0.34	0.59	1.04	0.34	0.72	1.04	0.34	0.91	1.02	0.33	0.67	1	0.33	0.47	0.97	0.33	0.56	0.98	0.34	0.74	0.98				
2	rs3767140	HSPG2	Mooyaart 2011*	CGM, T1D/T2D	A	C	0.23	0.81	1.02	0.22	0.74	1.03	0.23	0.81	1	0.23	0.79	1.02	0.23	0.88	1	0.22	0.47	1.04	0.22	0.84	0.99				
3	rs39059	CPVL/CHN2	Pezzolesi 2009	GWAS T1D-DN	G	A	0.36	0.48	0.96	0.36	0.66	0.97	0.36	0.52	0.96	0.36	0.67	0.99	0.36	0.92	1	0.36	1	1	0.37	0.96	0.99				
4	rs12917707	UMOD	Köttgen 2010	GWAS CKD	T	G	0.22	0.71	0.99	0.22	0.74	1.02	0.22	0.64	0.98	0.22	0.85	1.01	0.22	0.97	1.02	0.22	0.57	0.97	0.22	0.59	0.96				
5	rs2358944	MSRB3-HMGA2	McDonough 2010	GWAS T2D-DN AA	A	G	0.84	0.66	0.98	0.84	0.82	0.98	0.84	0.66	0.97	0.84	0.8	0.98	0.84	0.92	0.99	0.84	0.8	0.99	0.84	0.75	0.99				
6	rs7769051	RPS12	McDonough 2010	GWAS T2D-DN AA	A	C	0.14	0.89	1	0.14	0.86	0.98	0.14	0.77	0.99	0.14	0.68	0.98	0.14	0.89	1	0.14	0.89	1	0.15	0.94	1.01				
7	rs841853	GLUT1	Mooyaart 2011*	CGM, T1D/T2D	C	A	0.69	0.74	1.01	0.68	0.93	0.99	0.69	0.72	1.01	0.68	0.93	0.99	0.69	0.71	0.97	0.68	0.8	1	0.67	0.75	0.97				
Results excluding the FinnDiane patients for SNPs were the source publication includes FinnDiane patients																															
8	<b>SNP</b>	<b>GENE</b>	<b>Source</b>	<b>Type</b>	<b>EA</b>	<b>NEA</b>	<b>EAF</b>	<b>OR</b>	<b>P</b>	<b>EAF</b>	<b>OR</b>	<b>P</b>	<b>EAF</b>	<b>OR</b>	<b>P</b>	<b>EAF</b>	<b>OR</b>	<b>P</b>	<b>EAF</b>	<b>OR</b>	<b>P</b>	<b>EAF</b>	<b>OR</b>	<b>P</b>	<b>EAF</b>	<b>OR</b>	<b>P</b>	<b>Direction</b>			
9	rs13293564	UNC13B	Mooyaart 2011*	CGM, T1D/T2D	T	G	0.41	0.83	0.03	0.42	0.80	0.02	0.42	0.83	0.11	0.43	0.93	0.87	0.42	1.00	0.78	0.42	0.88	0.31	0.42	0.77	0.02	Opposite			
10	rs2838302	SIK1	Sambo 2014	GWAS, T1D-ESRD	G	A	0.09	1.23	0.22	0.08	1.20	0.55	0.09	1.27	0.14	0.08	1.52	0.04	0.09	1.39	0.09	0.09	1.22	0.28	0.09	1.19	0.33	same			
11	rs12137135	WNT4-ZBTB40	Sambo 2014	GWAS, T1D-ESRD	G	A	0.15	0.81	0.04	0.16	0.89	0.29	0.16	0.76	0.04	0.17	0.81	0.11	0.16	0.91	0.32	0.15	0.97	0.62	0.15	0.77	0.08	Opposite			
12	rs699	AGT	Mooyaart 2011	CGM, T1D/T2D	G	A	0.43	1.09	0.33	0.43	1.24	0.05	0.42	0.98	0.79	0.43	1.08	0.59	0.43	1.08	0.67	0.43	0.98	0.65	0.43	1.00	0.74				
13	rs7583877	AFF3	Sandholm 2012	GWAS, T1D-ESRD	T	C	0.66	1.12	0.19	0.66	1.21	0.07	0.66	1.08	0.72	0.66	1.07	0.49	0.66	1.03	0.89	0.67	1.03	0.98	0.66	1.03	0.83				
14	rs5186	AGTR1	Mooyaart 2011	CGM, T1D/T2D	C	A	0.30	1.17	0.10	0.29	1.08	0.71	0.30	1.21	0.11	0.28	1.10	0.86	0.29	1.07	0.96	0.30	0.94	0.78	0.30	1.17	0.08				
15	rs1801282	PPARG	Mooyaart 2011	CGM, T1D/T2D	G	C	0.11	1.18	0.10	0.11	1.20	0.20	0.11	1.18	0.18	0.11	1.31	0.11	0.12	1.18	0.24	0.12	1.12	0.23	0.12	1.08	0.47				
16	rs7588550	ERBB4	Sandholm 2012	GWAS, T1D-DN	A	G	0.96	0.92	0.57	0.96	0.71	0.10	0.96	1.00	0.95	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA			
17	rs1799987	CCR5	Mooyaart 2011	CGM, T1D/T2D	G	A	0.45	1.09	0.65	0.46	1.21	0.11	0.45	1.03	0.74	0.44	1.02	0.63	0.45	0.97	0.36	0.44	0.99	0.56	0.45	1.17	0.22				
18	rs12917114	SEMA6D-SLC24A5	Sambo 2014	GWAS, T1D-ESRD	T	C	0.08	0.86	0.13	0.08	0.87	0.27	0.08	0.86	0.24	0.07	0.94	0.68	0.07	1.05	0.94	0.07	1.08	0.98	0.07	0.94	0.74				
19	rs1564939	GLRA3	Sandholm 2014	GWAS, T1D-AER	C	T	0.22	0.92	0.34	0.22	0.94	0.82	0.22	0.90	0.27	0.21	0.82	0.13	0.21	0.84	0.19	0.20	1.02	0.79	0.20	0.92	0.39				
20	rs10011025	GLRA3	sandholm 2014	GWAS, T1D-AER	G	A	0.21	0.92	0.32	0.21	0.92	0.69	0.21	0.91	0.27	0.20	0.83	0.14	0.20	0.85	0.21	0.20	0.98	0.61	0.19	0.91	0.33				
21	rs12437854	RGMA-MCTP2	Sandholm 2012	GWAS, T1D-ESRD	G	T	0.06	1.03	0.73	0.06	1.15	0.47	0.06	0.95	0.99	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.06	1.29	0.19				
22	rs2410601	PSD3-SH2D4A	Sandholm 2014	GWAS T1D-AER	C	G	0.53	1.05	0.41	0.53	0.95	0.92	0.54	1.10	0.31	0.54	1.03	0.83	0.54	1.02	0.86	0.54	0.98	0.96	0.54	0.89	0.25				
23	rs1670754	Chr 4p15.1	Sambo 2014	GWAS, T1D-ESRD	A	G	0.20	0.96	0.82	0.21	1.09	0.46	0.20	0.89	0.32	0.20	1.00	0.90	0.20	0.98	0.76	0.20	0.97	0.93	0.20	1.13	0.25				
24	<b>N subjects</b>						<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	<b>Case</b>	<b>Ctrl</b>	<b>Total</b>	
25	SDR + Eurodiab + Cambridge						761	980	1,741	337	980	1,317	418	980	1,398	159	781	940	159	1,234	1,393	276	832	1,108	328	596	924				

Direction: Direction of effect compared between this and the original study; Opposite, NS: Association was non-significant in the previous meta-analysis, trending in the opposite direction. CGM: meta-analysis of candidate gene studies. P-value required for statistical significance after adjustment for multiple testing is 0.0011 (significance level  $\alpha=0.05$ , 46 loci), highlighted with green background and bold text. \*Variant was significant in the literature-based meta-analysis<sup>56</sup>. Source: Sambo 2014<sup>57</sup>; Sandholm 2012<sup>2</sup>; Mooyaart 2011<sup>56</sup>; Tong 2008<sup>58</sup>; shimazaki 2005<sup>59</sup>; Pezzolesi 2009<sup>60</sup>; Craig 2009<sup>61</sup>; Sandholm 2014<sup>62</sup>; Köttgen 2010<sup>63</sup>; McDonough 2010<sup>64</sup>.

**Supplemental Table 10: Association between diabetic kidney complications and genetic risk scores of related phenotypes**

DKD phenotype	trait	OR	95% CI	P-value
Late DKD	Body mass index (z transformed)	2,51	1,64 - 3,84	<b>2,20E-05</b>
Late DKD	Body mass index (BMI)	2,06	1,37 - 3,07	<b>4,50E-04</b>
ESRD vs. no DKD	Body mass index (BMI)	2,52	1,49 - 4,26	<b>5,40E-04</b>
Combined DKD	Type 2 diabetes (inclu. lipid SNPs)	1,28	1,11 - 1,47	<b>6,10E-04</b>
Combined DKD	Body mass index (z transformed)	1,92	1,32 - 2,78	<b>6,30E-04</b>
CKD	Body mass index (BMI)	2,04	1,33 - 3,13	<b>1,00E-03</b>
CKD	Body mass index (z transformed)	2,04	1,33 - 3,14	<b>1,10E-03</b>
Late DKD	Type 2 diabetes (inclu. lipid SNPs)	1,28	1,1 - 1,5	<b>1,90E-03</b>
Combined DKD	Type 2 diabetes	1,19	1,07 - 1,32	<b>1,90E-03</b>
ESRD vs. no ESRD	Body mass index (BMI)	2,1	1,3 - 3,39	<b>2,50E-03</b>
Late DKD	Type 2 diabetes	1,21	1,07 - 1,36	2,80E-03
Combined DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1,18	1,05 - 1,32	5,60E-03
Late DKD	Fasting proinsulin (BMI+FG adj.)	2,78	1,35 - 5,72	5,70E-03
CKD and DKD	Body mass index (BMI)	1,92	1,2 - 3,09	6,90E-03
ESRD vs. no DKD	Body mass index (z transformed)	2,03	1,2 - 3,44	8,30E-03
ESRD vs. no DKD	Type 2 diabetes (inclu. lipid SNPs)	1,32	1,07 - 1,63	8,30E-03
CKD and DKD	Low-density lipoprotein C	1,79	1,15 - 2,79	9,70E-03
Late DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1,18	1,04 - 1,34	1,30E-02
CKD and DKD	Type 2 diabetes	1,19	1,03 - 1,37	1,70E-02
Late DKD	Waist-Hip Ratio (BMI adj.)	1,76	1,1 - 2,79	1,80E-02
CKD and DKD	Body mass index (z transformed)	1,77	1,09 - 2,86	2,00E-02
Combined DKD	Body mass index (BMI)	1,52	1,06 - 2,17	2,10E-02
Combined DKD	Fasting proinsulin (BMI+FG adj.)	2,13	1,11 - 4,09	2,20E-02
CKD and DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1,19	1,02 - 1,38	2,70E-02
CKD and DKD	Type 2 diabetes (inclu. lipid SNPs)	1,21	1,01 - 1,46	4,00E-02
Late DKD	Insulin resistance	13,96	1,12 - 174,72	4,10E-02
Early DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1,18	1 - 1,39	4,50E-02
Early DKD	Type 2 diabetes (inclu. lipid SNPs)	1,22	1 - 1,49	4,70E-02
CKD	Waist-Hip Ratio (BMI adj.)	1,65	1,01 - 2,71	4,80E-02
Early DKD	Type 2 diabetes	1,16	1 - 1,36	5,30E-02
Combined DKD	Insulin resistance	9,11	0,95 - 87,3	5,50E-02
ESRD vs. no ESRD	Type 2 diabetes (inclu. lipid SNPs)	1,2	0,99 - 1,45	6,30E-02
CKD	Fasting proinsulin (BMI+FG adj.)	2,07	0,95 - 4,5	6,60E-02
ESRD vs. no DKD	Type 2 diabetes	1,16	0,99 - 1,36	7,10E-02
Early DKD	Fasting glucose (BMI adj.)	4,71	0,86 - 25,96	7,50E-02
ESRD vs. no DKD	Low-density lipoprotein C	1,58	0,95 - 2,61	7,70E-02
Late DKD	ln(Fasting insulin) BMI adj.	5,53	0,83 - 37,02	7,80E-02
ESRD vs. no DKD	High-density lipoprotein C	1,95	0,91 - 4,15	8,40E-02
Early DKD	Insulin resistance	15,17	0,61 - 376,25	9,70E-02
ESRD vs. no DKD	Type 2 diabetes (inclu. glycaemic SNPs)	1,15	0,97 - 1,36	1,00E-01
ESRD vs. no ESRD	Low-density lipoprotein C	1,49	0,92 - 2,4	1,00E-01
Combined DKD	ln(Fasting insulin) BMI adj.	4,07	0,74 - 22,36	1,10E-01
Early DKD	Low-density lipoprotein C	1,51	0,91 - 2,5	1,10E-01
ESRD vs. no DKD	Systolic blood pressure	0,45	0,17 - 1,19	1,10E-01

DKD phenotype	trait	OR	95% CI	P-value
1				
2	CKD and DKD	Waist-Hip Ratio (BMI adj.)	1,56 0,9 - 2,71	1,10E-01
3	CKD and DKD	Fasting proinsulin (BMI+FG adj.)	1,96 0,85 - 4,5	1,10E-01
4	CKD	Systolic blood pressure	0,53 0,23 - 1,19	1,20E-01
5	CKD	Type 2 diabetes (inclu. glycaemic SNPs)	1,11 0,97 - 1,28	1,30E-01
6	CKD	Type 2 diabetes (inclu. glycaemic SNPs)	1,11 0,97 - 1,28	1,30E-01
7	Early DKD	ln(Fasting insulin) BMI adj.	6,39 0,57 - 72,23	1,30E-01
8	ESRD vs. no ESRD	Body mass index (z transformed)	1,43 0,89 - 2,29	1,40E-01
9	Combined DKD	Fasting glucose (BMI adj.)	2,45 0,75 - 8	1,40E-01
10	Combined DKD	Fasting glucose (BMI adj.)	2,45 0,75 - 8	1,40E-01
11	Combined DKD	Waist-Hip Ratio (BMI adj.)	1,37 0,9 - 2,06	1,40E-01
12	ESRD vs. no ESRD	High-density lipoprotein C	1,69 0,84 - 3,38	1,40E-01
13	CKD	Type 2 diabetes (inclu. lipid SNPs)	1,13 0,96 - 1,34	1,40E-01
14	Late DKD	High-density lipoprotein C	1,52 0,86 - 2,7	1,50E-01
15	Late DKD	High-density lipoprotein C	1,52 0,86 - 2,7	1,50E-01
16	ESRD vs. no DKD	Fasting proinsulin (BMI+FG adj.)	1,94 0,76 - 4,94	1,60E-01
17	ESRD vs. no ESRD	HbA1c	0,28 0,04 - 1,8	1,80E-01
18	Late DKD	2hr-Glucose (BMI adj.)	0,75 0,49 - 1,15	1,90E-01
19	Late DKD	2hr-Glucose (BMI adj.)	0,75 0,49 - 1,15	1,90E-01
20	CKD and DKD	ln(Fasting insulin) BMI adj.	4,32 0,46 - 40,29	2,00E-01
21	CKD and DKD	Insulin resistance	6,99 0,36 - 135,72	2,00E-01
22	CKD and DKD	Insulin resistance	6,99 0,36 - 135,72	2,00E-01
23	CKD and DKD	Systolic blood pressure	0,56 0,23 - 1,38	2,10E-01
24	ESRD vs. no DKD	HbA1c	0,29 0,04 - 2,14	2,30E-01
25	Combined DKD	High-density lipoprotein C	1,36 0,82 - 2,26	2,30E-01
26	CKD and DKD	Fasting glucose (BMI adj.)	2,65 0,53 - 13,22	2,40E-01
27	CKD and DKD	Fasting glucose (BMI adj.)	2,65 0,53 - 13,22	2,40E-01
28	CKD	Type 2 diabetes	1,08 0,95 - 1,23	2,40E-01
29	ESRD vs. no DKD	Waist-Hip Ratio (BMI adj.)	1,43 0,77 - 2,67	2,60E-01
30	ESRD vs. no DKD	2hr-Glucose (BMI adj.)	0,74 0,43 - 1,26	2,70E-01
31	CKD and DKD	Triglycerides	0,67 0,32 - 1,37	2,70E-01
32	CKD and DKD	Triglycerides	0,67 0,32 - 1,37	2,70E-01
33	ESRD vs. no DKD	ln(Fasting insulin) BMI adj.	3,84 0,34 - 42,91	2,80E-01
34	Late DKD	Systolic blood pressure	0,66 0,31 - 1,4	2,80E-01
35	Early DKD	Body mass index (BMI)	0,76 0,46 - 1,27	3,00E-01
36	CKD and DKD	High-density lipoprotein C	1,42 0,72 - 2,77	3,10E-01
37	CKD and DKD	High-density lipoprotein C	1,42 0,72 - 2,77	3,10E-01
38	Combined DKD	Low-density lipoprotein C	1,2 0,84 - 1,71	3,20E-01
39	Late DKD	HbA1c	0,46 0,1 - 2,21	3,30E-01
40	ESRD vs. no ESRD	2hr-Glucose (BMI adj.)	0,8 0,48 - 1,31	3,70E-01
41	ESRD vs. no ESRD	2hr-Glucose (BMI adj.)	0,8 0,48 - 1,31	3,70E-01
42	ESRD vs. no ESRD	Type 2 diabetes (inclu. glycaemic SNPs)	1,07 0,92 - 1,26	3,80E-01
43	ESRD vs. no ESRD	Systolic blood pressure	0,67 0,27 - 1,67	3,90E-01
44	ESRD vs. no ESRD	Systolic blood pressure	0,67 0,27 - 1,67	3,90E-01
45	Late DKD	Triglycerides	0,77 0,42 - 1,41	4,00E-01
46	CKD	Fasting glucose (BMI adj.)	0,54 0,13 - 2,26	4,00E-01
47	CKD	HOMA-B	0,57 0,15 - 2,17	4,10E-01
48	CKD	Low-density lipoprotein C	1,19 0,78 - 1,82	4,10E-01
49	CKD	Low-density lipoprotein C	1,19 0,78 - 1,82	4,10E-01
50	Late DKD	Fasting glucose (BMI adj.)	1,73 0,46 - 6,47	4,10E-01
51	CKD and DKD	HOMA-IR	3,01 0,2 - 44,97	4,30E-01
52	Combined DKD	2hr-Glucose (BMI adj.)	0,86 0,58 - 1,26	4,40E-01
53	Early DKD	Fasting proinsulin (BMI+FG adj.)	1,43 0,56 - 3,65	4,50E-01
54	Early DKD	Fasting proinsulin (BMI+FG adj.)	1,43 0,56 - 3,65	4,50E-01
55	ESRD vs. no ESRD	Type 2 diabetes	1,06 0,91 - 1,22	4,60E-01
56	CKD	High-density lipoprotein C	1,26 0,68 - 2,34	4,60E-01
57	ESRD vs. no DKD	Insulin resistance	3,4 0,13 - 90,6	4,60E-01
58	Late DKD	HOMA-IR	2,32 0,24 - 22,65	4,70E-01
59	Late DKD	HOMA-IR	2,32 0,24 - 22,65	4,70E-01
60	CKD	2hr-Glucose (BMI adj.)	1,18 0,74 - 1,86	4,90E-01



	DKD phenotype	trait	OR	95% CI	P-value
1					
2	CKD	HOMA-IR	0,46	0,04 - 4,77	5,10E-01
3	ESRD vs. no ESRD	Insulin resistance	0,38	0,02 - 8,04	5,30E-01
4	ESRD vs. no DKD	Triglycerides	0,78	0,35 - 1,74	5,50E-01
5	ESRD vs. no ESRD	Triglycerides	0,8	0,38 - 1,69	5,60E-01
6	ESRD vs. no ESRD	Triglycerides	0,8	0,38 - 1,69	5,60E-01
7	Early DKD	HOMA-B	0,63	0,13 - 3,03	5,60E-01
8	Early DKD	HbA1c	1,83	0,22 - 15,06	5,70E-01
9	CKD and DKD	Type 1 diabetes	0,98	0,93 - 1,04	5,80E-01
10	ESRD vs. no ESRD	Fasting proinsulin (BMI+FG adj.)	1,28	0,54 - 3,02	5,80E-01
11	Combined DKD	Systolic blood pressure	0,83	0,42 - 1,63	5,90E-01
12	ESRD vs. no ESRD	Waist-Hip Ratio (BMI adj.)	1,17	0,65 - 2,09	6,00E-01
13	ESRD vs. no ESRD	HOMA-IR	0,51	0,04 - 6,97	6,20E-01
14	ESRD vs. no ESRD	HOMA-IR	1,68	0,22 - 12,67	6,20E-01
15	Combined DKD	HOMA-IR	1,68	0,22 - 12,67	6,20E-01
16	Early DKD	Systolic blood pressure	0,79	0,3 - 2,04	6,20E-01
17	ESRD vs. no ESRD	HOMA-B	1,44	0,33 - 6,25	6,30E-01
18	ESRD vs. no ESRD	HOMA-B	1,44	0,33 - 6,25	6,30E-01
19	ESRD vs. no ESRD	HOMA-B	1,44	0,33 - 6,25	6,30E-01
20	CKD	Type 1 diabetes	0,99	0,94 - 1,04	6,80E-01
21	Early DKD	Body mass index (z transformed)	1,11	0,66 - 1,86	6,90E-01
22	Combined DKD	HbA1c	0,75	0,18 - 3,14	7,00E-01
23	Early DKD	High-density lipoprotein C	1,15	0,57 - 2,33	7,00E-01
24	ESRD vs. no DKD	HOMA-B	1,35	0,28 - 6,59	7,10E-01
25	ESRD vs. no DKD	Type 1 diabetes	0,99	0,94 - 1,05	7,30E-01
26	ESRD vs. no DKD	Type 1 diabetes	0,99	0,94 - 1,05	7,30E-01
27	CKD	ln(Fasting insulin) BMI adj.	0,72	0,1 - 5,39	7,50E-01
28	CKD	HbA1c	1,31	0,23 - 7,44	7,60E-01
29	CKD	HbA1c	1,31	0,23 - 7,44	7,60E-01
30	CKD	Triglycerides	0,9	0,46 - 1,76	7,60E-01
31	ESRD vs. no ESRD	Fasting glucose (BMI adj.)	0,78	0,15 - 4,13	7,80E-01
32	ESRD vs. no ESRD	Fasting glucose (BMI adj.)	0,78	0,15 - 4,13	7,80E-01
33	CKD and DKD	HOMA-B	0,81	0,19 - 3,49	7,80E-01
34	CKD and DKD	2hr-Glucose (BMI adj.)	0,93	0,57 - 1,54	7,90E-01
35	Early DKD	Waist-Hip Ratio (BMI adj.)	1,08	0,6 - 1,95	7,90E-01
36	Late DKD	HOMA-B	1,17	0,34 - 3,98	8,00E-01
37	Late DKD	HOMA-B	1,17	0,34 - 3,98	8,00E-01
38	ESRD vs. no ESRD	ln(Fasting insulin) BMI adj.	1,31	0,14 - 12,29	8,10E-01
39	ESRD vs. no DKD	Fasting glucose (BMI adj.)	1,24	0,21 - 7,41	8,10E-01
40	ESRD vs. no DKD	Fasting glucose (BMI adj.)	1,24	0,21 - 7,41	8,10E-01
41	Early DKD	2hr-Glucose (BMI adj.)	1,06	0,61 - 1,86	8,30E-01
42	ESRD vs. no ESRD	Type 1 diabetes	1	0,94 - 1,05	8,70E-01
43	Late DKD	Type 1 diabetes	1	0,95 - 1,04	8,70E-01
44	Combined DKD	Type 1 diabetes	1	0,96 - 1,04	8,70E-01
45	Combined DKD	Type 1 diabetes	1	0,96 - 1,04	8,70E-01
46	Early DKD	Type 1 diabetes	1	0,95 - 1,06	8,80E-01
47	Combined DKD	HOMA-B	0,92	0,31 - 2,76	8,80E-01
48	Combined DKD	Triglycerides	0,96	0,56 - 1,65	8,80E-01
49	CKD	Insulin resistance	0,84	0,06 - 12,46	9,00E-01
50	Early DKD	Triglycerides	1,02	0,47 - 2,19	9,70E-01
51	ESRD vs. no DKD	HOMA-IR	0,96	0,05 - 17,34	9,80E-01
52	ESRD vs. no DKD	HOMA-IR	0,96	0,05 - 17,34	9,80E-01
53	Late DKD	Low-density lipoprotein C	1	0,67 - 1,5	9,80E-01
54	Early DKD	HOMA-IR	0,99	0,06 - 17,58	1,00E+00
55	Early DKD	HOMA-IR	0,99	0,06 - 17,58	1,00E+00
56	CKD and DKD	HbA1c	1	0,16 - 6,4	1,00E+00

Significant  $p$ -values ( $p < 2.6 \times 10^{-3}$ ,  $\alpha = 0.05$  Bonferroni corrected for the 19 examined traits) are highlighted with ***bold italics***.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

References for the SNPs included in the genetic risk scores (GRS): Waist-Hip-ratio (adjusted for body mass index [BMI],  $N_{\text{SNPs}}=54$ )<sup>26</sup>, BMI (untransformed,  $N_{\text{SNPs}}=96$ <sup>27</sup> and z-transformed,  $N_{\text{SNPs}}=24$ <sup>28</sup>), systolic blood pressure (SBP,  $N_{\text{SNPs}}=22$ )<sup>29</sup>, low-density lipoprotein cholesterol (LDL-C,  $N_{\text{SNPs}}=24$ ), triglycerides (TRIG,  $N_{\text{SNPs}}=20$ ), high-density lipoprotein cholesterol (HDL-C,  $N_{\text{SNPs}}=26$ )<sup>30</sup>, T1D ( $N_{\text{SNPs}}=51$ )<sup>31</sup>, T2D<sup>32</sup> (including all SNPs ( $N_{\text{SNPs}}=70$ ), and without any other effects other than on T2D or lipids ( $N_{\text{SNPs}}=56$ )<sup>30</sup> and T2D or glycemic traits ( $N_{\text{SNPs}}=62$ )<sup>33,34</sup>), 2-hr glucose (adjusted for BMI,  $N_{\text{SNPs}}=15$ )<sup>35</sup>, fasting glucose (FG, adjusted for BMI,  $N_{\text{SNPs}}=21$ )<sup>34</sup>, glycated haemoglobin (HbA1c,  $N_{\text{SNPs}}=15$ )<sup>36</sup>, fasting insulin (natural log transformed and adjusted for BMI,  $N_{\text{SNPs}}=13$ )<sup>34</sup>, fasting pro-insulin (adjusted for BMI and FG,  $N_{\text{SNPs}}=10$ )<sup>37</sup>, HOMA-B ( $N_{\text{SNPs}}=15$ ), HOMA-IR ( $N_{\text{SNPs}}=15$ )<sup>38</sup> and insulin resistance<sup>39</sup>.

For Peer Review

Supplemental Table 11: MAGENTA Gene set enrichment results with FDR<0.05

pheno	DB	Gene set	EFF GS SIZE	P	FDR	EXP # GENES	OBS # GENES	# GENES FLAGGED	FLAGGED GENE NAMES
CKDDN	BIOCARTA	Shh pathway	16	1.00E-05	0.0001	1	7	16	DYRK1A, GLI1, GLI2, GLI3, GSK3B, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, PTCH1, SHH, SMO, DYRK1B, SUFU
Combined DKD	KEGG	ascorbate and aldarate metabolism	17	9.00E-06	0.0001	1	7	22	ALDH2, ALDH1B1, ALDH9A1, ALDH3A2, ALDH7A1, UGDH, UGT2B4, UGT2B7, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, MIOX, UGT2A3
Combined DKD	KEGG	pentose and glucuronate interconversions	20	3.00E-06	0.0002	1	8	24	AKR1B1, GUSB, RPE, UGDH, UGP2, UGT2B4, UGT2B7, XYLB, UGT2B11, UGT2A1, DHDH, CRYL1, DCXR, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UGT2A3
Combined DKD	KEGG	porphyrin and chlorophyll metabolism	31	8.50E-05	0.0020	2	8	38	ALAD, ALAS1, ALAS2, BLVRA, BLVRB, COX10, COX15, CP, CPOX, EPRS, FECH, FTH1, GUSB, HCCS, HMBS, HMOX1, HMOX2, PPOX, UGT2B4, UGT2B7, UROD, UROS, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UGT2A3, FTMT, EARS2, MMAB
Early DKD	PANTHER BIOLOGICAL PROCESS	Hearing	27	1.00E-04	0.0020	1	8	29	TIMM8A, DFNA5, COCH, MYO6, MYO7A, MYO7B, P2RX1, P2RX3, P2RX4, P2RX5, P2RX7, TCOF1, WFS1, ZFAND5, P2RX6, KCNQ4, ITM2B, WDR1, P2RX2, DFNB31, TIMM13, TIMM8B, MYO15A, CDHR5, CDH23, ESPN, OTOA, STRC, OC90
Combined DKD	KEGG	drug metabolism other enzymes	39	3.00E-04	0.0102	2	8	48	NAT1, NAT2, CDA, CES1, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP3A4, CYP3A5, DPYD, DPYS, TYMP, GUSB, HPRT1, IMPDH1, IMPDH2, ITPA, TK1, TK2, TPMT, UGT2B4, UGT2B7, UCK2, UMPS, UPP1, XDH, CES2, GMPS, UGT2B11, UGT2A1, UPB1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UCKL1, CYP3A43, UGT2A3, UCK1, UPP2, CES5A
Combined DKD	KEGG	drug metabolism cytochrome p450	49	5.00E-04	0.0107	2	9	68	ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH3A1, ALDH1A3, ALDH3B1, ALDH3B2, AOX1, CYP1A2, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2C18, CYP2D6, CYP2E1, CYP3A4, CYP3A5, FMO1, FMO2, FMO3, FMO4, FMO5, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, GSTZ1, MAOA, MAOB, MGST1, MGST2, MGST3, UGT2B4, UGT2B7, GSTO1, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CYP3A43, UGT2A3, GSTO2, GSTA5, GSTK1
Combined DKD	KEGG	metabolism of xenobiotics by cytochrome p450	47	5.00E-04	0.0125	2	9	66	ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH1A1, CYP1A1, CYP1A2, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2C18, CYP3A4, CYP3A5, CYP4A11, CYP26A1, RDH5, RPE65, UGT2B4, UGT2B7, PNPLA4, RDH16, DGAT1, ALDH1A2, LRAT, DHRS3, DHRS9, UGT2B11, DHRS4, UGT2A1, RDH8, RDH11, BCMO1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, RETSAT, CYP26B1, CYP3A43, UGT2A3, DGAT2, RDH12, RDH10, AWAT2, CYP4A22, DHRS4L2, CYP26C1
Combined DKD	REACTOME	Glucuronidation	13	2.84E-04	0.0238	1	5	16	UGDH, UGP2, UGT2B4, UGT2B7, UGT2B11, UGT2A1, SLC35D1, UGT2B28, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3

## Supplementary information: Genome-wide dissection of diabetic kidney disease

pheno	DB	Gene set	EFF GS SIZE	P	FDR	EXP # GENES	OBS # GENES	# GENES FLAGGED	FLAGGED GENE NAMES
CKD	Panther	Cholesterol biosynthesis	10	8.00E-04	0.0252	1	4	11	<i>FDFT1, FDPS, HMGCR, HMGCS1, HMGCS2, IDI1, MVD, MVK, PMVK, PDSS1, IDI2</i>
Combined DKD	GOTERM	Glucuronosyltransferase activity	15	1.00E-04	0.0304	1	6	20	<i>EXT1, EXT2, UGT2B4, UGT2B7, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CSGALNACT1, UGT2A3, UGT3A1, UGT3A2</i>
Combined DKD	KEGG	glutathione metabolism	40	3.20E-03	0.0350	2	7	49	<i>ANPEP, G6PD, GGT1, GGT7, GGT5, GCLC, GCLM, GPX1, GPX2, GPX3, GPX4, GPX5, GPX7, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, ODC1, PGD, RRM1, RRM2, SMS, SRM, GSTO1, OPLAH, RRM2B, LAP3, TXNDC12, GGCT, GSTO2, GGT6, GSTA5, GPX6, GSTK1</i>
CKD+DKD	BIOCARTA	Cystic Fibrosis Transmembrane Conductance Regulator And Beta 2 Adrenergic Receptor Pathway	12	2.50E-03	0.0366	1	4	12	<i>ADCY1, ADRB2, CFTR, GNAS, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, EZR, SLC9A3R1</i>
CKD+DKD	BIOCARTA	Attenuation of GPCR Signaling Pathway	13	3.50E-03	0.0384	1	4	13	<i>ARRB1, GNAS, GNB1, GNMT1, GRK4, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, PRKCA, PRKCB</i>
Combined DKD	KEGG	starch and sucrose metabolism	40	4.00E-03	0.0391	2	7	46	<i>AGL, AMY2A, AMY2B, G6PC, GAA, GANC, GBE1, GCK, GPI, GUSB, GYS1, GYS2, HK1, HK2, HK3, ENPP1, ENPP3, PGM1, PYGB, PYGL, PYGM, SI, UGDH, UGP2, UGT2B4, UGT2B7, MGAM, UGT2B11, UGT2A1, TREH, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, PGM2, GBA3, G6PC2, UGT2A3, UXS1, PGM2L1</i>
CKD+DKD	BIOCARTA	Repression of Pain Sensation by the Transcriptional Regulator DREAM	14	3.60E-03	0.0394	1	4	14	<i>CREB1, CREM, FOS, JUN, OPRK1, POLR2A, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, MAPK3, KCNIP3</i>
CKD+DKD	BIOCARTA	Cytokines and Inflammatory Response	26	1.50E-03	0.0404	1	6	29	<i>CD4, CSF1, CSF2, CSF3, HLA-DRA, HLA-DRB1, IFNA1, IFNB1, IFNG, IL1A, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL10, IL11, IL12A, IL12B, IL13, IL15, LTA, PDGFA, TGFB1, TGFB2, TGFB3, TNF</i>
CKD+DKD	REACTOME	Cell extracellular matrix interactions	14	5.00E-04	0.0417	1	5	16	<i>ACTN1, FLNA, FLNC, ILK, ITGB1, LIMS1, PXN, RSU1, TESK1, VASP, ARHGEF6, FERMT2, PARVB, FBLIM1, LIMS2, PARVA</i>
Combined DKD	Panther	FAS signaling pathway	22	1.10E-03	0.0424	1	6	22	<i>PARP1, PARP4, CAPG, CASP6, CASP7, CASP8, CASP10, CYC1, DFFB, GSN, LMNA, LMNB1, CFLAR, PARP2, PARP3, NOD1, FAF1, NLRP1, LMNB2, SCIN, IFLT1, NLRP10</i>
CKD+DKD	BIOCARTA	Phospholipase C-epsilon pathway	12	2.10E-03	0.0426	1	4	12	<i>ADCY1, ADRB2, GNAS, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, PTGER1, RAP2B, PLCE1</i>
Combined DKD	KEGG	steroid hormone biosynthesis	41	4.70E-03	0.0480	2	7	52	<i>STS, AKR1C4, COMT, CYP1A1, CYP1B1, CYP3A7, CYP3A4, CYP3A5, CYP7A1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2, AKR1C1, AKR1C2, HSD3B1, HSD3B2, HSD11B1, HSD11B2, HSD17B1, HSD17B3, HSD17B2, SRD5A1, SRD5A2, AKR1D1, SULT1E1, SULT2B1, UGT2B4, UGT2B7, HSD17B8, HSD17B6, AKR1C3, CYP7B1, UGT2B11, UGT2A1, HSD17B12, HSD17B7, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CYP3A43, SRD5A3, UGT2A3</i>

Supplemental Table 12: Characteristics of the patients selected for the whole exome sequencing

Group Subgroup	FinnDiane				Steno				SDR	
	Controls (no DKD)		Cases (Late DKD)		Controls (no DKD)		Cases (Late DKD)		Controls (no DKD)	Cases (Late DKD)
	no RT	RT	maA	ESRD	no RT	RT	maA	ESRD	*	maA
<b>N (Male%)</b>	125 (26)	125 (50)	125 (51)	125 (56)	46 (54) 53±12 (30-80)	74 (42) 55±10 (31-78)	139 (57) 39±9 (22-70)	49 (78) 38±8 (20-59)	130 (49) 55±13 (33-84)	62 (61) 52±12 (29-84)
<b>Age ± sd (yr)</b>	57±9	56±9	46±10	45±9	15±10 (0-32)	16±9 (1-35)	13±8 (1-33)	15±8 (0-31)	15±9 (0-35)	14±8 (1-35)
<b>Age at Onset ± sd (yr)</b>	13±7	13±7	13±7	15±7	38±8 (30-63)	39±6 (30-53)	- -	- -	40±10 (27-74)	38±11 (13-66)
<b>Duration ± sd (yr)</b>	-	-	16 ± 3 (8-20)	-	-	-	18±3 (12-25)	-	-	29±11 (11-64)
<b>Time to maA ± sd (yr) (range)</b>	-	-	-	20 ± 3 (15-27)	-	-	-	26±5 (18-24)	-	-
<b>Time to ESRD ± sd (yr) (range)</b>	-	26 ± 8 (12-47)	17 ± 5 (8-33)	16 ± 5 (2-33)	-	28±7 (12-41)	19±5 (8-35)	16±4 (6-27)	-	-
<b>Time to RT/ laser ± sd (yr) (range)</b>	8.4 ± 1.0	8.4 ± 0.9	8.5 ± 1.5	8.9 ± 1.5	8.4±1.0	8.7±1.2	9.5±1.4	9.8±1.5	7.0±0.9	8.1±1.2
<b>HbA1c ± sd (%)</b>									no record of proliferative retinopathy was available for patients who did not have DN	61/62 cases had proliferative RT
<b>Further definitions</b>									all cases had proliferative RT	

RT: diabetic retinopathy, based on either a clinical diagnosis or laser treatment

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 13. Top 20 results of single variant analysis for WES 'ESRD vs. no DKD' using the score test**

Chr:pos	Id	Maf	Pval	Ref/alt	Ctrlcnt	Cascent	Gene	type
1:224492543	rs188427269	0.0023184	3.3046e-07	G/T	482/0/0	166/3/0	NVL	INTRON
2:212243703	rs13003941	0.3524	3.5931e-06	G/T	182/229/71	92/67/10	ERBB4	UTR_3_PRIME
9:37729786	rs1359590	0.20015	4.8522e-06	C/T	277/189/16	132/35/2	FRMPD1	NON_SYNONYMOUS_CODING
21:34697316	rs112371220	0.0054687	5.4552e-06	C/T	474/1/0	164/4/1	IFNAR1	UTR_5_PRIME
19:1782842	rs146522765	0.003864	7.4797e-06	G/T	482/0/0	164/5/0	ATP8B3	EXON
7:27168590	rs1801085	0.10974	1.2659e-05	A/G	402/77/3	113/52/4	HOXA4	UPSTREAM
7:27159136	rs6969780	0.11283	1.4914e-05	G/C	399/80/3	113/51/5	HOXA3	INTRON
2:43518932	2:43518932	0.0092736	1.7014e-05	AC/A	479/3/0	160/9/0	THADA	INTRON
2:43804334	rs149038509	0.0092736	1.7014e-05	C/T	479/3/0	160/9/0	THADA	EXON
19:4502778	19:4502778	0.0030912	1.7702e-05	G/A	482/0/0	165/4/0	PLIN4	DOWNSTREAM
2:212251864	rs3748962	0.3408	2.0785e-05	T/C	192/222/68	94/65/10	ERBB4	SYNONYMOUS_CODING
5:157078632	rs13181859	0.0015528	2.9199e-05	G/A	479/0/0	167/2/0	SOX30	NON_SYNONYMOUS_CODING
1:64015722	rs41285382	0.0092736	2.9641e-05	T/C	480/2/0	159/10/0	DLEU2L	EXON
12:62996508	12:62996508	0.0015576	3.1046e-05	G/A	477/0/0	167/2/0	C12orf61	UPSTREAM
5:132086671	rs111822821	0.0015456	3.2297e-05	G/A	482/0/0	167/2/0	SEPT8	SYNONYMOUS_CODING
12:53468971	rs142430651	0.0015456	3.2926e-05	G/C	482/0/0	167/2/0	SPRYD3	SYNONYMOUS_CODING
8:107531123	8:107531123	0.0015456	3.5069e-05	G/T	482/0/0	167/2/0	OXR1	INTRON
X:12908121	rs192357402	0.0015456	3.5163e-05	C/T	482/0/0	167/2/0	.	.
3:188595287	rs182465976	0.0015456	3.7313e-05	A/G	482/0/0	167/2/0	LPP	UTR_3_PRIME
7:27146202	rs61384251	0.12133	3.8108e-05	A/G	390/88/4	111/54/4	HOXA3	UPSTREAM

Supplemental Table 14. Top 20 associations for WES 'Late DKD' using the single variant score test

Chr:pos	Id	Maf	Pval	Ref/alt	Casect	Ctrlcnt	Gene	type
15:75762082	rs117245151	0.011992	4.0048e-05	G/A	458/21/0	478/2/0	<i>PTPN9</i>	INTRON
7:27168590	rs1801085	0.1147	5.3839e-05	A/G	400/76/3	352/118/10	<i>HOXA4</i>	UPSTREAM
1:35562965	rs2971408	0.10323	6.0045e-05	G/A	2/70/407	5/114/361	<i>ZMYM1</i>	NON_SYNONYMOUS_CODING
7:27159136	rs6969780	0.11731	7.3659e-05	G/C	397/79/3	351/118/11	<i>HOXA3</i>	INTRON
1:1222958	rs111819661	0.015328	7.7877e-05	C/T	450/25/0	467/4/0	<i>SCNN1D</i>	DOWNSTREAM
6:126334041	rs2206941	0.29406	8.2189e-05	G/A	28/187/264	57/207/216	<i>TRMT11</i>	INTRON
7:137561465	rs77218976	0.03806	9.2539e-05	G/A	427/52/0	459/21/0	<i>CREB3L2</i>	UTR_3_PRIME
1:1195690	rs11260568	0.013034	0.0001173	G/C	457/22/0	477/3/0	<i>LOC100128842</i>	INTRON
1:1196374	rs72894077	0.013034	0.0001173	C/T	457/22/0	477/3/0	<i>LOC100128842</i>	INTRON
6:126299264	rs9388464	0.29249	0.00013887	A/T	28/187/264	57/204/219	<i>HINT3</i>	UTR_3_PRIME
6:126288023	rs3757212	0.29041	0.00013905	T/C	26/189/264	57/202/221	<i>HINT3</i>	INTRON
11:10650350	rs190761149	0.0067779	0.00014425	G/A	466/13/0	480/0/0	<i>MRVI1</i>	SYNONYMOUS_CODING
6:126300270	rs6909664	0.29145	0.0001443	G/A	27/188/264	57/203/220	<i>HINT3</i>	UTR_3_PRIME
19:4945974	rs2250978	0.039749	0.00015331	T/C	2/50/426	0/22/456	<i>UHRF1</i>	SYNONYMOUS_CODING
12:70914045	rs5798988	0.028676	0.00015412	A/AAAGT	438/41/0	466/14/0	<i>PTPRB</i>	UTR_3_PRIME
15:37109504	rs17417429	0.10949	0.00015916	G/C	358/110/11	409/64/7	<i>CSNK1A1P</i>	INTRON
6:126299984	rs10659948	0.29197	0.00016327	A/ACT	27/189/263	56/205/219	<i>HINT3</i>	UTR_3_PRIME
2:223783841	rs13000358	0.051616	0.00016344	G/A	414/60/5	453/25/2	<i>ACSL3</i>	SYNONYMOUS_CODING
2:212243703	rs13003941	0.34619	0.00017464	G/T	180/228/71	229/208/43	<i>ERBB4</i>	UTR_3_PRIME
2:71413771	rs357781	0.20177	0.0001777	G/C	330/136/13	278/179/23	<i>PAIP2B</i>	UTR_3_PRIME



Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 15: Top 10 associations to WES 'Late DKD' with VT with 4 masks**

Position	n.pass.v	P-value	Gene
<b>PTV+missense</b>			
11:68673615-68707139	17	4.9e-05	<i>IGHMBP2</i>
13:53035097-53049198	8	0.00012	<i>CKAP2</i>
20:57415627-57430300	13	0.00012	<i>GNAS</i>
3:123213786-123286612	3	0.00014	<i>PTPLB</i>
14:24837601-24846073	12	0.00025	<i>NFATC4</i>
10:45798933-45803264	5	0.00036	<i>OR13A1</i>
20:1099459-1146882	9	0.00049	<i>PSMF1</i>
19:36509815-36518135	5	0.0005	<i>CLIP3</i>
11:35454383-35515695	14	0.00056	<i>PAMR1</i>
15:59750819-59813476	8	0.00063	<i>FAM81A</i>
<b>PTV+broad</b>			
22:38013000-38028693	5	3.1e-05	<i>GGA1</i>
11:68673615-68707139	9	0.00012	<i>IGHMBP2</i>
19:12954416-12984677	7	0.00028	<i>MAST1</i>
11:102094424-102101456	2	0.00029	<i>YAP1</i>
20:1099459-1146882	8	0.00049	<i>PSMF1</i>
13:28794420-28866586	6	0.00059	<i>PAN3</i>
17:38933291-38938348	5	0.00062	<i>KRT27</i>
14:24837601-24846073	9	0.00063	<i>NFATC4</i>
5:110835655-110835762	2	0.00066	<i>STARD4</i>
18:77891038-77896253	6	0.00067	<i>ADNP2</i>
<b>PTV+strict</b>			
19:6743822-6744853	2	0.00021	<i>TRIP10</i>
10:49931476-50018711	2	0.0006	<i>WDFY4</i>
19:19166642-19168396	2	0.00062	<i>ARMC6</i>
5:133686100-133702055	3	0.00072	<i>CDKL3</i>
11:128781680-128781799	2	0.00087	<i>KCNJ5</i>
19:33370070-33450911	4	0.00089	<i>CCDC123</i>
2:163124596-163144807	7	0.00103	<i>IFIH1</i>
11:76157998-76170978	2	0.00113	<i>C11orf30</i>
1:151734628-151734961	2	0.0012	<i>MRPL9</i>
3:54952509-54952627	2	0.0012	<i>LRTM1</i>
<b>PTV+only</b>			
11:67815031-67818400	2	0.00088	<i>TCIRG1</i>
3:54952509-54952627	2	0.00113	<i>LRTM1</i>
10:49931476-50018711	2	0.0012	<i>WDFY4</i>
2:163124596-163144807	7	0.0015	<i>IFIH1</i>
17:8701157-8701167	2	0.0016	<i>MFSD6L</i>
2:43458439-43804337	3	0.0022	<i>THADA</i>
19:15233517-15235879	2	0.0025	<i>ILVBL</i>
6:101079090-101248282	2	0.0027	<i>ASCC3</i>
5:149676827-149677481	2	0.0028	<i>ARSI</i>
14:50117073-50141063	2	0.003	<i>POLE2</i>

N.pass.v = number of variants passing the mask definitions

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 16: Top 10 associations to WES 'Late DKD' using SKAT-O with 4 different masks.**

Position	n.pass.v	n.sing.v	P-value	Gene
<b>PTV+missense</b>				
13:53035097-53049198	8	4	0.00012156	<i>CKAP2</i>
10:45798933-45803264	5	4	0.00048573	<i>OR13A1</i>
3:54952509-54959089	5	2	0.00063959	<i>LRTM1</i>
1:151139478-151140817	6	3	0.0006738	<i>SCNM1</i>
20:57415627-57430300	13	9	0.00086146	<i>GNAS</i>
7:18066456-18067243	5	3	0.0012014	<i>PRPS1L1</i>
19:6730150-6736607	19	8	0.0012488	<i>GPR108</i>
17:38933291-38938348	6	2	0.0012682	<i>KRT27</i>
19:42392130-42410847	17	8	0.0013578	<i>ARHGEF1</i>
3:122103120-122128670	3	1	0.0015433	<i>FAM162A</i>
<b>PTV+broad</b>				
11:68673615-68707139	9	6	0.00024156	<i>IGHMBP2</i>
13:53035097-53049198	7	4	0.0004632	<i>CKAP2</i>
7:18066456-18067059	4	3	0.00054833	<i>PRPS1L1</i>
3:54952509-54952627	2	0	0.00064301	<i>LRTM1</i>
10:45799065-45799733	2	1	0.00076937	<i>OR13A1</i>
18:77891038-77896253	6	3	0.0011557	<i>ADNP2</i>
13:28794420-28866586	6	3	0.0011976	<i>PAN3</i>
17:38933291-38938348	5	2	0.0013916	<i>KRT27</i>
5:37815803-37816112	3	1	0.0014264	<i>GDNF</i>
3:122103120-122128670	3	1	0.0015433	<i>FAM162A</i>
<b>PTV+strict</b>				
3:54952509-54952627	2	0	0.00064301	<i>LRTM1</i>
3:150384657-150421396	4	2	0.00066435	<i>FAM194A</i>
3:39228815-39229781	3	2	0.0035418	<i>XIRP1</i>
6:45909349-45916999	2	0	0.0035639	<i>CLIC5</i>
9:75774283-75777764	2	1	0.0072129	<i>ANXA1</i>
1:151773808-151774922	4	2	0.0076929	<i>LINGO4</i>
17:8701157-8701167	2	1	0.0088381	<i>MFS6L</i>
17:40933276-40948304	4	3	0.0089785	<i>WNK4</i>
1:46016829-46034879	3	1	0.0094446	<i>AKR1A1</i>
3:38307398-38318485	2	1	0.0094456	<i>SLC22A13</i>
<b>PTV+only</b>				
3:54952509-54952627	2	0	0.00064301	<i>LRTM1</i>
19:15233517-15235879	2	1	0.0016954	<i>ILVBL</i>
17:8701157-8701167	2	1	0.0088381	<i>MFS6L</i>
3:38307398-38318485	2	1	0.0094456	<i>SLC22A13</i>
2:43458439-43804337	3	2	0.010444	<i>THADA</i>
16:334920-336888	5	1	0.010482	<i>PDIA2</i>
17:5486023-5487821	2	1	0.01087	<i>NLRP1</i>
22:41257273-41257834	3	2	0.01437	<i>DNAJB7</i>
22:19189003-19220052	2	1	0.017846	<i>CLTCL1</i>
5:111500816-111519735	2	1	0.018258	<i>EPB41L4A</i>

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 17: Top 10 associations to WES 'Late DKD' using SKAT with 4 masks**

Position	n.pass.v	n.sing.v	P-value	Gene
<b>PTV+missense</b>				
13:53035097-53049198	8	4	0.00041305	<i>CKAP2</i>
3:54952509-54959089	5	2	0.00060623	<i>LRTM1</i>
10:45798933-45803264	5	4	0.00072656	<i>OR13A1</i>
7:18066456-18067243	5	3	0.00091793	<i>PRPS1L1</i>
1:151139478-151140817	6	3	0.0011152	<i>SCNM1</i>
5:37815803-37816112	5	3	0.0013631	<i>GDNF</i>
8:70585265-70744856	14	6	0.0018813	<i>SLCO5A1</i>
14:75321989-75330435	10	4	0.0022685	<i>PROX2</i>
7:1855776-2269648	13	9	0.0026609	<i>MAD1L1</i>
18:42260994-42643270	16	12	0.0028434	<i>SETBP1</i>
<b>PTV+broad</b>				
13:53035097-53049198	7	4	0.00056746	<i>CKAP2</i>
3:54952509-54952627	2	0	0.00059024	<i>LRTM1</i>
10:45799065-45799733	2	1	0.00072803	<i>OR13A1</i>
7:18066456-18067059	4	3	0.0010284	<i>PRPS1L1</i>
5:37815803-37816112	3	1	0.0013592	<i>GDNF</i>
18:42281357-42618578	13	10	0.0023793	<i>SETBP1</i>
7:1937887-2269648	11	8	0.0024099	<i>MAD1L1</i>
6:45882076-45922972	7	2	0.0029219	<i>CLIC5</i>
1:186862169-186946869	3	2	0.0030571	<i>PLA2G4A</i>
3:150377770-150421666	10	6	0.0031755	<i>FAM194A</i>
<b>PTV+strict</b>				
3:150384657-150421396	4	2	0.00057312	<i>FAM194A</i>
3:54952509-54952627	2	0	0.00059024	<i>LRTM1</i>
6:45909349-45916999	2	0	0.0025361	<i>CLIC5</i>
1:46016829-46034879	3	1	0.0062285	<i>AKR1A1</i>
9:75774283-75777764	2	1	0.0062769	<i>ANXA1</i>
17:40933276-40948304	4	3	0.0069954	<i>WNK4</i>
17:34861135-34881073	3	2	0.0076076	<i>MYO19</i>
3:121491422-121544920	5	3	0.0081831	<i>IQCB1</i>
3:39228815-39229781	3	2	0.0098747	<i>XIRP1</i>
19:15233517-15235879	4	1	0.010502	<i>ILVBL</i>
<b>PTV+only</b>				
3:54952509-54952627	2	0	0.00059024	<i>LRTM1</i>
19:15233517-15235879	2	1	0.0024413	<i>ILVBL</i>
16:334920-336888	5	1	0.0067681	<i>PDIA2</i>
3:38307398-38318485	2	1	0.013673	<i>SLC22A13</i>
17:8701157-8701167	2	1	0.015528	<i>MFSD6L</i>
17:5486023-5487821	2	1	0.018495	<i>NLRP1</i>
17:72363857-72366663	2	1	0.021549	<i>GPR142</i>
14:24566139-24569423	5	4	0.024283	<i>PCK2</i>
22:19189003-19220052	2	1	0.024653	<i>CLTCL1</i>
3:149238595-149245675	1	0	0.024785	<i>WWTR1</i>

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental table 18: Top 10 associations to WES 'ESRD vs. no DKD' with VT and 4 masks**

Position	n.pass.v	P-value	Gene
<b>PTV+missense</b>			
12:518580-550003	7	2.1e-05	<i>CCDC77</i>
16:28877711-28884952	7	3.1e-05	<i>SH2B1</i>
12:102108407-102120196	4	8.6e-05	<i>CHPT1</i>
14:23846482-23848306	3	0.00012	<i>CMTM5</i>
11:5775980-5776749	5	0.00019	<i>OR52N4</i>
12:100685365-100732822	8	0.00032	<i>SCYL2</i>
15:44065537-44068996	7	0.00035	<i>ELL3</i>
9:130494915-130496639	6	0.00037	<i>TOR2A</i>
20:61907925-61919795	12	0.00053	<i>ARFGAP1</i>
1:156182876-156209351	6	0.0006	<i>PMF1</i>
<b>PTV+broad</b>			
12:102113935-102120196	3	3.4e-05	<i>CHPT1</i>
6:31525437-31526261	3	0.000124	<i>NFKBIL1</i>
14:23846482-23848306	3	0.00015	<i>CMTM5</i>
13:28794420-28866586	6	0.00018	<i>PAN3</i>
16:28877939-28884858	5	0.00029	<i>SH2B1</i>
6:160543080-160577058	9	0.00054	<i>SLC22A1</i>
1:229730547-229738417	4	0.00073	<i>TAF5L</i>
1:228612639-228612822	3	0.00077	<i>HIST3H3</i>
14:52472205-52534758	18	0.0008	<i>NID2</i>
11:5775984-5776749	4	0.00104	<i>OR52N4</i>
<b>PTV+strict</b>			
8:22884744-22885843	2	0.00019	<i>TNFRSF10B</i>
17:77100210-77102746	2	0.0006	<i>HRNBP3</i>
8:133083602-133090167	2	0.00083	<i>HHLA1</i>
6:136560616-136560647	2	0.00114	<i>FAM54A</i>
4:38798235-38800282	5	0.0012	<i>TLR1</i>
19:8138170-8203184	3	0.0016	<i>FBN3</i>
17:72954475-72960618	2	0.0017	<i>C17orf28</i>
18:21752415-21957382	3	0.0018	<i>OSBPL1A</i>
6:34003851-34100981	4	0.0018	<i>GRM4</i>
8:38834236-38845519	3	0.0025	<i>HTRA4</i>
<b>PTV-only</b>			
8:22884744-22885843	2	0.00017	<i>TNFRSF10B</i>
8:133083602-133090167	2	0.00072	<i>HHLA1</i>
19:8138170-8203184	3	0.0012	<i>FBN3</i>
3:4355014-4355131	2	0.0025	<i>SETMAR</i>
11:121008192-121058691	3	0.0035	<i>TECTA</i>
4:47538723-47574170	2	0.0035	<i>ATP10D</i>
10:75184515-75187483	2	0.0041	<i>ZMYND17</i>
3:9960192-9974543	3	0.0049	<i>IL17RC</i>
2:169727989-169728004	2	0.0056	<i>SPC25</i>
22:42473722-42473986	3	0.0061	<i>FAM109B</i>

N.pass.v = number of variants passing the mask definitions

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 19: Top 10 associations to WES 'ESRD vs. no DKD' with SKAT-O with 4 masks**

Position	n.pass.v	n.sing.v	P-value	Gene
<b>PTV+missense</b>				
11:5775980-5776749	4	3	2.8913e-05	<i>OR52N4</i>
12:102108407-102120196	3	1	4.3482e-05	<i>CHPT1</i>
14:23846482-23848306	2	2	8.5563e-05	<i>CMTM5</i>
12:100685365-100732822	6	2	8.6197e-05	<i>SCYL2</i>
12:518580-550003	7	4	9.0216e-05	<i>CCDC77</i>
2:43458176-43819161	21	12	0.00015065	<i>THADA</i>
11:62575105-62598496	5	3	0.00016229	<i>STX5</i>
15:44065537-44068996	3	2	0.00016763	<i>ELL3</i>
20:61907925-61919795	9	4	0.00027894	<i>ARFGAP1</i>
13:28794420-28866586	7	5	0.00030024	<i>PAN3</i>
<b>PTV+broad</b>				
12:102113935-102120196	2	0	1.8982e-05	<i>CHPT1</i>
13:28794420-28866586	5	3	2.0813e-05	<i>PAN3</i>
6:31525437-31526261	2	2	8.4194e-05	<i>NFKBIL1</i>
14:23846482-23848306	2	2	8.5563e-05	<i>CMTM5</i>
11:5775984-5776749	3	2	0.00017668	<i>OR52N4</i>
11:62592777-62598496	3	1	0.00021827	<i>STX5</i>
20:44047493-44054249	8	7	0.0002694	<i>PIGT</i>
5:39376125-39394413	3	1	0.00029884	<i>DAB2</i>
17:7094043-7107367	5	4	0.00049654	<i>DLG4</i>
19:49407625-49424482	8	6	0.00054261	<i>NUCB1</i>
<b>PTV+strict</b>				
8:22884744-22885843	2	2	9.8064e-05	<i>TNFRSF10B</i>
4:38798235-38800282	4	3	0.00046089	<i>TLR1</i>
17:77100210-77102746	1	0	0.00062522	<i>HRNBP3</i>
19:10738409-10748401	3	2	0.0010388	<i>SLC44A2</i>
16:61687916-61689548	1	0	0.0012592	<i>CDH8</i>
4:186111299-186111306	2	1	0.0013119	<i>KIAA1430</i>
8:133083602-133090167	2	2	0.0013399	<i>HHLA1</i>
8:38834236-38845519	2	1	0.0013474	<i>HTRA4</i>
16:89985750-89986215	2	1	0.0014125	<i>MC1R</i>
17:41004777-41006634	2	1	0.0014339	<i>AOC3</i>
<b>PTV+only</b>				
8:22884744-22885843	2	2	9.8064e-05	<i>TNFRSF10B</i>
8:133083602-133090167	2	2	0.0013399	<i>HHLA1</i>
16:89985750-89986215	2	1	0.0014125	<i>MC1R</i>
11:67786064-67789293	2	0	0.0020716	<i>ALDH3B1</i>
3:4355014-4355131	2	2	0.0020738	<i>SETMAR</i>
19:8138170-8203184	1	1	0.0028026	<i>FBN3</i>
4:47538723-47574170	1	1	0.0032767	<i>ATP10D</i>
22:41257273-41257834	3	2	0.0033414	<i>DNAJB7</i>
11:121008192-121058691	2	2	0.0033577	<i>TECTA</i>
1:151493123-151508777	1	1	0.0037668	<i>CGN</i>

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 20: Top 10 associations to WES 'ESRD vs. no DKD' with SKAT with 4 masks**

Position	n.pass.v	n.sing.v	P-value	Gene
<b>PTV+missense</b>				
2:43458176-43819161	21	12	8.3459e-05	<i>THADA</i>
5:39376125-39394413	8	2	0.00018914	<i>DAB2</i>
17:34071959-34079805	9	5	0.00020671	<i>GAS2L2</i>
12:102108407-102120196	3	1	0.00021871	<i>CHPT1</i>
14:23846482-23848306	2	2	0.00026538	<i>CMTM5</i>
11:62575105-62598496	5	3	0.00038847	<i>STX5</i>
12:57345928-57351029	3	2	0.00055704	<i>RDH16</i>
5:63986481-64013795	5	3	0.00066429	<i>FAM159B</i>
5:157053392-157078632	7	5	0.00088391	<i>SOX30</i>
4:186111299-186112220	4	3	0.0010538	<i>KIAA1430</i>
<b>PTV+broad</b>				
12:102113935-102120196	2	0	0.00021073	<i>CHPT1</i>
5:39376125-39394413	3	1	0.00022996	<i>DAB2</i>
6:31525437-31526261	2	2	0.00025304	<i>NFKBIL1</i>
14:23846482-23848306	2	2	0.00026538	<i>CMTM5</i>
11:62592777-62598496	3	1	0.00049172	<i>STX5</i>
5:63986481-63991426	4	2	0.00061686	<i>FAM159B</i>
17:7094043-7107367	5	4	0.00086232	<i>DLG4</i>
5:157053392-157078632	7	5	0.00088391	<i>SOX30</i>
17:77100210-77111580	2	1	0.0010418	<i>HRNBP3</i>
22:21235389-21242054	1	0	0.0010726	<i>SNAP29</i>
<b>PTV+strict</b>				
8:22884744-22885843	2	2	0.0002888	<i>TNFRSF10B</i>
17:77100210-77102746	1	0	0.00062522	<i>HRNBP3</i>
19:10738409-10748401	3	2	0.00089608	<i>SLC44A2</i>
16:89985750-89986215	2	1	0.001117	<i>MC1R</i>
17:41004777-41006634	2	1	0.0011256	<i>AOC3</i>
4:186111299-186111306	2	1	0.0012193	<i>KIAA1430</i>
11:67786064-67789293	2	0	0.001238	<i>ALDH3B1</i>
16:61687916-61689548	1	0	0.0012592	<i>CDH8</i>
1:104116940-104117921	2	0	0.0022375	<i>AMY2B</i>
19:8138170-8203184	1	1	0.0028026	<i>FBN3</i>
<b>PTV+only</b>				
8:22884744-22885843	2	2	0.0002888	<i>TNFRSF10B</i>
16:89985750-89986215	2	1	0.001117	<i>MC1R</i>
11:67786064-67789293	2	0	0.001238	<i>ALDH3B1</i>
19:8138170-8203184	1	1	0.0028026	<i>FBN3</i>
4:47538723-47574170	1	1	0.0032767	<i>ATP10D</i>
12:55863064-55863661	3	1	0.0034269	<i>OR6C70</i>
1:151493123-151508777	1	1	0.0037668	<i>CGN</i>
2:169727989-169728004	1	1	0.0037668	<i>SPC25</i>
13:40235019-40261900	1	1	0.0042598	<i>COG6</i>
16:10837724-10846536	1	1	0.0042598	<i>NUBP1</i>

N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 21: Gene-sets which showed enrichment in WES association data on the 'Late DKD' phenotype, with permutation (N=100) results**

Gene set	Gene s	SNP s	SKATO mask	Real data				Random data (# of times a better finding is observed in the random data)/100				
				NES	Pval**	FDR	FWER	NES	Pval	FDR	FWER	NES & FDR
FUNC_meta_T1D-ESRDvsNonESRD_emmax_FD-SDR-ED1	16	120	Ptv.miss.0.01	2,1	0.002	0.039	0.044	0.04	0.1	0.08	0.09	0.03
TOP_meta_T1D-macro-ESRD_emmax_FD-SDR-Cam-ED1	43	147	Ptv.strict.broad.0.01	2,3	0.000*	0.012	0.013	0	0	0.02	0.02	0

**Non-significant, tested gene sets**

Gene set	Genes
Orpha.kidney	466
GWAS.kidney	65
GO.BP.kidney	357
MGI.kidney	836
expression.kidney	1597
LitMS.kidney	1349
overexpressed.in.isolated.mouse.podocytes	756
mouse.K.O.has.abnormal.podocyte	39
causes.rare.human.glomerular.disease	45
TOP_meta_T1D-CKD_emmax_FD-SDR-ED1	67
TOP_meta_T1D-CKDDN_emmax_FD-SDR-ED1	69
TOP_meta_T1D-ESRD_emmax_FD-SDR-ED1	243
TOP_meta_T1D-ESRDvsNonESRD_emmax_FD-SDR-ED1	56
TOP_meta_T1D-micro_emmax_FD-SDR-Cam-ED1	22
TOP_Meta_T1D-T2D_CKDDN_min_emmax_131202	93
TOP_Meta_T1D-T2D_ESRDvsALL_min_emmax	289
TOP_Meta_T1D-	
T2D_ESRDvsCONTROL_min_emmax_131101	449
TOP_Meta_T1D-T2D_MACROESRD_min_emmax_131101	181
TOP_Meta_T1D-T2D_MICRO_min_emmax_131101	35
TOP_Meta_T2D_CKD_min_emmax_131202	4



1	TOP_Meta_T2D_DN_min_emmax_131101	6
2	TOP_Meta_T2D_eGFR_min_emmax_131128	26
3	TOP_Meta_T2D_ESRDvsALL_min_emmax_131128	186
4	FUNC_meta_T1D-CKD_emmax_FD-SDR-ED1	13
5	FUNC_meta_T1D-CKDDN_emmax_FD-SDR-ED1	6
6	FUNC_meta_T1D-DN_emmax_FD-SDR-Cam-ED1	1
7	FUNC_meta_T1D-ESRD_emmax_FD-SDR-ED1	30
8	FUNC_meta_T1D-macro-ESRD_emmax_FD-SDR-Cam-ED1	4
9	FUNC_Meta_T1D-T2D_CKD_min_emmax_131202	3
10	FUNC_Meta_T1D-T2D_CKDDN_min_emmax_131202	12
11	FUNC_Meta_T1D-T2D_MACROESRD_min_emmax_131101	23
12	FUNC_Meta_T2D_eGFR_min_emmax_131128	14
13	FUNC_Meta_T2D_MACROESRD_min_emmax_131101	6
14	FUNC_Meta_T2D_MICRO_min_emmax_131101	2
15	Podo_Axonal Guidance Signaling	159
16	Podo_Signaling by Rho Family GTPases	97
17	Podo_Epithelial Adherens Junction Signaling	66
18	Podo_ILK Signaling	79
19	Podo_RhoA Signaling	57
20	Podo_Integrin Signaling	79
21	Podo_Germ Cell-Sertoli Cell Junction Signaling	65
22	*NES= Normalised Enrichment Score	

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

\*\*In the GSEA report, a p value of zero (0.0) indicates an actual p value of less than 1/number-of-permutations. For example, if the analysis performed 100 permutations, a reported p value of 0.0 indicates an actual p value of less than 0.001. For a more accurate p-value, increase the number of permutations performed by the analysis.

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 22: ABACUS association analysis results for the top SNPs from the GWAS discovery**

Pheno	Cohort	SNP	CHR	P value	Gene
CKD	FINNDIANE	rs1622208	1	4.80E-06	<i>MAST2</i>
CKD	FINNDIANE	rs6682683	1	4.51E-06	<i>MAST2</i>
ESRD vs. NO DKD	FINNDIANE	rs17024167	1	7.97E-07	<i>PHGDH</i>
CKD	EURODIAB	rs13384229	2	3.16E-06	<i>ALS2</i>
CKD+ DKD	EURODIAB	rs11898503	2	4.31E-06	<i>KLHL29</i>
DKD & Late DKD	EURODIAB	rs906651	2	4.51E-06	<i>LRP1B</i>
CKD+DKD	FINNDIANE	rs7577925	2	7.97E-07	<i>NCKAP5</i>
Late DKD	FINNDIANE	rs3773786	3	3.77E-07	<i>IQCJ-SCHIP1</i>
Late DKD & CKD+DKD	FINNDIANE	rs6785153	3	3.77E-07	<i>IQCJ-SCHIP1</i>
Combined DKD	FINNDIANE	rs1061860	3	7.97E-07	<i>MB21D2</i>
Combined DKD	FINNDIANE	rs2986	3	7.97E-07	<i>MB21D2</i>
Late DKD	FINNDIANE	rs1434546	4	4.03E-06	<i>BMPR1B</i>
Late DKD	FINNDIANE	rs1545326	4	4.27E-06	<i>BMPR1B</i>
Late DKD	FINNDIANE	rs17022885	4	4.31E-06	<i>BMPR1B</i>
CKD	FINNDIANE	rs4352548	4	6.35E-07	<i>BTC</i>
CKD	FINNDIANE	rs3796588	4	6.34E-07	<i>GUCY1A3</i>
Late DKD	FINNDIANE	rs10037055	5	1.73E-06	<i>NSD1</i>
Late DKD	FINNDIANE	rs2244012	5	4.00E-06	<i>RAD50</i>
Early DKD	SDR	rs1970549	6	4.77E-06	<i>KCNQ5</i>
Early DKD	EURODIAB	rs1019046	7	1.64E-06	<i>GLI3</i>
CKD	SDR	rs7778308	7	3.65E-06	<i>GRM8</i>
ESRD vs. NO DKD	FINNDIANE	rs6983307	8	1.09E-06	<i>ST18</i>
Late DKD & CKD+DKD & ESRD vs. NO DKD	FINNDIANE	rs10121901	9	1.89E-06	<i>ABCA1</i>
Late DKD & CKD+DKD & ESRD vs. NO DKD	FINNDIANE	rs2066720	9	1.96E-06	<i>ABCA1</i>
CKD	FINNDIANE	rs2855171	9	4.37E-06	<i>ABL1</i>
Late DKD	SDR	rs10794197	10	4.66E-06	<i>CTBP2</i>
Early DKD	NFS-ORPS	rs2236418	10	1.73E-06	<i>GAD2</i>
Early DKD	NFS-ORPS	rs10508715	10	1.73E-06	<i>MYO3A</i>
Early DKD	NFS-ORPS	rs994502	10	1.73E-06	<i>MYO3A</i>
CKD	FINNDIANE	rs1784175	11	4.39E-06	<i>OPCML</i>
Late DKD & Combined DKD	FINNDIANE	rs3059	11	1.73E-06	<i>POLR2L</i>

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Pheno	Cohort	SNP	CHR	P value	Gene
Late DKD	FINNDIANE	rs3741935	12	1.80E-06	<i>PRMT8</i>
Combined DKD	EURODIAB	rs9540711	13	4.03E-06	<i>PCDH9</i>
Late DKD	FINNDIANE	rs2278709	15	2.15E-06	<i>ARNT2</i>
Early DKD	SDR	rs678892	15	3.53E-06	<i>PIGB</i>
Late DKD	FINNDIANE	rs173839	16	3.65E-06	<i>CDH13</i>
ESRD vs. NO DKD	EURODIAB	rs4782574	16	2.89E-06	<i>OSGIN1</i>
Late DKD	FINNDIANE	rs8075035	17	2.15E-06	<i>AIPL1</i>
CKD+DKD	SDR	rs1972933	17	1.28E-06	<i>MAP2K6</i>
Early DKD	NFS-ORPS	rs7234763	18	7.18E-07	<i>PTPRM</i>
Late DKD	FINNDIANE	rs2544795	19	3.20E-06	<i>SULT2B1</i>
Late DKD	FINNDIANE	rs2665579	19	2.74E-06	<i>SULT2B1</i>
ESRD vs. NO DKD	EURODIAB	rs17420378	20	6.34E-07	<i>STK4</i>
ESRD vs. NO DKD	EURODIAB	rs6073622	20	6.34E-07	<i>STK4</i>
ESRD vs. NO DKD	EURODIAB	rs7266289	20	6.34E-07	<i>STK4</i>
ESRD vs. NO DKD	EURODIAB	rs7271519	20	6.34E-07	<i>STK4</i>

Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 23: ABACUS association analysis results for the top SNPs from the WES discovery**

Pheno	Cohort	SNP	CHR	P value	Gene
ESRD vs. no DKD	FINNDIANE	rs2297955_G_A	1	1.66E-06	<i>ACTN2</i>
ESRD vs. no DKD	FINNDIANE	rs41293273_C_T	1	1.14E-07	<i>NSUN4</i>
ESRD vs. no DKD	FINNDIANE	rs41293275_T_A	1	3.41E-07	<i>NSUN4</i>
Late DKD	STENO	rs2289239_A_G	2	4.09E-06	<i>POLR1A</i>
Late DKD	SDR	rs6775309_T_C	3	2.15E-06	<i>GPD1L</i>
Late DKD	SDR	rs6788436_C_T	3	2.15E-06	<i>GPD1L</i>
Late DKD	SDR	rs6799559_G_A	3	2.15E-06	<i>GPD1L</i>
Late DKD	SDR	rs6799728_T_A	3	2.15E-06	<i>GPD1L</i>
Late DKD	SDR	rs2813_C_T	3	3.08E-06	<i>GPD1L</i>
ESRD vs. no DKD	STENO	rs55642964_C_T	4	1.82E-06	<i>SH3TC1</i>
ESRD vs. no DKD	STENO	rs2136662_G_T	16	9.10E-07	<i>OSGIN1</i>
ESRD vs. no DKD	STENO	rs3087852_A_G	17	8.89E-07	<i>PSMD3</i>
ESRD vs. no DKD	STENO	rs12102_A_G	18	2.05E-06	<i>SERPINB2</i>
ESRD vs. no DKD	STENO	rs3217292_G_GTGAGA	18	2.05E-06	<i>SERPINB2</i>
ESRD vs. no DKD	STENO	rs6093_T_C	18	2.05E-06	<i>SERPINB2</i>
ESRD vs. no DKD	STENO	rs6095_G_C	18	2.05E-06	<i>SERPINB2</i>
ESRD vs. no DKD	STENO	rs6098_G_A	18	2.05E-06	<i>SERPINB2</i>
ESRD vs. no DKD	STENO	var_chr18_61569819_T_TTTAAGTTTCTGGGGC	18	2.05E-06	<i>SERPINB2</i>
ESRD vs. no DKD	FINNDIANE	rs2295490_G_A	20	4.64E-06	<i>TRIB3</i>
Late DKD	FINNDIANE	rs2073278_A_G	22	2.65E-06	<i>SBF1</i>

**Supplemental Table 24: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on GWAS data**

Key Terms	Genes	Score
macromolecular complex subunit organization, protein oligomerization	<i>AGTR1,APC,CCDC88C,COLEC12,GTF3C4,H3F3B,HELLS,KCNQ5,NCK2,NDUFS4,PFKP,PPARGC1A,PRKAA2,SYT1,TRIM27,YWHAB</i>	3.16
kidney & urogenital system development, positive regulation of developmental process	<i>AGTR1,APC,GLI3,GNAS,HELLS,IL7R,NTN1,ROBO1,SART1,SLIT2,TGFBR2</i>	2.76
adenyl nucleotide binding, ATP binding, Serine/threonine protein kinase	<i>ABL1,AOX1,CARM1,CDC7,CELF2,CHST11,CTBP2,GNAS,GTF3C4,HELLS,KARS,KIF13B,KRAS,MAP2K6,MGAT5,MYH6,MYH9,MYO3A,NDUFS4,NUAK2,OPA1,PAK7,PAPOLA,PDE10A,PFKP,PGM1,PIGB,PPARGC1A,PRKAA2,PRKAG2,PTPRM,PTPRN2,STK4,SULT2B1,TEC,TGFBR2,TRIM27,WEE1</i>	2.15
hemopoietic or lymphoid organ development, leukocyte/lymphocyte activation & differentiation	<i>APC,BLNK,BRCA2,CD40LG,HELLS,IL7R,KIF13B,MYH9,NCK2,TGFBR2,TLR1,TLR3</i>	2.09
positive regulation of kinase activity, positive regulation of transferase activity	<i>ABL1,AGTR1,ALS2,APC,CASP9,CCDC88C,FSHR,GAP43,GNAS,KRAS,MAP2K6,NCK2,NDUFS4,PRKAG2,RPS3,TGFBR2,TLR3,YWHAB</i>	2.06
cellular response to stress, regulation of apoptosis	<i>ABL1,APC,BIRC5,BRCA2,CASP9,CD40LG,CHST11,FOXN3,GLI3,HELLS,KRAS,MAP2K6,NUAK2,PAK7,RPA3,RPS3,SART1,SCAP,STK4,TNFRSF8,YWHAB</i>	1.91
actin cytoskeleton organization	<i>ABL1,APC,ATG4A,BIRC5,BRCA2,CNTROB,DIAPH2,KRAS,LIMA1,MYH6,MYH9,MYO3A,NCK2,NUAK2</i>	1.77
lipid moiety-binding region:S-palmitoyl cysteine, lipoprotein, palmitate	<i>ABL1,AGTR1,GAD2,GAP43,GNAS,KRAS,LRP1B,RGS7,SYT1</i>	1.70
glycoprotein, glycosylation site:N-linked (GlcNAc...)	<i>ABL1,AGTR1,APBB1IP,APC,ARSF,BLNK,CACNA2D1,CBL,CD40LG,CHST11,COLEC12,CTBP2,FSHR,GABRA2,GAD2,GAP43,GNAS,GRB10,GRIK4,GRM8,HLA-E,IGSF21,IL7R,KAL1,KCNK2,KCNQ5,KRAS,LIMA1,LPHN3,LRMP,LRP1B,MGAT5,MYH6,MYH9,NTN1,PCDH9,PIGB,PPARGC1A,PRELP,PTPRM,PTPRN2,RGS7,ROBO1,RPS3,SCAP,SLC34A3,SLC8A1,SLIT2,STAB2,SYT1,TF,TGFBR2,TLR1,TLR3,TLR8,TNFRSF8,TRIM27</i>	1.62
inflammatory response, Toll-Interleukin receptor, positive regulation of cytokine biosynthetic process	<i>ALS2,AOX1,BLNK,CD40LG,COLEC12,FSHR,PRELP,SLIT2,STAB2,TF,TLR1,TLR3,TLR8,TNFRSF8</i>	1.60
leukocyte proliferation/activation, lymphocyte proliferation, mononuclear cell proliferation	<i>APC,BLNK,CD40LG,HELLS,IL7R,KIF13B,MYH9,NCK2</i>	1.54
SH2 domain	<i>ABL1,BLNK,CBL,GRB10,NCK2,TEC</i>	1.54
axon guidance, axonogenesis, cell morphogenesis involved in differentiation, cell motion	<i>ABL1,ALS2,APC,CBL,GAD2,GAP43,GLI3,GRIK4,IL7R,KAL1,KRAS,LIMA1,MYH6,MYH9,NCK2,NTN1,OPA1,PAK7,PPARGC1A,PTPRM,ROBO1,SLIT2,STK4</i>	1.52
regulation of myeloid leukocyte differentiation, regulation of osteoclast differentiation	<i>APC,GNAS,TLR3</i>	1.43
insulin signalling pathway, regulation of cellular ketone metabolic process,regulation of fatty acid metabolic	<i>AGTR1,CBL,KRAS,PPARGC1A,PRKAA2,PRKAG2,RAPGEF1,SCAP</i>	1.38

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Key Terms	Genes	Score
process		
apoptosis	<i>BIRC5,CASP9,EGLN3,KRAS,NTN1,NUAK2,OPA1,RPS3,STK4,YWHAB</i>	1.37
positive regulation of cellular component organization	<i>APC,CBL,NCK2,NTN1,PPARGC1A,ROBO1,SLIT2</i>	1.35
actin-dependent ATPase activity, calmodulin-binding, microfilament motor activity, myosin	<i>GAP43,KIF13B,MYH6,MYH9,MYO3A,SLC8A1,SYT1</i>	1.32
angiogenesis, blood vessel endothelial cell migration	<i>MYH9,ROBO1,SLIT2,STAB2,TGFBR2</i>	1.32
protein kinase binding	<i>ALS2,APC,BIRC5,DIAPH2,KIF13B,PRKAG2,RPS3,SUPT5H,TGFBR2,YWHAB</i>	1.28
positive regulation of leukocyte/lymphocyte activation & differentiation	<i>IL7R,NCK2,SART1,TGFBR2,TLR3,TLR8</i>	1.25
low-density lipoprotein binding	<i>COLEC12,LRP1B,STAB2</i>	1.24
nuclear lumen, nucleoplasm	<i>ABL1,BIRC5,BRCA2,CDC7,CTBP2,GLI3,GRHL1,GTF3C4,MYH6,PAPOLA,PPARG C1A,PRKAA2,PRKAG2,PRPF8,RPA3,SUPT5H,TRIM27,WEE1,YWHAB</i>	1.23
cytokinesis, interphase, tubulin binding	<i>ABL1,APC,ATG4A,BIRC5,BRCA2,CDC7,CNTROB,DIAPH2,FOXN3,GFI1B,HELLS, MAP2K6,MYH9,SART1,SUPT5H,WEE1</i>	1.23
cell morphogenesis involved in differentiation, cell motion	<i>ALS2,APC,GAP43,KAL1,MYH9,NCK2,NTN1,PTPRM,ROBO1,SLIT2</i>	1.22
cell junction, presynaptic membrane, synaptic vesicle membrane	<i>ALS2,APBB1IP,APC,CTBP2,GABRA2,GAD2,GAP43,GRIK4,GRM8,KCNQ5,LIMA 1,MYH6,MYH9,OPA1,PTPRM,ROBO1,SYT1</i>	1.21
embryonic development, striated muscle differentiation	<i>ALS2,BRCA2,GLI3,KRAS,MYH6,MYH9</i>	1.14
adherens junction, anchoring junction	<i>APBB1IP,APC,LIMA1,MYH6,MYH9,PTPRM</i>	1.14
chordate embryonic development	<i>ALS2,BRCA2,CHST11,GLI3,GNAS,MYH6,MYH9,TGFBR2</i>	1.10
hypertrophic cardiomyopathy (HCM)	<i>CACNA2D1,MYH6,PRKAA2,PRKAG2,SLC8A1</i>	0.97
regulation of lipid metabolic process	<i>AGTR1,PPARGC1A,PRKAA2,PRKAG2,SCAP</i>	0.88
Toll-Interleukin receptor, positive regulation of cytokine biosynthetic process	<i>TLR1,TLR3,TLR8,TNFRSF8</i>	0.87
domain:EGF-like	<i>LRP1B,SLIT2,STAB2</i>	0.86
fatty acid biosynthesis	<i>ELOVL5,PRKAA2,PRKAG2</i>	0.84
regulation of system process	<i>AGTR1,CELF2,GRM8,KRAS,MYH6,SLC8A1,TF</i>	0.82
negative regulation of cell proliferation	<i>APC,BRCA2,CTBP2,GLI3,NCK2,PTPRM,TGFBR2,TNFRSF8</i>	0.80
negative regulation of nucleobase, nucleoside, nucleotide, transcriptional repressor complex	<i>BRCA2,CTBP2,FOXN3,GFI1B,GLI3,GRM8,HELLS,RPS3,SCAP,SUPT5H,TRIM27, YWHAB</i>	0.72
metal-binding	<i>ABL1,ADH1A,AOX1,ARSF,BIRC5,CACNA2D1,CBL,CDC7,COLEC12,CYP4F2,EGL N3,GFI1B,GLI3,KARS,LIMA1,NUAK2,PDE10A,PFKP,PGM1,PRKAA2,STK4,SYT1 ,TAB3,TEC,TF,TGFBR2,TRIM27,WEE1</i>	0.70

**Supplemental Table 25: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on WES data**

Key Terms	Genes	Score
protein dimerization activity, homodimerization activity	<i>ACTN2, AMBP, ATF6, AXIN1, BCAT1, CD4, DVL2, FAAH, GCC2, GPD1L, HEXB, IL12B, K YNU, MYO9B, NEUROD1, PCSK9, TAS1R3, TGFB2</i>	3.90
serpin, serine-type endopeptidase inhibitor activity	<i>AMBP, CASP3, SERPINA11, SERPINB10, SERPINB2, SERPINF1, TRIAP1, TRIB3</i>	2.46
lipoprotein, phospholipid metabolic process, phosphotransferase activity	<i>ACSL3, EPT1, FASN, GGT5, GPD1L, HEXB, LRP1, PCSK9, PIGN, PIGX, PLA2G4D, PRKA B2, SGMS2</i>	2.26
carboxylic acid, fatty acid metabolic process, pyridoxal phosphate	<i>ACSL3, ACSL5, BCAT1, EPT1, FAAH, FASN, GGT5, HEXB, KYNU, PIGN, PIGX, PRKAB2, SGMS2, SLC27A6</i>	2.25
fatty-acid ligase activity, fatty acid metabolic process, long-chain-fatty-acid-CoA ligase activity	<i>ACSL3, ACSL5, FAAH, FASN, GGT5, PCSK9, PRKAB2, SGMS2, SLC27A6</i>	1.84
nucleoside and nucleotide biosynthetic process	<i>AMPD1, ATIC, ATP5A1, BCAT1, KYNU, MYO9B, PPAT, TGFB2</i>	1.61
transmembrane region	<i>ABCA4, ABCB11, ACSL3, ACSL5, ALG5, ATF6, ATP5A1, CACNA1D, CD4, CDON, DGKG , EPT1, ERBB4, FAAH, GCC2, GPD5, GGT5, GLIPR1, GNG4, HLA- DQB1, IL31RA, IMMT, ITPR3, KCNMB2, LRP1, PIGN, PIGX, PLA2G4D, PTGFR, PTPRD , RSAD2, SCN10A, SGMS2, SLC10A6, SLC17A4, SLC27A6, SSR1, ST3GAL1, STOML1, S TX2, SYVN1, TAS1R3, TBXA2R, TRPC6</i>	1.45
glycoprotein, glycosylation site:N-linked (GlcNAc...)	<i>ABCA4, ABCB11, ALG5, AMBP, ATF6, CACNA1D, CD4, CDON, CGA, DNAH14, ELSPB P1, ERBB4, GPD5, GGT5, GIP, GLIPR1, HEXB, HLA- DQB1, IL12B, IL31RA, KCNMB2, KLK8, LRP1, PCSK9, PIGN, PIGX, PTGFR, PTPRD, SCN 10A, SERPINA11, SERPINB2, SERPINF1, SLC10A6, SLC17A4, SLIT3, SSR1, ST3GAL1, SYVN1, TAS1R3, TBXA2R, TGFB2, TPPP, TRPC6</i>	1.41
regulation of protein kinase activity	<i>AXIN1, CASP3, CD4, DGKG, IL31RA, KAT2B, KIF13B, LRP1, MAP2K1, MYO9B, PRKAB 2, TGFB2, TRIB3</i>	1.39
endoplasmic reticulum	<i>ACSL3, ACSL5, ALG5, ATF6, ATP5A1, CD4, FAAH, IMMT, ITPR3, PCSK9, PIGN, PIGX, R SAD2, SGMS2, SSR1, ST3GAL1, SYVN1</i>	1.26
carboxylic acid catabolic process	<i>AMDHD1, BCAT1, FAAH, KYNU</i>	1.24
cell fraction, insoluble fraction, membrane fraction	<i>ABCA4, ABCB11, ACSL3, ACSL5, AMBP, CGA, GIP, HEXB, ITPR3, KYNU, LRP1, MAP2K 1, MYO9B, PRKCQ, SLC17A4, SLIT3, STX2, TPPP</i>	1.21
cofactor metabolic process	<i>AMBP, GGT5, KYNU, NARFL, PPCDC</i>	1.15
regulation of leukocyte activation, regulation of T cell activation	<i>CASP3, CD4, IL12B, IL31RA, PRKCQ</i>	1.11
response to endogenous stimulus, response to hormone stimulus	<i>ATF6, CASP3, CD4, CGA, ERBB4, GNG4, KAT2B, KYNU, MAP2K1, NEUROD1, PCSK9, PRKCQ, TGFB2</i>	1.07
adipocytokine signalling pathway	<i>ACSL3, ACSL5, PRKAB2, PRKCQ</i>	1.07
regulation of cellular response to stress	<i>AMBP, AXIN1, KLK8, TGFB2</i>	1.00
neuron differentiation, positive regulation of cell	<i>CASP3, CDON, DGKG, ERBB4, KLK8, MAP2K1, NEUROD1, ONECUT2, PCSK9, PRKCQ</i>	0.99



## Supplementary information: Genome-wide dissection of diabetic kidney disease

Key Terms	Genes	Score
migration, positive regulation of cell motion	<i>,SALL1,SLIT3,TGFB2</i>	
regulation of protein kinase activity, regulation of transferase activity	<i>AXIN1,CASP3,CD4,DGKG,DVL2,LRP1,MAP2K1,TGFB2,TRIB3</i>	0.98
plasma membrane part	<i>ABCA4,ABCB11,ACTN2,AXIN1,CACNA1D,CD4,ERBB4,GNG4,HLA-DQB1,ITPR3,KCNMB2,LRP1,PCSK9,PLA2G4D,PRKCQ,PTGFR,PTPRD,RSAD2,SCN10A,SGMS2,SLC17A4,STX2,TBXA2R</i>	0.95
positive regulation of cytokine biosynthetic process, regulation of leukocyte activation, regulation of T cell activation	<i>ATF6,CASP3,CD4,IL12B,IL31RA,NEUROD1,NPAS2,NR5A2,ONECUT2,PRKCQ,TGFB2</i>	0.92
ion transport	<i>ATP5A1,CACNA1D,ITPR3,KCNMB2,SCN10A,SLC10A6,SLC17A4,TRPC6</i>	0.85
positive regulation of protein modification process	<i>AXIN1,CD4,IL31RA,PLK1,PSMD3</i>	0.85
protein kinase C, phorbol ester/diacylglycerol binding	<i>DGKG,MYO9B,PRKCQ</i>	0.83
ATP-binding	<i>ABCA4,ABCB11,ACSL3,ACSL5,ATP5A1,DGKG,DNAH14,ERBB4,KIF13B,MAP2K1,MYLK4,MYO9B,PLK1,PRKCQ</i>	0.81
calcium channel, Vascular smooth muscle contraction	<i>ATP5A1,CACNA1D,ITPR3,KCNMB2,MAP2K1,PRKCQ,SCN10A,SLC10A6,SLC17A4,TRPC6</i>	0.79
negative regulation of growth	<i>CGA,GNG4,OSGIN1,TGFB2</i>	0.77
duplication	<i>ACTN2,AMBP,CD4,DGKG,GIP,PRKCQ</i>	0.76
cell proliferation	<i>BCAT1,ERBB4,KLK8,LRP1,MAP2K1,PLK1,SERPINF1,TGFB2</i>	0.69
negative regulation of response to stimulus, zymogen	<i>AMBP,CASP3,GGT5,HEXB,KLK8,PCSK9,SERPINF1,TGFB2</i>	0.54
chemical homeostasis, homeostatic process	<i>CASP3,ERBB4,HEXB,IL31RA,ITPR3,KCNMB2,NARFL,NEUROD1,NR5A2,PCSK9,TRPC6</i>	0.52
positive regulation of macromolecule metabolic process	<i>ATF6,AXIN1,CD4,IL12B,IL31RA,MAP2K1,NEUROD1,NPAS2,NR5A2,ONECUT2,PCSK9,PLK1,PRKCQ,PSMD3,TGFB2</i>	0.52

**Supplemental Table 26: Phenotype definitions. Table A: albuminuria- and eGFR based definitions. Table B: Case – control phenotypes.**

**Table A:**

Class	Definitions
Normoalbuminuria	AER <20 µg/min OR AER <30 mg/24 h OR ACR <2.5 mg/mmol for men ACR <3.5 for women
Microalbuminuria	At least 2 out of 3 consecutive measurements with: AER ≥20 AND <100 µg/min OR AER ≥30 AND <150 mg/24 hr OR ACR ≥2.5 AND <12.5 for men ACR ≥3.5 AND <17.5 for women.
High microalbuminuria	At least one measurement with: AER ≥100 AND <200 µg/min OR AER ≥150 AND <300 mg/24 hr OR ACR ≥12.5 AND <25 for men ACR ≥17.5 AND <35 for women
Macroalbuminuria	At least one measurement* with: AER ≥200 µg/min OR AER ≥300 mg/24 h OR ACR ≥25 mg/mmol for men ACR ≥35 for women
ESRD	eGFR ≤15 ml/min/1.73m <sup>2</sup> OR dialysis OR kidney transplantation.
eGFR	eGFR was estimated wither with the MDRD4 <sup>7</sup> or CKD-EPI formula <sup>8</sup> , depending of the study. When IDMS-calibrated serum creatinine was used, the MDRD4 formula was multiplied by 175/186 <sup>65</sup> .
CKD	eGFR < 60 ml/min/1.73m <sup>2</sup>

**Table B:**

Phenotype name	Cases	Controls
DKD	microalbuminuria OR high microalbuminuria OR macroalbuminuria OR ESRD	normoalbuminuria AND diabetes duration >15 years
Early DKD	microalbuminuria OR high microalbuminuria	normoalbuminuria AND diabetes duration >15 years
Late DKD	macroalbuminuria OR ESRD	normoalbuminuria AND diabetes duration >15 years
ESRD vs. no DKD	ESRD	normoalbuminuria AND diabetes duration >15 years
ESRD vs. non-ESRD	ESRD	patients with no ESRD AND diabetes duration >15 years
CKD	CKD (eGFR<60 ml/min/1.73m <sup>2</sup> )	eGFR≥60 ml/min/1.73m <sup>2</sup> AND diabetes duration >15 years
CKD+DKD	(eGFR < 45 ml/min OR ESRD/1.73m <sup>2</sup> ) AND (High micro OR Macro OR ESRD)	eGFR ≥ 60 ml/min/1.73m <sup>2</sup> AND normo- albuminuria AND diabetes duration >15 years

Supplementary information: Genome-wide dissection of diabetic kidney disease

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

**Supplemental Table 27: Membership of the GENIE Consortium**

FinnDiane, Finland:	Niina Sandholm <sup>1,2,3</sup> , Carol Forsblom <sup>1,2</sup> , Valma Harjutsalo <sup>1,2,4</sup> , Ville-Petteri Mäkinen <sup>1,2, 4,6</sup> , Aila J Ahola <sup>1,2</sup> , Emma Dahlström <sup>1,2</sup> , Daniel Gordin <sup>1,2</sup> , Outi Heikkilä <sup>1,2</sup> , Kustaa Hietala <sup>1,7</sup> , Janne Kytö <sup>1,7</sup> , Markku Lehto <sup>1,2</sup> , Raija Lithovius <sup>1,2</sup> , Nicolae Mircea Panduru <sup>1,8</sup> , Maija Parkkonen <sup>1,2</sup> , Milla Rosengård-Bärlund <sup>1,2</sup> , Markku Saraheimo <sup>1,2</sup> , Jenny Söderlund <sup>1,2</sup> , Aino Soro-Paavonen <sup>1,2</sup> , Anna Syreeni <sup>1,2</sup> , Lena M Thorn <sup>1,2</sup> , Nina Tolonen <sup>1,2</sup> , Johan Wadén <sup>1,2</sup> , Per-Henrik Groop <sup>1,2,9</sup>
Belfast, UK:	Amy Jayne McKnight <sup>10</sup> , Gareth J. McKay <sup>10</sup> , Alexander P. Maxwell <sup>10,11</sup>
Boston, MA, USA:	Rany M. Salem <sup>12,13,14</sup> , Tamara Isakova <sup>15,16</sup> , Cameron Palmer <sup>12,13</sup> , Candace Guiducci <sup>12</sup> , Andrew Taylor <sup>12,17</sup> , Daniel B. Mirel <sup>12</sup> , Winfred W. Williams <sup>14,17</sup> , Joel N. Hirschhorn <sup>12,13,14</sup> , Jose C. Florez <sup>12,14,17</sup>
Dublin, Ireland:	Eoin P. Brennan <sup>18,19</sup> , Denise M. Sadlier <sup>18,19</sup> , Finian Martin <sup>18,19</sup> , Catherine Godson <sup>18,19</sup>
Affiliations:	<ol style="list-style-type: none"> <li>1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland</li> <li>2. Department of Medicine, Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland</li> <li>3. Department of Biomedical Engineering and Computational Science, Aalto University, Espoo, Finland</li> <li>4. Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.</li> <li>5. Department of Integrative Biology and Physiology, University of California Los Angeles, United States</li> <li>6. South Australian Health and Medical Research Institute, Adelaide, Australia</li> <li>7. Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland.</li> <li>8. Chair of pathophysiology, 2nd clinical Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.</li> <li>9. Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</li> <li>10. Nephrology Research, Centre for Public Health, Queen's University of Belfast, Belfast, UK.</li> <li>11. Regional Nephrology Unit, Level 11, Tower Block, Belfast City Hospital, Belfast, UK.</li> <li>12. Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.</li> <li>13. Endocrine Research Unit, Department of Endocrinology, Children's Hospital, Boston, MA, USA.</li> <li>14. Department of Medicine, Harvard Medical School, Boston, MA, USA.</li> <li>15. Division of Nephrology and Hypertension, University of Miami, Miami, Florida, USA</li> <li>16. Center for Translational Metabolism and Health - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</li> <li>17. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.</li> <li>18. Diabetes Research Centre, Conway Institute, School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland.</li> <li>19. Mater Misericordiae Hospital, Dublin, Ireland.</li> </ol>

**Supplemental Table 28: List of the FinnDiane centers and participating physicians and nurses.**

FinnDiane Study Centers	Physicians and nurses
Anjalankoski Health Center	S. Koivula, T. Uggeldahl
Central Finland Central Hospital, Jyväskylä	T. Forslund, A. Halonen, A. Koistinen, P. Koskiaho, M. Laukkanen, J. Saltevo, M. Tiihonen
Central Hospital of Åland Islands, Mariehamn	M. Forsen, H. Granlund, A-C. Jonsson, B. Nyroos
Central Hospital of Kanta-Häme, Hämeenlinna	P. Kinnunen, A. Orvola, T. Salonen, A. Vähänen
Central Hospital of Länsi-Pohja, Kemi	H. Laukkanen, P. Nyländen, A. Sademies
Central Ostrabothnian Hospital District, Kokkola	S. Anderson, B. Asplund, U. Byskata, M. Kuusela, P. Liedes, T. Virkkala
City of Espoo Health Centre:	
-Espoonlahti	A. Nikkola, E. Ritola
-Samaria	E. Oukko-Ruponen, T. Virtanen
-Tapiola	M. Niska, H. Saarinen
-Viherlaakso	A. Lyytinen
City of Helsinki Health Centre:	
-Puistola	H. Kari, T. Simonen
-Suutarila	A. Kaprio, J. Kärkkäinen, B. Rantaeskola
-Töölö	J. Haaga, P. Kääriäinen, A-L. Pietiläinen
City of Hyvinkää Health Centre	S. Klemetti, T. Nyandoto, E. Rontu, S. Satuli-Autere
City of Vantaa Health Centre:	
-Korso	R. Toivonen, H. Virtanen
-Länsimäki	R. Ahonen, M. Ivaska-Suomela, A. Jauhiainen
-Martinlaakso	M. Laine, T. Pellonpää, R. Puranen
-Myyrmäki	A. Airas, J. Laakso, K. Rautavaara
-Rekola	M. Erola, E. Jatkola
-Tikkurila	R. Lönnblad, A. Malm, J. Mäkelä, E. Rautamo
Heinola Health Centre	P. Hentunen, J. Lagerstam
Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland	M. Feodoroff, C. Forsblom, D. Gordin, PH Groop, V. Harjutsalo, S. Hägg-Holmberg, K. Hietala, M. Kallio, R. Lithovious, M. Parkkonen, M. Rahkonen, M. Rosengård-Bärlund, A.-R. Salonen, L. Salovaara, A. Sandelin, M. Saraheimo, T. Soppela, A. Soro-Paavonen, L. Thorn, N. Tolonen, J. Tuomikangas, J. Wadén,
Ophthalmology, University of Helsinki and Helsinki	P.Summanen

1		
2	FinnDiane Study Centers	Physicians and nurses
3		
4	University Hospital, Helsinki, Finland	
5	Herttoniemi Hospital, Helsinki	V. Sipilä
6		
7	Hospital of Lounais-Häme, Forssa	T. Kalliomäki, J. Koskelainen, R. Nikkanen, N. Savolainen, H. Sulonen, E. Valtonen
8	Hyvinkää Hospital	A. Hämäläinen, L. Norvio
9	Iisalmi Hospital	E. Toivanen
10		
11	Jokilaakso Hospital, Jämsä	A. Parta, I. Pirttiniemi
12	Jorvi Hospital, Helsinki University Central Hospital	S. Aranko, S. Ervasti, R. Kauppinen-Mäkelin, A. Kuusisto, T. Leppälä, K. Nikkilä, L. Pekkonen
13	Jyväskylä Health Centre, Kyllö	K. Nuorva, M. Tiihonen
14		
15	Kainuu Central Hospital, Kajaani	S. Jokelainen, P. Kempainen, A-M. Mankinen, M. Sankari
16	Kerava Health Centre	H. Stuckey, P. Suominen
17		
18	Kirkkonummi Health Centre	A. Lappalainen, M. Liimatainen, J. Santaholma
19	Kivelä Hospital, Helsinki	A. Aimolahti, E. Huovinen
20	Koskela Hospital, Helsinki	V. Ilkka, M. Lehtimäki
21		
22	Kotka Health Centre	E. Pälikkö-Kontinen, A. Vanhanen
23	Kouvola Health Centre	E. Koskinen, T. Siitonen
24		
25	Kuopio University Hospital	E. Huttunen, R. Ikäheimo, P. Karhapää, P. Kekäläinen, T. Lakka, M. Laakso, E. Lampainen, L. Moilanen, L. Niskanen, U. Tuovinen, I. Vauhkonen, E. Voutilainen
26		
27	Kuusamo Health Centre	E. Isopoussu, T. Kääriäinen
28		
29	Kuusankoski Hospital	E. Kilkki, I. Koskinen, L. Riihelä
30	Laakso Hospital, Helsinki	T. Meriläinen, P. Poukka, R. Savolainen, N. Uhlenius
31	Lahti City Hospital	A. Mäkelä, M. Tanner
32		
33	Lapland Central Hospital, Rovaniemi	L. Hyvärinen, S. Severinkangas, T. Tulokas
34	Lappeenranta Health Centre	P. Linkola, I. Pulli
35	Lohja Hospital	T. Granlund, M. Saari, T. Salonen
36		
37	Loimaa Health Centre	P. Eloranta, A. Mäkelä
38	Länsi-Uusimaa Hospital, Tammisaari	I-M. Jousmaa, J. Rinne
39		
40	Malmi Hospital, Helsinki	H. Lanki, S. Moilanen, M. Tilly-Kiesi
41	Mikkeli Central Hospital	A. Gynther, R. Manninen, P. Nironen, M. Salminen, T. Vänttinen
42	Mänttä Regional Hospital	A-M. Hänninen, I. Pirttiniemi
43		
44	North Karelian Hospital, Joensuu	U-M. Henttula, P. Kekäläinen, M. Pietarinen, A. Rissanen, M. Voutilainen
45		

## Supplementary information: Genome-wide dissection of diabetic kidney disease

1		
2	FinnDiane Study Centers	Physicians and nurses
3		
4	Nurmijärvi Health Centre	A. Burgos, K. Urtamo
5	Oulankangas Hospital, Oulainen	E. Jokelainen, P-L. Jylkkä, E. Kaarlela, J. Vuolaspuro
6		
7	Oulu Health Centre	L. Hiltunen, R. Häkkinen, S. Keinänen-Kiukaanniemi
8	Oulu University Hospital	R. Ikäheimo
9		
10	Päijät-Häme Central Hospital	H. Haapamäki, A. Helanterä, S. Hämäläinen, V. Ilvesmäki, H. Miettinen
11	Palokka Health Centre	P. Sopenan, L. Welling
12	Pieksämäki Hospital	V. Javtsenko, M. Tamminen
13		
14	Pietarsaari Hospital	M-L. Holmbäck, B. Isomaa, L. Sarelin
15	Pori City Hospital	P. Ahonen, P. Merensalo, K. Sävelä
16	Porvoo Hospital	M. Kallio, B. Rask, S. Rämö
17		
18	Raahe Hospital	A. Holma, M. Honkala, A. Tuomivaara, R. Vainionpää
19	Rauma Hospital	K. Laine, K. Saarinen, T. Salminen
20	Riihimäki Hospital	P. Aalto, E. Immonen, L. Juurinen
21		
22	Salo Hospital	A. Alanko, J. Lapinleimu, P. Rautio, M. Virtanen
23	Satakunta Central Hospital, Pori	M. Asola, M. Juhola, P. Kunelius, M-L. Lahdenmäki, P. Pääkkönen, M. Rautavirta
24	Savonlinna Central Hospital	E. Korpi-Hyövälti, T. Latvala, E. Leijala
25		
26	South Karelia Central Hospital, Lappeenranta	T. Ensala, E. Hussi, R. Härkönen, U. Nyholm, J. Toivanen
27		
28	Tampere Health Centre	P. Alarotu, L. Calonius, S. Gummerus, M. Helin, T. Kaitala, H. Kirkkopelto-Jokinen, E. Kujansuu, T. Niskanen, A. Vaden, T. Vatanen
29		
30	Tampere University Hospital	I. Ala-Houhala, T. Kuningas, P. Lampinen, M. Määttä, H. Oksala, T. Oksanen, K. Salonen, H. Tauriainen, S. Tulokas
31		
32	Tiirismaa Health Centre, Hollola	T. Kivelä, L. Petlin, L. Savolainen
33		
34	Turku Health Centre	I. Hämäläinen, H. Virtamo, M. Vähätalo
35		
36	Turku University Central Hospital	K. Breitholz, R. Eskola, K. Metsärinne, U. Pietilä, P. Saarinen, R. Tuominen, S. Äyräpää
37	Vaajakoski Health Centre	K. Mäkinen, P. Sopenan
38		
39	Vaasa Central Hospital	S. Bergkulla, U. Hautamäki, V-A. Myllyniemi, I. Rusk
40	Valkeakoski Regional Hospital	T. Immonen, S. Ojanen, M. Rautiainen, E. Valtonen, H. Ylönen
41	Vammala Regional Hospital	I. Isomäki, R. Kroneld, M. Tapiolinna-Mäkelä
42		
43		
44		
45		
46		
47		
48		
49		



Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Table 29: Membership of the SUMMIT Consortium**

<b>Partner</b>	<b>Name</b>	<b>Position</b>
1	<b>Michael Mark</b>	<b>Coordinator, WP6 leader</b>
Boehringer-Ingelheim	Markus Albertini	Project manager
Ingelheim, Germany	Carine Boustany	Chronic Kidney Disease, Head of Lab
	Alexander Ehlgren	Transmed
	Martin Gerl	Biomarker & Bioanalysis, Group leader
	Jochen Huber	In vivo Scientist CMDR, Head of Lab
	Corinna Schölch	Biomarker & Bioanalysis, Head of Lab
	Heike Zimdahl-Gelling	Pharmacogenomics, Head of Lab
2	<b>Leif Groop</b>	Prof. Endocrinology; Coordinator Managing entity IMI-JU; PI; <b>WP1 and WP6 leader</b>
Lund University	Elisabet Agardh	Prof. Ophthalmology
Clinical Research Centre	Emma Ahlqvist	Postdoc
Malmö, Sweden	Tord Ajanki	Communication strategist
	Nibal Al Maghrabi	Research nurse
	Peter Almgren	Biostatistician
	Jan Apelqvist	Diabetologist
	Eva Bengtsson	Assis. Prof. Cardiovascular research
	Lisa Berglund	Postdoc
	Harry Björckbacka	Assis. Prof. Cardiovascular research
	Ulrika Blom-Nilsson	LUDC administrator
	Mattias Borell	Website, server management
	Agneta Burström	Research nurse
	Corrado Cilio	Assoc. Prof. Cellular autoimmunity
	Magnus Cinthio	Assist. Prof. Electrical Measurements, Lund Technical University
	Karl Dreja	Nephrologist
	Pontus Dunér	Postdoc Exp. Cardiovasc. Research
	Daniel Engelbertsen	PhD student Exp. Cardiovasc. Research
	Joao Fadista	Postdoc
	Maria Gomez	Assoc. Prof. Cardiovascular disease, <b>WP4 co-leader</b>
	Isabel Goncalves	Assis. Prof. Cardiovascular research
	Bo Hedblad	Prof. Cardiovascular epidemiology
	Anna Hultgårdh	Prof. Vessel Wall Biology
	Martin E. Johansson	Pathologist
	Cecilia Kennbäck	Laboratory Engineer
	Jasmina Kravic	Database manager
	Claes Ladenvall	Genetic statistician
	Åke Lernmark	Prof. Type 1 diabetes and celiac disease
	Eero Lindholm	Physician, Researcher Diabetic Complications
	Charlotte Ling	Assist. Prof. Epigenetics
	Holger Luthman	Prof. Medical genetics

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Partner	Name	Position
	Olle Melander	Assoc. Prof. Hypertension and cardiovascular disease
	Malin Neptin	Biomedical analyst
	Jan Nilsson	Prof. Experimental Cardiovascular research, <b>WP3 leader</b>
	Peter Nilsson	Prof. Internal medicine
	Tobias Nilsson	PhD student Electrical Measurements, Lund Technical University
	Gunilla Nordin Fredriksson	Prof. Cardiovascular research
	Marju Orho-Melander	Prof. Genetic epidemiology
	Emilia Ottoson-Laakso	PhD student
	Annie Persson	Research nurse
	Margaretha Persson	Laboratory Engineer
	Mats-Åke Persson	Database manager
	Jacqueline Postma	Project manager
	Elisabeth Pranter	Research nurse
	Sara Rattik	PhD student Exp. Cardiovasc. Research
	Gunnar Sterner	Chief physician Internal Medicine Research Unit
	Lilian Tindberg	Research nurse
	Maria Wigren	Postdoc Exp. Cardiovasc. Research
	Anna Zetterqvist	PhD student
	Mikael Åkerlund	Postdoc
	Gerd Östling	Laboratory Engineer
	<b>3 Timo Kanninen</b>	Technical director; PI
Biocomputing Platforms (BC Platforms)	Anni Ahonen-Bishopp	Software development manager
Espoo, Finland	Anita Eliasson	Financial and administrative director
	Timo Herrala	System (server) specialist
	Päivi Tikka-Kleemola	Service manager
	<b>4 Anders Hamsten</b>	Prof. Cardiovascular disease; Atherosclerosis Research Unit; PI
Karolinska Institute	Christer Betsholtz	Prof. Vascular biology
Stockholm, Sweden	Ami Björkholm	Administrator
	Ulf de Faire	Professor emeritus Cardiovascular epidemiology
	Fariba Foroogh	Research engineer
	Guillem Genové	Scientist
	Karl Gertow	Research Assist. Prof. Cardiovascular genetics
	Bruna Gigante	Assoc. Professor Cardiovascular epidemiology
	Bing He	Postdoc
	Karin Leander	Assoc. Professor Cardiovascular epidemiology
	Olga McLeod	Postdoc
	Maria Nastase-Mannila	Postdoc
	Jaako Patrakka	Postdoc

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Partner	Name	Position
	Angela Silveira	Assoc. Prof. Cardiovascular genetics
	Rona Strawbridge	Postdoc
	Karl Tryggvason	Prof. Medical Chemistry
	Max Vikström	Statistician
	John Öhrvik	Professor
	Anne-May Österholm	Postdoc
5	<b>Barbara Thorand</b>	Nutritional scientist, epidemiologist
Helmholtz Centre Munich, Germany	Christian Gieger	Statistician
	Harald Grallert	Biologist
	Tonia Ludwig	Statistician
	Barbara Nitz	Scientist
	Andrea Schneider	Data manager
	Rui Wang-Sattler	Scientist
	Astrid Zierer	Statistician
6	<b>Giuseppe Remuzzi</b>	Institute director; PI
Mario Negri Institute for Pharmacological Research	Ariela Benigni	Head of department Molecular Medicine
	Roberta Donadelli	Scientist
	Maria Domenica Lesti	Researcher
Bergamo, Italy	Marina Noris	Head Laboratory Immunology and genetics of transplantation and rare diseases
	Norberto Perico	Senior scientist
	Annalisa Perna	Biostatistician
	Rossella Piras	Postdoc
	Piero Ruggenenti	Head of department Renal medicine, Assist. Prof. Nephrology and dialysis
	Erica Rurali	Postdoc
7	<b>David Dunger (att: Jane Horsford)</b>	Prof. Paediatrics; PI
University of Cambridge	Ludo Chassin	Senior Data Manager
UK	Neil Dalton, London	Clinical biochemistry
	John Deanfield, London	Paediatric cardiology
	Jane Horsford	PA to Prof. Dunger
	Clare Rice	Operations manager/financial contact
	James Rudd	Cardiovascular imaging
	Neil Walker	Head Data services
	Karen Whitehead	Technician
	Max Wong	Postdoc
8	<b>Helen Colhoun</b>	Prof. Public health and epidemiology; PI; Vice coordinator Managing entity; <b>WP2 leader</b>

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Partner	Name	Position
	Fiona Adams	
University of Dundee	Tahira Akbar	PA to Helen Colhoun
Scotland	Jill Belch	Prof. Vasucular disease
	Harshal Deshmukh	PhD student
	Fiona Dove	
	Angela Ellingford	NHS Tayside Diabetic Retinopathy Screening Programme manager
	Bassam Farran	Statistician
	Mike Ferguson	Dean of research Biological chemistry and drug discovery
	Gary Henderson	
	Graeme Houston	Consultant radiologist/senior lecturer
	Faisal Khan	Reader, Vascular & Inflammatory Diseases Research Unit
	Graham Leese	Consultant diabetologist/reader
	Yiyuan Liu	PhD student
	Shona Livingstone	Senior statistician
	Helen Looker	Epidemiologist
	Margaret McCann	Project assistant
	Stuart McGurnaghan	Lead data programmer
	Andrew Morris	Prof. Diabetic medicine
	David Newton	
	Colin Palmer	Prof. Pharmacogenomics
	Ewan Pearson	Consultant diabetologist/senior lecturer
	Gillian Reekie	Research Nurse
	Natalie Smith	Research Nurse
	<b>9 Angela Shore</b>	Prof. Cardiovascular Science, PI
Peninsula Medical School	Kuni Aizawa	Postdoc
Exeter, UK	Claire Ball	Research nurse
	Nick Bellenger	Cardiologist
	Francesco Casanova	Associate Research Fellow Vascular medicine
	Tim Frayling	Prof. Genetics
	Phil Gates	Senior lecturer Cardiovascular science
	Kim Gooding	Postdoc Vascular medicine
	Andrew Hattersley	Prof. Molecular medicine
	Roland Ling	Consultant ophthalmologist
	David Mawson	Research technician
	Robin Shandas	Prof. Bioengineering (Colorado)
	David Strain	Stroke physician, clinical lecturer
	Clare Thorn	Postdoc Vascular medicine
	<b>10 Ulf Smith</b>	Prof. ; PI
University of	Ann Hammarstedt	Researcher Molecular and clinical medicine

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Partner	Name	Position
Gothenburg		
Sweden	Hans Häring	Prof. University of Tübingen
	Oluf Pedersen	Prof. Steno Centre, Copenhagen
	Georgio Sesti	Prof. Universtiy of Catanzaro
	<b>11 Per-Henrik Groop</b>	Prof. Diabetes genetics; PI
	Emma Fagerholm	PhD student, genetics
Folkhälsan	Carol Forsblom	Clinical coordinator
Helsinki, Finland	Valma Harjutsalo	
	Maikki Parkkonen	Laboratory manager
	Niina Sandholm	DSc(PhD); GWAS and bioinformatics
	Nina Tolonen	MD PhD
	Iiro Toppila	BSc, bioinformatician
	Erkka Valo	MSc, bioinformatician
	<b>12 Veikko Salomaa</b>	Prof. Epidemiology; PI; <b>deputy leader WP2</b>
The National Institute for Health and Welfare	Aki Havulinna	DSc. (tech), statistician
Helsinki, Finland	Kati Kristiansson	Postdoc
	Pia Okamo	THL press officer
	Tomi Peltola	
	Markus Perola	Professor
	Arto Pietilä	Statistician
	Samuli Ripatti	Professor, Statistics
	Marketta Taimi	Research assistant
	<b>13 Seppo Ylä-Herttuala</b>	Prof.; PI; <b>WP4 leader</b>
University of Eastern Finland	Mohan Babu	PhD student
Kuopio, Finland	Marike Dijkstra	PhD student
	Erika Gurzeler	PhD student
	Jenni Huusko	PhD student
	Ivana Kholová	Postdoc
	Markku Laakso	Prof.
	Mari Merentie	PhD student
	Marja Poikolainen	PA Prof Ylä-Herttuala
	<b>14 Mark McCarthy</b>	Prof. Human type 2 diabetes; Oxford Centre for Diabetes, Endocrinology and Metabolism; Wellcome Trust Centre for Human Genetics; PI; <b>deputy leader WP1</b>
University of Oxford	Chris Groves	Technical staff
UK	Thorhildur Juliusdottir	PhD student
	Fredrik Karpe	PI OCDEM

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Partner	Name	Position
	Vasiliki Lagou	Postdoc
	Andrew Morris	Wellcome Trust Senior Fellow; Bioinformatics and statistical genetics
	Will Rayner	Database manager
	Neil Robertson	Informatics
	Natalie van Zuydam	Postdoc
15	<b>Claudio Cobelli</b>	Prof. ; PI; <b>WP5 leader</b>
University of Padova	Barbara Di Camillo	Assist. Prof.
Italy	Francesca Finotello	PhD student
-	Francesco Sambo	Postdoctoral fellow
-	Gianna Toffolo	Prof.
-	Emanuele Trifoglio	PhD student
-	-	-
16	<b>Riccardo Bellazzi</b>	Prof. Bioengineering; PI; <b>deputy leader WP5</b>
	Nicola Barbarini	Postdoctoral fellow
University of Pavia	Mauro Bucalo	Software engineer
Italy	Christiana Larizza	Assist. Prof.
	Paolo Magni	Assoc. Prof.
	Alberto Malovini	Postdoctoral fellow
	Simone Marini	Postdoctoral fellow
	Francesca Mulas	Postdoctoral fellow
	Silvana Quaglino	Prof.
	Lucia Sacchi	Assist. Prof.
	Francesca Vitali	
17	<b>Ele Ferrannini</b>	Prof. Medicine; PI
	Beatrice Boldrini	Postdoctoral fellow
University of Pisa	Michaela Kozakova	Senior investigator Medical Pathophysiology
Italy	Andrea Mari	Senior researcher Biomedical engineering (ISIB-CNR, Padova)
	Carmela Morizzo	Biologist, Sonographer Cardiovascular ultrasound
	Lucrecia Mota	EGIR administrative office
	Andrea Natali	Assoc. Prof. Medicine
	Carlo Palombo	Assoc. Prof. Medicine; <b>deputy leader WP3</b>
	Elena Venturi	Researcher
	Mark Walker	Prof. Molecular diabetic medicine (Univ Newcastle-upon-Tyne )
18	<b>Carlo Patrono</b>	Prof. Pharmacology; PI
Catholic University of Rome	Francesca Pagliaccia	PhD student
Italy	Bianca Rocca	Assist. Prof. Pharmacology
19	<b>Pirjo Nuutila</b>	Prof. ; PI

## Supplementary information: Genome-wide dissection of diabetic kidney disease

Partner	Name	Position
University of Turku	Johanna Haukkala	PhD student
Finland	Juhani Knuuti	Prof. ; Director Turku PET Centre
	Anne Roivainen	Prof.
	Antti Saraste	Adj. Prof.
20	<b>Paul McKeague</b>	Prof. Genetic Epidemiology; PI
University of Edinburgh	Norma Brown	Research administrator, Public Health Services
Scotland	Marco Colombo	Bioinformaticist
21	<b>Birgit Steckel-Hamann</b>	Deputy coordinator; PI, Manager IMI, LRL
Eli Lilly	Krister Bokvist	Biostatistician
	Sudha Shankar	Diabetologist
	Melissa Thomas	Translational Science
22	<b>Li-ming Gan</b>	Prof.; Translational Science Director Cardiovascular Disease; PI, <b>WP3 leader</b>
AstraZeneca	Suvi Heinonen	PhD, Internal AZ postdoc, Bioscience
	Ann-Cathrine Jönsson-Rylander	PhD, Assoc. Prof., Team Leader Bioscience, <b>WP4 leader</b>
	Remi Momo	Postdoctoral fellow
	Volker Schneck	Informatician Translational Science, <b>WP5 leader</b>
	Robert Unwin	Translational Science Director Diabetic Nephropathy
	Anna Walentinsson	Geneticist Translational Science
	Carl Whatling	Bioscientist
23	<b>Everson Nogoceke</b>	Pre-clinical and clinical aspects of metabolic and vascular disease; PI; <b>WP2 leader</b>
Roche	Gonzalo Durán Pacheco	Senior Research Statistician
	Ivan Formentini	Biomarker & Experimental Medicine Leader
	Thomas Schindler	Pre-clinical and clinical and clinical biomarkers
24	<b>Piero Tortoli</b>	Professor of Electronics
University of Florence	Luca Bassi	Postdoctoral fellow
	Enrico Boni	Postdoctoral fellow
	Alessandro Dallai	Postdoctoral fellow
	Francesco Guidi	Technician
	Matteo Lenge	PhD student
	Riccardo Matera	PhD student
	Alessandro Ramalli	PhD student
	Stefano Ricci	Assist. Prof.
	Jacopo Viti	PhD student
25	<b>Bernd Jablonka</b>	SAD internal IMI coordinator




## Supplementary information: Genome-wide dissection of diabetic kidney disease

Partner	Name	Position
Sanofi-aventis	Dan Crowther	Biomarker researcher
	Johan Gassenhuber	Biostatistician
	Sibylle Hess	Biomarker researcher
	Thomas Hübschle	Pharmacologist Diabetes
	Hans-Paul Juretschke	Imaging
	Hartmut Rütten	Head Translational Medicine
	Thorsten Sadowski	Pharmacologist Diabetes
	Paulus Wohlfart	Pharmacologist Diabetes
	26 <b>Julia Brosnan</b>	Biochemist, (pre)clinical research CVD, Pfizer US; <b>WP2 leader</b>
Pfizer	Valerie Clerin	Cardio-renal biologist, WP2
	Eric Fauman	Computational biologist
	Craig Hyde	Statistician
	Anders Malarstig	Human genetics, Pfizer Europe; <b>WP1 leader</b>
	Nick Pullen	Renal Disease Research Director
	Mera Tilley	
	Theresa Tuthill	Imaging specialist
	Ciara Vangjeli	Cardiovascular genetic epidemiologist, Pfizer Europe
	Daniel Ziemek	Computational biologist



## SUPPLEMENTAL FIGURES

**Supplemental Figure 1: Schematic picture of the study plan.** In the GWAS setting, the stage 1 included T1D patients from the FinnDiane, EURODIAB, SDR, and Cambridge studies. Stage 1 GWAS meta-analysis results were used for evaluation of the previously reported loci, analysis of genetic risk scores, LD score regression, and for the pathway analyses. Stage 2 included patients from the UK-ROI, GoKinD US, French-Danish effort, DCCT/EDIC, and Joslin studies. Stage 3 replication consisted of additional T1D FinnDiane patients not part of the FinnDiane GWAS. Whole exome sequencing (WES) included patients from the FinnDiane, SDR, and Steno studies. Finally, the bivariate association analyses were performed in all GWAS stage 1 studies and in WES studies.





Supplementary information: Genome-wide dissection of diabetic kidney disease



**Supplemental Figure 2: Manhattan and QQ-plots for the seven studied phenotype definitions.** Manhattan and QQ-plots of the seven studied case-control phenotype definitions: A) Combined DKD (cases with micro- or macroalbuminuria or ESRD vs. controls with normal AER); B) Late DKD (cases with macroalbuminuria or ESRD vs. normal AER); C) ESRD vs. no DKD (cases with ESRD vs. controls with normal AER); D) ESRD vs. non-ESRD (cases with ESRD vs. everyone else); E) Early DKD (cases with microalbuminuria vs. controls with normal AER); F) CKD (cases with CKD (eGFR  $\leq$  60 ml/min) vs. controls without CKD (eGFR  $>$  60 ml/min); G) CKD+DKD (cases with severe CKD (eGFR  $\leq$  45 ml/min) and microalbuminuria or worse vs. controls with normal AER and no CKD (eGFR  $>$  60 ml/min).

**A) Combined DKD****B) Late DKD**



C) ESRD vs. no DKD



D) ESRD vs. non-ESRD





E) Early DKD





Supplementary information: Genome-wide dissection of diabetic kidney disease

F) CKD



G) CKD + DKD











review


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Supplemental Figure 3: LocusZoom and Forest plots of the top loci. A) rs72809865 for DKD. B) rs61277444 for ESRD versus normal AER. C) rs7562121 for ESRD versus non-ESRD. D) rs1989248 for CKD+DKD.**




**Supplemental Figure 4: P-value distribution of association at the previously reported loci for DKD or CKD in the general population.**





Supplemental Figure 5: Association at previously reported loci plotted by the previously reported A) p-values and by B) Z-scores.









Supplementary information: Genome-wide dissection of diabetic kidney disease

**Supplemental Figure 8: WES QQ-plots of the p-value distribution of associations with 'Late DKD' and 'ESRD vs. no DKD' using the score test. A and B: DKD. C and D: ESRD. A and C: all SNPs. B and D: SNPs by MAF.**




Supplemental Figure 9: WES QQ-plots for 'Late DKD' for different masks using SKAT-O.



Supplementary information: Genome-wide dissection of diabetic kidney disease


## Supplemental Figure 10: WES QQ-plots for 'ESRD vs. no DKD' for different masks using SKAT-O.





Supplemental Figure 11: Top 20 associations for 'Late DKD' for the three gene based tests; VT, SKAT-O and SKAT with the PTV+broad and PTV+missense masks.

Phenotype: DN, Cohort: all\_studies, Test: VT,skato,skat, Masks: ptv.strict.broad.0.01,ptv.missense.0.01 - Top 20 genes (56 unique)




view



Supplementary information: Genome-wide dissection of diabetic kidney disease


Supplemental Figure 12: Top 20 associations for 'ESRD vs. no DKD' for the three gene based tests; VT, SKAT-O and SKAT with the PTV+broad and PTV+missense masks.

Phenotype: ESRD, Cohort: all\_studies, Test: VT,skato,skat, Masks: ptv.strict.broad.0.01,ptv.missense.0.01 - Top 20 genes (38 unique)



view

**Supplemental Figure 13: Statistical power to detect association at the WES with exome-wide statistical significance ( $p < 9 \times 10^{-8}$ ) for 'Late DKD' setting (panels A and C) and for the 'ESRD vs. no DKD' comparison (panels B and D). The top panels show the statistical power for the effect allele frequency range from 0 to 1. The bottom panels show the statistical power for the effect allele frequency range from 0 to 10%.**



Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  

## REFERENCES

1. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Waden J, Ronnback M, Rosengard-Barlund M, Bjorkesten CG, Taskinen MR, Groop PH, FinnDiane Study Group: Metabolic syndrome in type 1 diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study). [Electronic version]. *Diabetes Care* 28: 2019-2024, 2005
2. Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ, Williams WW, Sadlier DM, Makinen VP, Swan EJ, Palmer C, Boright AP, Ahlqvist E, Deshmukh HA, Keller BJ, Huang H, Ahola AJ, Fagerholm E, Gordin D, Harjutsalo V, He B, Heikkila O, Hietala K, Kyto J, Lahermo P, Lehto M, Lithovius R, Osterholm AM, Parkkonen M, Pitkanieni J, Rosengard-Barlund M, Saraheimo M, Sarti C, Soderlund J, Soro-Paavonen A, Syreeni A, Thorn LM, Tikkanen H, Tolonen N, Tryggvason K, Tuomilehto J, Waden J, Gill GV, Prior S, Guiducci C, Mirel DB, Taylor A, Hosseini SM, DCCT/EDIC Research Group, Parving HH, Rossing P, Tarnow L, Ladvall C, Alhenc-Gelas F, Lefebvre P, Rigalleau V, Roussel R, Tregouet DA, Maestroni A, Maestroni S, Falhammar H, Gu T, Mollsten A, Cimponeriu D, Ioana M, Mota M, Mota E, Serafinceanu C, Stavarachi M, Hanson RL, Nelson RG, Kretzler M, Colhoun HM, Panduru NM, Gu HF, Brismar K, Zerbini G, Hadjadj S, Marre M, Groop L, Lajer M, Bull SB, Waggott D, Paterson AD, Savage DA, Bain SC, Martin F, Hirschhorn JN, Godson C, Florez JC, Groop PH, Maxwell AP: New susceptibility loci associated with kidney disease in type 1 diabetes. [Electronic version]. *PLoS Genet* 8: e1002921, 2012
3. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold. [Electronic version]. *Kidney Int* 60: 219-227, 2001
4. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD: Classifying diabetes according to the new WHO clinical stages. [Electronic version]. *Eur J Epidemiol* 17: 983-989, 2001
5. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, Marcovecchio L, Neil A, Dalton RN, Dunger DB: Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: Prospective observational study. [Electronic version]. *BMJ* 336: 697-701, 2008
6. Marcovecchio ML, Dalton RN, Schwarze CP, Prevost AT, Neil HA, Acerini CL, Barrett T, Cooper JD, Edge J, Shield J, Widmer B, Todd JA, Dunger DB: Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. [Electronic version]. *Diabetologia* 52: 1173-1181, 2009
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. modification of diet in renal disease study group. [Electronic version]. *Ann Intern Med* 130: 461-470, 1999
8. Levey AS, & Stevens LA: Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. [Electronic version]. *Am J Kidney Dis* 55: 622-627, 2010
9. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. [Electronic version]. *Nat Genet* 38: 904-909, 2006

- 1 10. Howie BN, Donnelly P, Marchini J: A flexible and accurate genotype imputation method for the next generation of  
2 genome-wide association studies. [Electronic version]. *PLoS Genet* 5: e1000529, 2009
- 3
- 4 11. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE,  
5 Kang HM, Marth GT, McVean GA: An integrated map of genetic variation from 1,092 human genomes.  
6 [Electronic version]. *Nature* 491: 56-65, 2012
- 7
- 8
- 9 12. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM: A program for annotating  
10 and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of drosophila  
11 melanogaster strain w1118; iso-2; iso-3. [Electronic version]. *Fly (Austin)* 6: 80-92, 2012
- 12
- 13
- 14 13. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F: Deriving the consequences of genomic variants  
15 with the ensembl API and SNP effect predictor. [Electronic version]. *Bioinformatics* 26: 2069-2070, 2010
- 16
- 17
- 18 14. Ruark E, Münz M, Renwick A, Clarke M, Ramsay E, Hanks S, Mahamdallie S, Elliott A, Seal S, Strydom A, Gerton L,  
19 Rahman N: The ICR1000 UK exome series: A resource of gene variation in an outbred population [version 1;  
20 referees: 2 approved]. *F1000Research* 42015
- 21
- 22 15. Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstrom K, Esko T, Magi R, Inouye M, Lappalainen T, Chan  
23 Y, Salem RM, Lek M, Flannick J, Sim X, Manning A, Ladenvall C, Bumpstead S, Hamalainen E, Aalto K, Maksimow  
24 M, Salmi M, Blankenberg S, Ardissino D, Shah S, Horne B, McPherson R, Hovingh GK, Reilly MP, Watkins H, Goel  
25 A, Farrall M, Girelli D, Reiner AP, Stitzel NO, Kathiresan S, Gabriel S, Barrett JC, Lehtimaki T, Laakso M, Groop L,  
26 Kaprio J, Perola M, McCarthy MI, Boehnke M, Altshuler DM, Lindgren CM, Hirschhorn JN, Metspalu A, Freimer  
27 NB, Zeller T, Jalkanen S, Koskinen S, Raitakari O, Durbin R, MacArthur DG, Salomaa V, Ripatti S, Daly MJ, Palotie  
28 A, Sequencing Initiative Suomi (SISu) Project: Distribution and medical impact of loss-of-function variants in the  
29 finnish founder population. [Electronic version]. *PLoS Genet* 10: e1004494, 2014
- 30
- 31
- 32 16. Yang J, Lee SH, Goddard ME, Visscher PM: GCTA: A tool for genome-wide complex trait analysis. [Electronic  
33 version]. *Am J Hum Genet* 88: 76-82, 2011
- 34
- 35
- 36 17. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common  
37 diseases and 3,000 shared controls. [Electronic version]. *Nature* 447: 661-678, 2007
- 38
- 39
- 40 18. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong SY, Freimer NB, Sabatti C, Eskin E: Variance component model to  
41 account for sample structure in genome-wide association studies. [Electronic version]. *Nat Genet* 42: 348-354,  
42 2010
- 43
- 44 19. Magi R, & Morris AP: GWAMA: Software for genome-wide association meta-analysis. [Electronic version]. *BMC*  
45 *Bioinformatics* 11: 288-2105-11-288, 2010
- 46
- 47
- 48 20. Willer CJ, Li Y, Abecasis GR: METAL: Fast and efficient meta-analysis of genomewide association scans. [Electronic  
49 version]. *Bioinformatics* 26: 2190-2191, 2010
- 50
- 51 21. Purcell S, Cherny SS, Sham PC: Genetic power calculator: Design of linkage and association genetic mapping  
52 studies of complex traits. [Electronic version]. *Bioinformatics* 19: 149-150, 2003
- 53
- 54
- 55 22. Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient than replication-based analysis for two-  
56 stage genome-wide association studies. [Electronic version]. *Nat Genet* 38: 209-213, 2006
- 57
- 58 23. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B:  
59 Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. [Electronic version]. *N Engl J Med*  
60 365: 2366-2376, 2011

- 1 24. DCCT/EDIC research group: Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term  
2 follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and  
3 complications study. [Electronic version]. *Lancet Diabetes Endocrinol* 2: 793-800, 2014  
4
- 5 25. Germain M, Pezzolesi MG, Sandholm N, McKnight AJ, Susztak K, Lajer M, Forsblom C, Marre M, Parving HH,  
6 Rossing P, Toppila I, Skupien J, Roussel R, Ko YA, Ledo N, Folkersen L, Civelek M, Maxwell AP, Tregouet DA,  
7 Groop PH, Tarnow L, Hadjadj S: SORBS1 gene, a new candidate for diabetic nephropathy: Results from a multi-  
8 stage genome-wide association study in patients with type 1 diabetes. [Electronic version]. *Diabetologia* 58: 543-  
9 548, 2015  
10
- 11 26. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, Fischer K,  
12 Justice AE, Workalemahu T, Wu JM, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson  
13 S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J, Fehrmann R,  
14 Karjalainen J, Kahali B, Liu CT, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL,  
15 Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, Kristiansson K, Mangino  
16 M, Mateo Leach I, Medina-Gomez C, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Stancakova A,  
17 Ju Sung Y, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Arnlöv J, Arscott GM,  
18 Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M, Bohringer S, Bonnet F, Bottcher Y, Bruinenberg M,  
19 Carba DB, Caspersen IH, Clarke R, Daw EW, Deelen J, Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR,  
20 Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB,  
21 Grassler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heikkila K, Herzig KH,  
22 Helmer Q, Hillege HL, Holmen O, Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP,  
23 Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J,  
24 Lobbens S, Lorentzon M, Mach F, Magnusson PK, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani  
25 L, Mills R, Moayyeri A, Monda KL, Mooijaart SP, Muhleisen TW, Mulas A, Muller G, Muller-Nurasyid M, Nagaraja  
26 R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM,  
27 Sanna S, Scharnagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Vernon Smith A, Stirrups K, Stringham  
28 HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A, Troffa C,  
29 van Oort FV, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A, Zhang Q, Hua  
30 Zhao J, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, Hedman AK, Hivert MF,  
31 Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu  
32 A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JR, Reinmaa E,  
33 Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, Westra HJ, Zondervan KT, ADIPOGen  
34 Consortium, CARDIOGRAMplusC4D Consortium, CKDGen Consortium, GEFOS Consortium, GENIE Consortium,  
35 GLGC, ICBP, International Endogene Consortium, LifeLines Cohort Study, MAGIC Investigators, MuTHER  
36 Consortium, PAGE Consortium, ReproGen Consortium, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman RN,  
37 Blangero J, Brown MJ, Burnier M, Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC,  
38 Danesh J, de Faire U, de Geus EJ, Dorr M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrieres J, Forouhi NG,  
39 Forrester T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliövaara  
40 M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hyppönen E, Illig T, Jarvelin MR,  
41 Johansen B, Jousilahti P, Jula AM, Kaprio J, Kee F, Keinänen-Kiukkaanniemi SM, Kooner JS, Kooperberg C, Kovacs  
42 P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lysenko V,  
43 Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Musk AW, Mohlenkamp S, Morris AD, Nelis M,  
44 Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP, Raitakari OT, Rankinen T, Rao  
45 DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE,  
46 Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tonjes A, Tremblay A, Tremoli E, Vohl MC,  
47 Volker U, Vollenweider P, Wilson JF, Wittteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C,  
48 Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ,  
49 Hamsten A, Hui J, Hveem K, Jockel KH, Kivimäki M, Kuh D, Laakso M, Liu Y, Marz W, Munroe PB, Njolstad I,  
50 Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R,  
51 Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U,  
52 Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ,  
53  
54  
55  
56  
57  
58  
59  
60



- 1 Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L,  
 2 Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Stefansson K, van  
 3 Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox  
 4 CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL: New  
 5 genetic loci link adipose and insulin biology to body fat distribution. [Electronic version]. *Nature* 518: 187-196,  
 6 2015  
 7
- 8
- 9 27. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-  
 10 Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR,  
 11 Workalemahu T, Faul JD, Smith JA, Hua Zhao J, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt  
 12 EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G,  
 13 Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim  
 14 U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis  
 15 S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S,  
 16 van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlov  
 17 J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M,  
 18 Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida Chen YD, Clarke R, Daw EW,  
 19 de Craen AJ, Delgado G, Dimitriou M, Doney AS, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME,  
 20 Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H,  
 21 Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA,  
 22 Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM,  
 23 Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C,  
 24 Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Sin Lo K, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PK,  
 25 Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken  
 26 MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW,  
 27 Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher  
 28 FR, Scott WR, Seufferlein T, Shi J, Vernon Smith A, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K,  
 29 Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer  
 30 JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D,  
 31 Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, LifeLines  
 32 Cohort Study, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG,  
 33 Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton  
 34 RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt  
 35 DR, Okada Y, Perry JR, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T,  
 36 Van't Hooft FM, Vinkhuyzen AA, Westra HJ, Zheng W, Zondervan KT, ADIPOGen Consortium, AGEN-BMI Working  
 37 Group, CARDIOGRAMplusC4D Consortium, CKDGen Consortium, GLGC, ICBP, MAGIC Investigators, MuTHER  
 38 Consortium, MIGen Consortium, PAGE Consortium, ReproGen Consortium, GENIE Consortium, International  
 39 Endogene Consortium, Heath AC, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H,  
 40 Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D,  
 41 Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB,  
 42 Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C,  
 43 Gottesman O, Gudnason V, Gyllensten U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorf LA, Hingorani AD,  
 44 Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel  
 45 KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJ, Keinanen-Kiukkaanniemi SM, Kiemenev  
 46 LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le  
 47 Marchand L, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL,  
 48 Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PA, Pasterkamp G, Peden  
 49 JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM,  
 50 Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PE, Sever  
 51 P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC,  
 52 Volker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL,  
 53 Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ,  
 54  
 55  
 56  
 57  
 58  
 59  
 60

- 1 Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J,  
2 Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A,  
3 Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C,  
4 Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D,  
5 Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M,  
6 van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen  
7 P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR,  
8 Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM,  
9 Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJ, Speliotes EK: Genetic studies of body mass  
10 index yield new insights for obesity biology. [Electronic version]. *Nature* 518: 197-206, 2015  
11  
12  
13 28. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, Styrkarsdottir U,  
14 Gretarsdottir S, Thorlacius S, Jonsdottir I, Jonsdottir T, Olafsdottir EJ, Olafsdottir GH, Jonsson T, Jonsson F, Borch-  
15 Johnsen K, Hansen T, Andersen G, Jorgensen T, Lauritzen T, Aben KK, Verbeek AL, Roeleveld N, Kampman E,  
16 Yanek LR, Becker LC, Tryggvadottir L, Rafnar T, Becker DM, Gulcher J, Kiemenev LA, Pedersen O, Kong A,  
17 Thorsteinsdottir U, Stefansson K: Genome-wide association yields new sequence variants at seven loci that  
18 associate with measures of obesity. [Electronic version]. *Nat Genet* 41: 18-24, 2009  
19  
20  
21 29. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM,  
22 Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P,  
23 O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sober S,  
24 Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan  
25 I, Igl W, Milaneschi Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH,  
26 Sjogren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B,  
27 Seielstad M, Sim X, Nguyen KD, Lehtimaki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou  
28 CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uitterwaal CS, Adeyemo A, Palmas W,  
29 Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND, CARDIoGRAM consortium, CKDGen Consortium,  
30 KidneyGen Consortium, EchoGen consortium, CHARGE-HF consortium, Aspelund T, Garcia M, Chang YP,  
31 O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL,  
32 Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Hopewell  
33 JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC, Kahonen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M,  
34 Pattaro C, Bolton JA, Kottgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J,  
35 Kulkarni SR, Bornstein SR, Grassler J, Groop L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F,  
36 Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL,  
37 Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Soler  
38 Artigas M, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL,  
39 Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A,  
40 Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y, Ogihara T, Ohkubo  
41 T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott  
42 J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stancakova A, Raffel LJ, Yao J,  
43 Kathiresan S, O'Donnell CJ, Schwartz SM, Ikram MA, Longstreth WT, Jr, Mosley TH, Seshadri S, Shrine NR, Wain  
44 LV, Morken MA, Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel  
45 A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani KR, Yajnik CS, Hofman A, Mattace-Raso FU,  
46 Oostra BA, Demirkan A, Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ,  
47 Lyytikainen LP, Soininen P, Tukiainen T, Wurtz P, Ong RT, Dorr M, Kroemer HK, Volker U, Volzke H, Galan P,  
48 Hercberg S, Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P,  
49 Terzic J, Kumar MV, Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, Schwarz  
50 PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M,  
51 Hveem K, Palmer LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Tai ES,  
52 Cooper RS, Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen  
53 D, Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker PM, Bandinelli S,  
54 Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller PP, Elosua R, Soranzo N,  
55  
56  
57  
58  
59  
60



- 1 Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason  
2 V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boerwinkle E, Vasan RS,  
3 Boehnke M, Larson MG, Jarvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn CM, Newton-  
4 Cheh C, Levy D, Caulfield MJ, Johnson T: Genetic variants in novel pathways influence blood pressure and  
5 cardiovascular disease risk. [Electronic version]. *Nature* 478: 103-109, 2011  
6  
7  
8 30. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham  
9 HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D,  
10 Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J,  
11 Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R,  
12 Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke  
13 KL, Abecasis GR: Newly identified loci that influence lipid concentrations and risk of coronary artery disease.  
14 [Electronic version]. *Nat Genet* 40: 161-169, 2008  
15  
16  
17 31. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C,  
18 Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS: Genome-wide  
19 association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. [Electronic version]. *Nat*  
20 *Genet* 41: 703-707, 2009  
21  
22  
23 32. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network  
24 Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium, Mexican American  
25 Type 2 Diabetes (MAT2D) Consortium, Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in  
26 multi-Ethnic Samples (T2D-GENES) Consortium, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T,  
27 Horikoshi M, Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, Adair LS, Almgren  
28 P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI,  
29 Benediktsson R, Bergman RN, Boehm BO, Boerwinkle E, Bonnycastle LL, Burtt N, Cai Q, Campbell H, Carey J,  
30 Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, Chen CH, Chen H, Chen YT, Chia KS,  
31 Chidambaram M, Chines PS, Cho NH, Cho YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van  
32 Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ,  
33 Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E,  
34 Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao Y,  
35 Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A,  
36 Han BG, Hara K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K,  
37 Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T,  
38 Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jockel KH, Jonsson A, Jowett JB, Kadowaki T,  
39 Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukkaanniemi KM, Kelly AM, Khan H,  
40 Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyovalti E, Kowlessur S, Kraft P,  
41 Kravic J, Kristensen MM, Krithika S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA,  
42 Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L,  
43 Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S,  
44 Magi R, Mannisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mihailov E, Moebus S,  
45 Mohan V, Mohlke KL, Morris AD, Muhleisen TW, Muller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro  
46 P, Ng PK, Nica AC, Nilsson PM, Njolstad I, Nothen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park  
47 KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, Peters A, Pinidiyapathirage JM, Platou CG, Potter  
48 S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD,  
49 Rehnberg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J,  
50 Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segre AV, Sehmi J, Sennblad B, Shah N, Shah S,  
51 Shera AS, Shu XO, Shuldiner AR, Sigurdsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY,  
52 Stancakova A, Stefansson K, Steinbach G, Steinthorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q,  
53 Suo C, Syvanen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir  
54 U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, Uitterlinden AG, Valladares-Salgado  
55 A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson  
56  
57  
58  
59  
60

- JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, Morris AP: Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. [Electronic version]. *Nat Genet* 46: 234-244, 2014
33. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Magi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PC, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks AA, An P, Muller-Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJ, Edkins S, Varga TV, Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJ, Kong A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, Uitterlinden AG, Palmer CN, Doney AS, Willemsen G, Smit JH, Campbell S, Polasek O, Bonnycastle LL, Hercberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, Lindstrom J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert H, DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province MA, Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, de Geus EJ, Penninx BW, Hofman A, Oostra BA, Psaty BM, Vollenweider P, Wilson JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PK, Kyvik KO, Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser PA, Beilby JP, Korner A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PE, Lakka TA, Rauramaa R, Adair LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki M, Hingorani A, Keinanen-Kiukaanniemi SM, Saaristo TE, Boomsma DI, Stefansson K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, Langenberg C, Ingelsson E, Prokopenko I, Barroso I: Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. [Electronic version]. *Nat Genet* 44: 991-1005, 2012
34. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin D, Liu CT, Bielak LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, Ingelsson E, Jackson AU, Johnson T, Kanoni S, Ladenvall C, Lagou V, Lahti J, Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser ME, Navarro P, Perry JR, Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, Tanaka T, van Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, Boban M, Boehnke M, Boerwinkle E, Bonnycastle LL, Boomsma DI, Borecki IB, Bottcher Y, Bouchard C, Brunner E, Budimir D, Campbell H, Carlson O, Chines PS, Clarke R, Collins FS, Corbaton-Anchuelo A, Couper D, de Faire U, Dedoussis GV, Deloukas P, Dimitriou M, Egan JM, Eiriksdottir G, Erdos MR, Eriksson JG, Eury E, Ferrucci L, Ford I, Forouhi NG, Fox CS, Franzosi MG, Franks PW, Frayling TM, Froguel P, Galan P, de Geus E, Gigante B, Glazer NL, Goel A, Groop L, Gudnason V, Hallmans G, Hamsten A, Hansson O, Harris TB, Hayward C, Heath S, Hercberg S, Hicks AA, Hingorani A, Hofman A, Hui J, Hung J, Jarvelin MR, Jhun MA, Johnson PC, Jukema JW, Jula A, Kao WH, Kaprio J, Kardia SL, Keinanen-Kiukaanniemi S, Kivimaki M, Kolcic I, Kovacs P, Kumari M, Kuusisto J, Kyvik KO, Laakso M, Lakka T, Lannfelt L, Lathrop GM, Launer LJ, Leander K, Li G, Lind L, Lindstrom J, Lobbens S, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Marmot M, Meneton P, Mohlke KL, Mooser V, Morken MA, Miljkovic I, Narisu N, O'Connell J, Ong KK, Oostra BA, Palmer LJ, Palotie A, Pankow JS, Peden JF, Pedersen NL, Pehlic M, Peltonen L, Penninx B, Pericic M, Perola M, Perusse L, Peyser PA, Polasek O, Pramstaller PP, Province MA, Raikonen K, Rauramaa R, Rehnberg E, Rice K, Rotter JI, Rudan I, Ruukonen A, Saaristo T, Sabater-Lleal M, Salomaa V, Savage DB, Saxena R, Schwarz P, Seedorf U, Sennblad B, Serrano-Rios M, Shuldiner AR, Sijbrands EJ, Siscovick DS, Smit JH, Small KS, Smith NL, Smith AV, Stancakova A, Stirrups K, Stumvoll M, Sun YV, Swift AJ, Tonjes A, Tuomilehto J, Trompet S, Uitterlinden AG, Uusitupa M, Vikstrom M, Vitart V, Vohl MC, Voight BF,

- 1 Vollenweider P, Waeber G, Waterworth DM, Watkins H, Wheeler E, Widen E, Wild SH, Willems SM, Willemsen G,  
2 Wilson JF, Wittteman JC, Wright AF, Yaghooskar H, Zelenika D, Zemunik T, Zgaga L, DIAbetes Genetics Replication  
3 And Meta-analysis (DIAGRAM) Consortium, Multiple Tissue Human Expression Resource (MUTHER) Consortium,  
4 Wareham NJ, McCarthy MI, Barroso I, Watanabe RM, Florez JC, Dupuis J, Meigs JB, Langenberg C: A genome-  
5 wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and  
6 insulin resistance. [Electronic version]. *Nat Genet* 44: 659-669, 2012  
7  
8  
9 35. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J,  
10 Jackson AU, Kao WH, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N,  
11 Boesgaard TW, Lecoeur C, Shrader P, O'Connell J, Ingelsson E, Couper DJ, Rice K, Song K, Andreasen CH, Dina C,  
12 Kottgen A, Le Bacquer O, Pattou F, Taneera J, Steinthorsdottir V, Rybin D, Ardlie K, Sampson M, Qi L, van Hoek  
13 M, Weedon MN, Aulchenko YS, Voight BF, Grallert H, Balkau B, Bergman RN, Bielinski SJ, Bonnefond A,  
14 Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Buchanan TA, Bumpstead SJ, Cavalcanti-Proenca C,  
15 Charpentier G, Chen YD, Chines PS, Collins FS, Cornelis M, J Crawford G, Delplanque J, Doney A, Egan JM, Erdos  
16 MR, Firmann M, Forouhi NG, Fox CS, Goodarzi MO, Graessler J, Hingorani A, Isomaa B, Jorgensen T, Kivimaki M,  
17 Kovacs P, Krohn K, Kumari M, Lauritzen T, Levy-Marchal C, Mayor V, McAteer JB, Meyre D, Mitchell BD, Mohlke  
18 KL, Morken MA, Narisu N, Palmer CN, Pakyz R, Pascoe L, Payne F, Pearson D, Rathmann W, Sandbaek A, Sayer  
19 AA, Scott LJ, Sharp SJ, Sijbrands E, Singleton A, Siscovick DS, Smith NL, Sparso T, Swift AJ, Syddall H, Thorleifsson  
20 G, Tonjes A, Tuomi T, Tuomilehto J, Valle TT, Waeber G, Walley A, Waterworth DM, Zeggini E, Zhao JH, GIANT  
21 consortium, MAGIC investigators, Illig T, Wichmann HE, Wilson JF, van Duijn C, Hu FB, Morris AD, Frayling TM,  
22 Hattersley AT, Thorsteinsdottir U, Stefansson K, Nilsson P, Syvanen AC, Shuldiner AR, Walker M, Bornstein SR,  
23 Schwarz P, Williams GH, Nathan DM, Kuusisto J, Laakso M, Cooper C, Marmot M, Ferrucci L, Mooser V, Stumvoll  
24 M, Loos RJ, Altshuler D, Psaty BM, Rotter JI, Boerwinkle E, Hansen T, Pedersen O, Florez JC, McCarthy MI,  
25 Boehnke M, Barroso I, Sladek R, Froguel P, Meigs JB, Groop L, Wareham NJ, Watanabe RM: Genetic variation in  
26 GIPR influences the glucose and insulin responses to an oral glucose challenge. [Electronic version]. *Nat Genet*  
27 42: 142-148, 2010  
28  
29  
30  
31  
32 36. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I,  
33 Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL, Stewart AF, Voight BF, Willenborg C,  
34 Wright B, Altshuler D, Arking D, Balkau B, Barnes D, Boerwinkle E, Bohm B, Bonnefond A, Bonnycastle LL,  
35 Boomsma DI, Bornstein SR, Bottcher Y, Bumpstead S, Burnett-Miller MS, Campbell H, Cao A, Chambers J, Clark R,  
36 Collins FS, Coresh J, de Geus EJ, Dei M, Deloukas P, Doring A, Egan JM, Elosua R, Ferrucci L, Forouhi N, Fox CS,  
37 Franklin C, Franzosi MG, Gallina S, Goel A, Graessler J, Grallert H, Greinacher A, Hadley D, Hall A, Hamsten A,  
38 Hayward C, Heath S, Herder C, Homuth G, Hottenga JJ, Hunter-Merrill R, Illig T, Jackson AU, Jula A, Kleber M,  
39 Knouff CW, Kong A, Kooner J, Kottgen A, Kovacs P, Krohn K, Kuhnel B, Kuusisto J, Laakso M, Lathrop M, Lecoeur  
40 C, Li M, Li M, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Malarstig A, Mangino M, Martinez-Larrad MT,  
41 Marz W, McArdle WL, McPherson R, Meisinger C, Meitinger T, Melander O, Mohlke KL, Mooser VE, Morken MA,  
42 Narisu N, Nathan DM, Nauck M, O'Donnell C, Oexle K, Olla N, Pankow JS, Payne F, Peden JF, Pedersen NL,  
43 Peltonen L, Perola M, Polasek O, Porcu E, Rader DJ, Rathmann W, Ripatti S, Rocheleau G, Roden M, Rudan I,  
44 Salomaa V, Saxena R, Schlessinger D, Schunkert H, Schwarz P, Seedorf U, Selvin E, Serrano-Rios M, Shrader P,  
45 Silveira A, Siscovick D, Song K, Spector TD, Stefansson K, Steinthorsdottir V, Strachan DP, Strawbridge R, Stumvoll  
46 M, Surakka I, Swift AJ, Tanaka T, Teumer A, Thorleifsson G, Thorsteinsdottir U, Tonjes A, Usala G, Vitart V, Volzke  
47 H, Wallaschofski H, Waterworth DM, Watkins H, Wichmann HE, Wild SH, Willemsen G, Williams GH, Wilson JF,  
48 Winkelmann J, Wright AF, WTCCC, Zabena C, Zhao JH, Epstein SE, Erdmann J, Hakonarson HH, Kathiresan S,  
49 Khaw KT, Roberts R, Samani NJ, Fleming MD, Sladek R, Abecasis G, Boehnke M, Froguel P, Groop L, McCarthy MI,  
50 Kao WH, Florez JC, Uda M, Wareham NJ, Barroso I, Meigs JB: Common variants at 10 genomic loci influence  
51 hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. [Electronic version]. *Diabetes* 59: 3229-3239,  
52 2010  
53  
54  
55  
56  
57 37. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas  
58 AS, Nica A, Wheeler E, Chen H, Voight BF, Taneera J, Kanoni S, Peden JF, Turrini F, Gustafsson S, Zabena C,  
59 Almgren P, Barker DJ, Barnes D, Dennison EM, Eriksson JG, Eriksson P, Eury E, Folkersen L, Fox CS, Frayling TM,  
60

- 1 Goel A, Gu HF, Horikoshi M, Isomaa B, Jackson AU, Jameson KA, Kajantie E, Kerr-Conte J, Kuulasmaa T, Kuusisto  
2 J, Loos RJ, Luan J, Makrilakis K, Manning AK, Martinez-Larrad MT, Narisu N, Nastase Mannila M, Ohrvik J,  
3 Osmond C, Pascoe L, Payne F, Sayer AA, Sennblad B, Silveira A, Stancakova A, Stirrups K, Swift AJ, Syvanen AC,  
4 Tuomi T, van 't Hooft FM, Walker M, Weedon MN, Xie W, Zethelius B, DIAGRAM Consortium, GIANT Consortium,  
5 MuTHER Consortium, CARDIoGRAM Consortium, C4D Consortium, Ongen H, Malarstig A, Hopewell JC, Saleheen  
6 D, Chambers J, Parish S, Danesh J, Kooner J, Ostenson CG, Lind L, Cooper CC, Serrano-Rios M, Ferrannini E,  
7 Forsen TJ, Clarke R, Franzosi MG, Seedorf U, Watkins H, Froguel P, Johnson P, Deloukas P, Collins FS, Laakso M,  
8 Dermitzakis ET, Boehnke M, McCarthy MI, Wareham NJ, Groop L, Pattou F, Gloyn AL, Dedoussis GV, Lyssenko V,  
9 Meigs JB, Barroso I, Watanabe RM, Ingelsson E, Langenberg C, Hamsten A, Florez JC: Genome-wide association  
10 identifies nine common variants associated with fasting proinsulin levels and provides new insights into the  
11 pathophysiology of type 2 diabetes. [Electronic version]. *Diabetes* 60: 2624-2634, 2011  
12  
13  
14  
15 38. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N,  
16 Gloyn AL, Lindgren CM, Magi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G,  
17 Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A,  
18 Perry JR, Egan JM, Lajunen T, Grarup N, Sparso T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P,  
19 Cavalcanti-Proenca C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell  
20 J, Luan J, Elliott A, McCarroll SA, Payne F, Ruccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B,  
21 Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond  
22 A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YD, Chines P,  
23 Clarke R, Coin LJ, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day IN, de Geus EJ, Delplanque J, Dina C, Erdos  
24 MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler  
25 J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL,  
26 Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J,  
27 Hung J, Isomaa B, Johnson PR, Jorgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B,  
28 Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, LeCoeur C, Li Y, Lyssenko V, Mahley R,  
29 Mangino M, Manning AK, Martinez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D,  
30 Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orru M, Pakyz R,  
31 Palmer CN, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AF, Pichler I, Polasek O,  
32 Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira  
33 F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ,  
34 Shields B, Sigurdsson G, Sijbrands EJ, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H,  
35 Syvanen AC, Tanaka T, Thorand B, Tichet J, Tonjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma  
36 D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H,  
37 Weedon MN, Wild SH, Willemsen G, Witteman JC, Yarnell JW, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH,  
38 Zillikens MC, DIAGRAM Consortium, GIANT Consortium, Global BPgen Consortium, Borecki IB, Loos RJ, Meneton  
39 P, Magnusson PK, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR,  
40 Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Rios M, Morris AD, Lind L, Palmer  
41 LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WH, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T,  
42 Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF, Anders  
43 Hamsten on behalf of Procardis Consortium, MAGIC investigators, Bergman RN, Buchanan TA, Collins FS, Mohlke  
44 KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JI, Siscovick DS, Penninx BW, Boomsma DI, Deloukas P, Spector TD,  
45 Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A,  
46 Schlessinger D, Uda M, Ruokonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V,  
47 Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI,  
48 Florez JC, Barroso I: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2  
49 diabetes risk. [Electronic version]. *Nat Genet* 42: 105-116, 2010  
50  
51  
52  
53  
54  
55  
56 39. Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon  
57 F, Crowe FL, Dekker JM, Fagherazzi G, Ferrannini E, Forouhi NG, Franks PW, Gavrila D, Giedraitis V, Grioni S,  
58 Groop LC, Kaaks R, Key TJ, Kuhn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quiros JR, Rolandsson O,  
59 Roswall N, Sacerdote C, Sala N, Sanchez MJ, Schulze MB, Siddiq A, Slimani N, Sluijs I, Spijkerman AM, Tjonneland  
60



- 1 A, Tumino R, van der ADL, Yaghoobkar H, RISC Study Group, EPIC-InterAct Consortium, McCarthy MI, Semple RK,  
2 Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB, Langenberg C, Wareham NJ: Common genetic variants  
3 highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity.  
4 [Electronic version]. *Diabetes* 63: 4378-4387, 2014  
5  
6  
7 40. Tobacco and Genetics Consortium: Genome-wide meta-analyses identify multiple loci associated with smoking  
8 behavior. [Electronic version]. *Nat Genet* 42: 441-447, 2010  
9  
10 41. Segre AV, DIAGRAM Consortium, MAGIC investigators, Groop L, Mootha VK, Daly MJ, Altshuler D: Common  
11 inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related  
12 glycemic traits. [Electronic version]. *PLoS Genet* 6: e1001058, 2010  
13  
14  
15 42. Lin DY, & Tang ZZ: A general framework for detecting disease associations with rare variants in sequencing  
16 studies. [Electronic version]. *Am J Hum Genet* 89: 354-367, 2011  
17  
18  
19 43. Moutsianas L, Agarwala V, Fuchsberger C, Flannick J, Rivas MA, Gaulton KJ, Albers PK, GoT2D Consortium, McVean  
20 G, Boehnke M, Altshuler D, McCarthy MI: The power of gene-based rare variant methods to detect disease-  
21 associated variation and test hypotheses about complex disease. [Electronic version]. *PLoS Genet* 11: e1005165,  
22 2015  
23  
24  
25 44. Price AL, Kryukov GV, de Bakker PI, Purcell SM, Staples J, Wei LJ, Sunyaev SR: Pooled association tests for rare  
26 variants in exon-resequencing studies. [Electronic version]. *Am J Hum Genet* 86: 832-838, 2010  
27  
28  
29 45. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X: Rare-variant association testing for sequencing data with the  
30 sequence kernel association test. [Electronic version]. *Am J Hum Genet* 89: 82-93, 2011  
31  
32  
33 46. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, NHLBI GO Exome Sequencing Project-ESP  
34 Lung Project Team, Christiani DC, Wurfel MM, Lin X: Optimal unified approach for rare-variant association  
35 testing with application to small-sample case-control whole-exome sequencing studies. [Electronic version]. *Am*  
36 *J Hum Genet* 91: 224-237, 2012  
37  
38  
39 47. Mahajan A, Sim X, Ng HJ, Manning A, Rivas MA, Highland HM, Locke AE, Grarup N, Im HK, Cingolani P, Flannick J,  
40 Fontanillas P, Fuchsberger C, Gaulton KJ, Teslovich TM, Rayner NW, Robertson NR, Beer NL, Rundle JK, Bork-  
41 Jensen J, Ladenvall C, Blanche C, Buck D, Buck G, Burt NP, Gabriel S, Gjesing AP, Groves CJ, Hollensted M,  
42 Huyghe JR, Jackson AU, Jun G, Justesen JM, Mangino M, Murphy J, Neville M, Onofrio R, Small KS, Stringham  
43 HM, Syvanen AC, Trakalo J, Abecasis G, Bell GI, Blangero J, Cox NJ, Duggirala R, Hanis CL, Seielstad M, Wilson JG,  
44 Christensen C, Brandslund I, Rauramaa R, Surdulescu GL, Doney AS, Lannfelt L, Linneberg A, Isomaa B, Tuomi T,  
45 Jorgensen ME, Jorgensen T, Kuusisto J, Uusitupa M, Salomaa V, Spector TD, Morris AD, Palmer CN, Collins FS,  
46 Mohlke KL, Bergman RN, Ingelsson E, Lind L, Tuomilehto J, Hansen T, Watanabe RM, Prokopenko I, Dupuis J,  
47 Karpe F, Groop L, Laakso M, Pedersen O, Florez JC, Morris AP, Altshuler D, Meigs JB, Boehnke M, McCarthy MI,  
48 Lindgren CM, Gloyn AL, T2D-GENES consortium and GoT2D consortium: Identification and functional  
49 characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-  
50 ABCB11 locus. [Electronic version]. *PLoS Genet* 11: e1004876, 2015  
51  
52  
53 48. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kahler  
54 A, Duncan L, Stahl E, Genovese G, Fernandez E, Collins MO, Komiyama NH, Choudhary JS, Magnusson PK, Banks  
55 E, Shakir K, Garimella K, Fennell T, DePristo M, Grant SG, Haggarty SJ, Gabriel S, Scolnick EM, Lander ES, Hultman  
56 CM, Sullivan PF, McCarroll SA, Sklar P: A polygenic burden of rare disruptive mutations in schizophrenia.  
57 [Electronic version]. *Nature* 506: 185-190, 2014  
58  
59  
60

- 1 49. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR,  
2 Lander ES, Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-  
3 wide expression profiles. [Electronic version]. *Proc Natl Acad Sci U S A* 102: 15545-15550, 2005  
4
- 5 50. Di Camillo B, Sambo F, Toffolo G, Cobelli C: ABACUS: An entropy-based cumulative bivariate statistic robust to  
6 rare variants and different direction of genotype effect. [Electronic version]. *Bioinformatics* 30: 384-391, 2014  
7
- 8 51. Huang da W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive  
9 functional analysis of large gene lists. [Electronic version]. *Nucleic Acids Res* 37: 1-13, 2009  
10
- 11 52. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID  
12 bioinformatics resources. [Electronic version]. *Nat Protoc* 4: 44-57, 2009  
13
- 14 53. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH: Predictors for the development  
15 of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. [Electronic  
16 version]. *BMJ* 328: 1105, 2004  
17
- 18 54. Harjutsalo V, Maric C, Forsblom C, Thorn L, Waden J, Groop PH, FinnDiane Study Group: Sex-related differences in  
19 the long-term risk of microvascular complications by age at onset of type 1 diabetes. [Electronic version].  
20 *Diabetologia* 54: 1992-1999, 2011  
21
- 22 55. Shankar A, Klein R, Klein BE, Moss SE: Association between glycosylated hemoglobin level and 16-year incidence  
23 of chronic kidney disease in type 1 diabetes. [Electronic version]. *Exp Clin Endocrinol Diabetes* 115: 203-206,  
24 2007  
25
- 26 56. Mooyaart A, Valk EJJ, van Es L, Bruijn J, de Heer E, Freedman B, Dekkers O, Baelde H: Genetic associations in  
27 diabetic nephropathy: A meta-analysis. [Electronic version]. *Diabetologia* 54: 544-553, 2011  
28
- 29 57. Sambo F, Malovini A, Sandholm N, Stavarachi M, Forsblom C, Makinen VP, Harjutsalo V, Lithovius R, Gordin D,  
30 Parkkonen M, Saraheimo M, Thorn LM, Tolonen N, Waden J, He B, Osterholm AM, Tuomilehto J, Lajer M, Salem  
31 RM, McKnight AJ, The GENIE Consortium, Tarnow L, Panduru NM, Barbarini N, Di Camillo B, Toffolo GM,  
32 Tryggvason K, Bellazzi R, Cobelli C, The FinnDiane Study Group, Groop PH: Novel genetic susceptibility loci for  
33 diabetic end-stage renal disease identified through robust naive bayes classification. *Diabetologia* 57: 1611-  
34 1622, 2014  
35
- 36 58. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon J, Pearson E, Buehler J, Chen Y, Yu B,  
37 Tinkham NH, Zabriskie NA, Zeng J, Luo L, Sun JK, Prakash M, Hamam RN, Tonna S, Constantine R, Ronquillo CC,  
38 Sadda S, Avery RL, Brand JM, London N, Anduze AL, King GL, Bernstein PS, Watkins S, Genetics of Diabetes and  
39 Diabetic Complication Study Group, Jorde LB, Li DY, Aiello LP, Pollak MR, Zhang K: Promoter polymorphism of  
40 the erythropoietin gene in severe diabetic eye and kidney complications. [Electronic version]. *Proc Natl Acad Sci*  
41 *U S A* 105: 6998-7003, 2008  
42
- 43 59. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D, Babazono T, Tanaka Y, Matsuda M,  
44 Kawai K, Iizumi T, Imanishi M, Shinosaki T, Yanagimoto T, Ikeda M, Omachi S, Kashiwagi A, Kaku K, Iwamoto Y,  
45 Kawamori R, Kikkawa R, Nakajima M, Nakamura Y, Maeda S: Genetic variations in the gene encoding ELMO1 are  
46 associated with susceptibility to diabetic nephropathy. [Electronic version]. *Diabetes* 54: 1171-1178, 2005  
47
- 48 60. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DPK, Placha G, Canani LH,  
49 Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS,  
50 Smiles A, Walker WH, Boright AP, Bull SB, 'DCCT/EDIC Research Group', Doria A, Rogus JJ, Rich SS, Warram JH,  
51 Krolewski AS: Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes.  
52 [Electronic version]. *Diabetes* 58: 1403-1410, 2009  
53  
54  
55  
56  
57  
58  
59  
60

- 1 61. Craig DW, Millis MP, DiStefano JK: Genome-wide SNP genotyping study using pooled DNA to identify candidate  
2 markers mediating susceptibility to end-stage renal disease attributed to type 1 diabetes. [Electronic version].  
3 *Diabet Med* 26: 1090-1098, 2009  
4
- 5 62. Sandholm N, Forsblom C, Makinen VP, McKnight AJ, Osterholm AM, He B, Harjutsalo V, Lithovius R, Gordin D,  
6 Parkkonen M, Saraheimo M, Thorn LM, Tolonen N, Waden J, Tuomilehto J, Lajer M, Ahlqvist E, Mollsten A,  
7 Marcovecchio ML, Cooper J, Dunger D, Paterson AD, Zerbini G, Groop L, SUMMIT Consortium, Tarnow L,  
8 Maxwell AP, Tryggvason K, Groop PH, FinnDiane Study Group: Genome-wide association study of urinary  
9 albumin excretion rate in patients with type 1 diabetes. [Electronic version]. *Diabetologia* 57: 1143-1153, 2014  
10  
11
- 12 63. Köttgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, O'Connell  
13 JR, Li M, Schmidt H, Tanaka T, Isaacs A, Ketkar S, Hwang SJ, Johnson AD, Dehghan A, Teumer A, Pare G, Atkinson  
14 EJ, Zeller T, Lohman K, Cornelis MC, Probst-Hensch NM, Kronenberg F, Tonjes A, Hayward C, Aspelund T,  
15 Eiriksdottir G, Launer LJ, Harris TB, Rampersaud E, Mitchell BD, Arking DE, Boerwinkle E, Struchalin M, Cavalieri  
16 M, Singleton A, Giallauria F, Metter J, de Boer IH, Haritunians T, Lumley T, Siscovick D, Psaty BM, Zillikens MC,  
17 Oostra BA, Feitosa M, Province M, de Andrade M, Turner ST, Schillert A, Ziegler A, Wild PS, Schnabel RB, Wilde S,  
18 Munzel TF, Leak TS, Illig T, Klopp N, Meisinger C, Wichmann HE, Koenig W, Zgaga L, Zemunik T, Kolcic I, Minelli C,  
19 Hu FB, Johansson A, Igl W, Zaboli G, Wild SH, Wright AF, Campbell H, Ellinghaus D, Schreiber S, Aulchenko YS,  
20 Felix JF, Rivadeneira F, Uitterlinden AG, Hofman A, Imboden M, Nitsch D, Brandstatter A, Kollerits B, Kedenko L,  
21 Magi R, Stumvoll M, Kovacs P, Boban M, Campbell S, Endlich K, Volzke H, Kroemer HK, Nauck M, Volker U,  
22 Polasek O, Vitart V, Badola S, Parker AN, Ridker PM, Kardia SL, Blankenberg S, Liu Y, Curhan GC, Franke A, Roach  
23 T, Paulweber B, Prokopenko I, Wang W, Gudnason V, Shuldiner AR, Coresh J, Schmidt R, Ferrucci L, Shlipak MG,  
24 van Duijn CM, Borecki I, Kramer BK, Rudan I, Gyllenstein U, Wilson JF, Witteman JC, Pramstaller PP, Rettig R,  
25 Hastie N, Chasman DI, Kao WH, Heid IM, Fox CS: New loci associated with kidney function and chronic kidney  
26 disease. [Electronic version]. *Nat Genet* 42: 376-384, 2010  
27  
28  
29  
30
- 31 64. McDonough CW, Palmer ND, Hicks PJ, Roh BH, An SS, Cooke JN, Hester JM, Wing MR, Bostrom MA, Rudock ME,  
32 Lewis JP, Talbert ME, Blevins RA, Lu L, Ng MC, Sale MM, Divers J, Langefeld CD, Freedman BI, Bowden DW: A  
33 genome-wide association study for diabetic nephropathy genes in african americans. [Electronic version]. *Kidney*  
34 *Int* 79: 563-572, 2011  
35  
36
- 37 65. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology  
38 Collaboration: Expressing the modification of diet in renal disease study equation for estimating glomerular  
39 filtration rate with standardized serum creatinine values. [Electronic version]. *Clin Chem* 53: 766-772, 2007  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60